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ABSTRACT 
Kristine Marie Wadosky: Cardiac muscle RING finger 1 inhibits adaptive hypertrophic remodeling 
induced by IGF-1, exercise, and thyroid hormone  
(Under the direction of Monte S. Willis) 
In the face of cardiac load, the heart responds by undergoing hypertrophy.  Under 
pathological conditions, ventricular wall thickening cannot be maintained, impairing function (heart 
failure).  In contrast, ventricular wall thickening in response to physiological stimuli does not impair 
cardiac function.  Pathological and physiological hypertrophy are driven by distinct signaling 
pathways—while vasoactive factors induce the former, growth hormones induce the latter.  
Understanding the mechanisms through which heart growth is adaptive has recently become a goal of 
cardiac research, in the hopes of using this information in the discovery of therapies that promote 
restoration of the myocardium following injury (since an effective treatment for heart failure has yet 
to be developed).  The purpose of this dissertation work is to describe new mechanisms by which 
physiological cardiac hypertrophy is regulated.  Signaling pathways activated in the heart following 
physiologic stimuli are receptor tyrosine kinases (RTKs) and nuclear receptors (NRs), of which the 
IGF-1/Akt and TRα pathways, respectively, are most understood.  The work presented here 
establishes the striated muscle specific ubiquitin ligase, Muscle RING finger 1 (MuRF1) as a novel 
regulator of physiological cardiac hypertrophy through its ubiquitination of transcription factors.  
MuRF1 inhibits cardiomyocyte growth in response to IGF-1 and aerobic exercise stimulation by 
poly-ubiquitinating and promoting the degradation of c-Jun, recently discovered to drive 
transcriptional expression of genes coding for members of the IGF-1 signaling cascade.  In contrast, 
MuRF1 mono-ubiquitinates TRα, thereby inhibiting TRα transcriptional activity and thyroid hormone 
(TH)-dependent cardiac hypertrophy.  Furthermore, it is established here that mono-ubiquitination of 
TRα by MuRF1 induces TRα accumulation in the cardiomyocyte nucleus where TRα interacts with 
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centrosome-associated protein 350 (CAP350).  This inhibitory mechanism, while being established 
for other NRs, is completely novel for TRα and has never been described in the heart.  Altogether, 
this dissertation contributes to the field of cardiac growth research by detailing the discovery of an 
inhibitor of not one, but two, signaling pathways that stimulate beneficial cardiac hypertrophy.  Given 
that MuRF1 inhibits both IGF-1/Akt and TRα signaling, the activity of this ubiquitin ligase may be as 
efficacious target for new cardiac therapies by virtue of MuRF1’s widespread influence on the 
cardiomyocyte.   
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PREFACE 
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“Regulation of the calpain and ubiquitin proteasome systems in a canine model of muscular 
dystrophy,” of which Kristine Marie Wadosky is first author and that has previously appeared in 
Muscle and Nerve.  The original citation for the publication composing the Appendix of this 
dissertation is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62.  Excerpts from a review 
article published by Kristine Marie Wadosky were used in Chapter Four: Discussion and Perspectives 
of this dissertation.  The original citation for this publication excerpted in Chapter Four is as follows 
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CHAPTER 1: INTRODUCTION 
Pathological and physiological cardiac hypertrophy have distinct characteristics 
 When the cardiac wall is exposed to increased mechanical and hemodynamic forces, 
cardiomyocytes counteract these forces by producing more sarcomeres, the smallest contractile unit 
responsible for force generation.  Amassing additional sarcomeres increases the volume of individual 
cardiomyocytes and initiates ventricular wall thickening—stabilizing wall stress and maintaining 
overall cardiac output1.   
Functionally, the heart’s response to ventricular wall thickening is largely dependent on the 
type of hypertrophic stimuli producing this response.  Pathologic stimuli, such as hypertension, aortic 
stenosis, myocardial infarction and certain sarcomeric gene mutations, increase cardiac afterload by 
inducing the release of angiotensin II (AngII), endothelin 1 (ET1), norepinephrine (NE), and other 
vasoactive factors.  These ligands bind to G protein-coupled receptors (GPCRs) and activate 
downstream mitogen-activated protein kinase (MAPK) cascades and G-protein-activated protein 
kinases.  Initially this growth maintains cardiac function, but chronic excessive activation of these 
signaling cascades stimulates the production of reactive oxygen species and apoptotic programs in the 
cardiomyocyte and inflammation and extracellular matrix deposition at the tissue level.  These 
cellular and structural changes adversely affect cardiac function by stiffening the ventricles, reducing 
capillary density, and impairing electrical stimulation of contraction and relaxation.  Consequently, 
this cardiac damage progresses to heart failure.  As a result of this maladaptive processes, this type of 
heart growth has been termed pathological cardiac hypertrophy2.       
Increases in cardiac mechanical and hemodynamic forces also occur during postnatal growth 
and in response to exercise conditioning and pregnancy in adults3.  In contrast to pathological cardiac 
hypertrophy, the myocardium’s response to increases in afterload induced by these stimuli is benign 
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—in that the morphological changes that occur in response to these physiological conditions do not 
cause cardiomyocyte apoptosis and necrosis, tissue fibrosis, or cardiac dysfunction, and in some 
cases, can enhance function3.  Additionally, in the case of either exercise or pregnancy, the cardiac 
hypertrophic remodeling is reversible once the stimulus is removed.  Consequently, cardiac growth 
induced by these stimuli is termed physiological hypertrophy2, 4, 5. 
Molecular mechanisms of physiological cardiac hypertrophy 
Multiple hormones and mechanical signals have been associated with promoting 
physiological heart growth downstream of post-natal growth signals, exercise, and pregnancy2, 3.  
While activation of physiological growth by extracellular signals compares to that of pathological 
growth, the types of receptors stimulated by physiological hypertrophy-inducing ligands contrast 
greatly with those that activate pathological hypertrophy—while pathological growth is largely 
attributed to the activation of GPCRs, physiological growth is primarily attributed to the activation of 
receptor tyrosine receptors (RTKs) and nuclear receptors (NRs)2, 3, 6-8.   
RTKs are transmembrane proteins comprised of a hydrophobic region flanked by 
extracellular N-terminal and intracellular C-terminal domains9, 10. The binding of ligand to the 
extracellular domain of its cognate RTK induces receptor dimerization and subsequent auto-
phosphorylation of the receptor’s intracellular domain by its partner9, 10.  The activated RTK 
intracellular domain then binds to and phosphorylates several different substrates.  While each RTK 
has a distinct set of substrates, most RTKs involved in myocardial signaling recruit phosphoinositide 
3-kinase (PI-3K) to the plasma membrane, via PI-3K’s direct binding to the phosphotyrosine residues 
within the RTK dimer, as the initial step in the activation of the downstream kinase cascade9, 10.   
In contrast to RTKs, NRs, as the name indicates, are localized to the cardiomyocyte nucleus 
when active, where they activate transcription by binding to their respective nucleotide motifs within 
the promoter regions of target genes6, 11.  In the absence of ligand, a transcriptional corepressor, such 
as nuclear receptor corepressor (NCoR), binds to and inhibits the nuclear receptor12.  A 
conformational change induced by the ligand causes the corepressor to dissociate, releasing inhibition 
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and allowing the NR to homodimerize or heterodimerize with its coreceptors and recruit coactivators, 
if required, to the promoter12.  The composition of the active transcriptional complex, whether a 
homodimer or heterodimer, including a co-activator or not, is specific to each nuclear receptor12.  
Also in contrast to RTKs, active NRs can be localized throughout the cell, achieving functions 
independent of transcriptional activation.  These functions of certain NRs have been shown to be 
important for physiological growth in the heart7, 11, 13.        
 The specific pathways that are known to induce physiological cardiac hypertrophy which 
have been most well-studied include the insulin-like growth factor-1 (IGF-1) and thyroid hormone 
(TH) signaling cascades.  In addition, these cascades represent pathways initiated by both a RTK and 
NR (respectively) (Figure 1)2, 3.  Considering that the basic information about the proteins, enzymatic 
cascades, transcriptional profiles, and regulatory processes involved for each of these signaling 
cascades has been established, the IGF-1 and TH pathways were focused on in this dissertation work 
so that an established and accepted mechanistic foundation was present to ensure that new 
experimental results could be interpreted accordingly.          
The IGF-1/Akt signaling cascade. Exercise triggers the release of growth hormone (GH) 
from the pituitary gland that induces IGF-1 production in and subsequent release from the liver 
(Figure 1).  While cardiomyocytes themselves transiently release IGF-1, circulating IGF-1 is the 
main source of IGF-1 for the cardiomyocyte, especially following exercise14-16.  IGF-1 binds to either 
its own receptor (IGF-1R) or the insulin receptor (IR), RTKs present at the cardiomyocyte plasma 
membrane (Figure 1)9.  Active IGF-1R or IR binds to and phosphorylates PI3K, which catalyzes the 
production of phosphatidylinositol (3,4,5)-triphosphate (PIP3) at the plasma membrane (Figure 1)2, 9.  
The presence of PIP3 induces phosphoinositide dependent kinase-1 (PDK1) translocation to the 
plasma membrane, where PDK1 phosphorylates Akt1 (Figure 1)2, 9, the main isoform of Akt in the 
heart (Akt2 is also present, but to a lesser extent), at T30817, 18.  PDK1-dependent phosphorylation of 
Akt1 (hereafter referred to as Akt) is the crucial step in the IGF-1 pathway, since Akt is central to this 
kinase cascade9, 19.  The T308 phosphorylated form of Akt is only partially active; therefore, the final 
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step in generating fully activated Akt is its phosphorylation by mammalian target of rapamycin C2 
(mTORC2) at S473 (Figure 1)9, 19.  Akt’s importance in promoting physiological hypertrophy is 
illustrated by studies that have shown that hypertrophy induced by exercise is inhibited by knocking 
out Akt20 and hypertrophy without dysfunction is induced by acute cardiac-specific transgenic 
expression of Akt21.  In addition, inducing transcription of Akt by activating c-Jun (Figure 1) (via 
knocking out the c-Jun inhibitor sirtuin 6 (SIRT6)) in vivo, promotes cardiac hypertrophy22).   
Akt promotes cardiac growth mainly by phosphorylating substrates involved in both 
transcription and translation.  Akt phosphorylates and inhibits Forkhead box O (FOXO) transcription 
factors (FOXO1 and FOXO3a) by promoting their nuclear export (Figure 1) and thereby prevents the 
transcription of the pro-atrophy gene expression profile induced by FOXOs3, 19, 23.  Glycogen synthase 
kinase-3β (GSK-3β), another protein which is inhibited by Akt-dependent phosphorylation, is itself 
an inhibitor of pro-growth transcription factors in the heart19, including GATA424, nuclear factor of 
activated T cells (NFAT)25, 26, myocardin27, c-myc28, c-Jun29, and β-catenin30; therefore Akt activates 
pro-growth transcription factors by inhibiting GSK-3β (Figure 1).   
Akt promotes protein translation via multiple mechanisms.  By inhibiting GSK-3β, Akt not 
only activates pro-growth transcription (as described above), but also activates translation since GSK-
3β is also an inhibitor of eukaryotic initiation factor 2Bε (eIF2Bε)15, 18, 25 (Figure 1).  Akt also 
promotes the formation of the mTORC1 kinase complex, which stimulates protein translation in 
multiple ways.  mTORC1 phosphorylates and activates p70S6 kinase, which subsequently activates 
ribosome biosynthesis by phosphorylating S6 and protein elongation by phosphorylating eukaryotic 
elongation factor 2 (eEF2)19 (Figure 1).   mTORC1 also activates translation initiation by 
phosphorylating 4E-binding protein 1 (4E-BP1), releasing 4E-BP1’s inhibition of eukaryotic 
initiation factor (eIF4E)2, 19 (Figure 1).    
Finally, Akt improves cardiomyocyte contractility in addition to promoting growth19.  
Cardiac-specific transgenic expression of constitutively active Akt not only induces growth on the 
level of the whole cardiomyocyte and individual myofibrils, but increases basal maximum left 
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ventricular (LV) dP/dt at baseline and at low concentrations of dobutamine24.  In addition, isolated 
cardiomyocytes from mice transgenically expressing Akt have increased rates of both contraction and 
relaxation, increased overall Ca2+ transients, and increased L-type Ca2+ channel current densities 
compared to wildtype cardiomyocytes31.  In that study31, as well as others32, 33, increased expression of 
Akt was associated with increased expression of sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a), 
the primary channel responsible for Ca2+ reuptake into the sarcoplasmic reticulum at the end of each 
contraction cycle (Figure 1).  Akt has also been shown to phosphorylate the SERCA2a inhibitor 
phospholamban (PLN), causing PLN to dissociate from and release its inhibition of SERCA2a 
(Figure 1), again allowing for enhanced Ca2+ influx into the SR32.  These studies show that Akt 
primarily affects cardiomyocyte contraction by improving sarcoplasmic reticulum Ca2+ loading, 
permitting for more efficient Ca2+ handling and excitation-contraction coupling.        
Activation of thyroid receptor (TR) by TH. Signaling mechanisms activated by TH in the 
cardiomyocyte also induce physiological hypertrophy2, 3, 34.  The primary form of TH secreted by the 
thyroid gland is the pro-hormone 3,5,3’,5’-tetraiodothyronine (T4), which is converted to 3,5,3’-
triiodothyronine (T3) by deiodinases (Figure 1)35.  Activity of deiodinases in the adult cardiomyocyte 
is marginal and only <7% of total T3 is generated by the cardiomyocyte itself; therefore, the primary 
source of T3 for the cardiomyocyte is from the circulation35.  T3 requires plasma membrane 
transporters to enter the cell36.  The transporters responsible for T3 movement across the plasma 
membrane which have been most well-studied include two members of the monocarboxylate 
transporter (MCT) family, MCT8 and 1036, 37.  These transporters are especially important to TH 
signaling in the cardiomyocyte, since the expression of MCT8 and 10 have recently been shown to be 
regulated by T3 in the heart in vivo (Figure 1)38.              
Once T3 has entered the cardiomyocyte, it can affect multiple signaling pathways6, 13, 39.  
However, T3-dependent activation of the NR transcription factors thyroid receptors (TRs) (Figure 1) 
is the most well-established mechanism controlling TH-dependent cardiomyocyte growth3, 11.  The 
TR isoforms expressed in the heart include TRα1 and 2 and TRβ1, where TRα accounts for 70% and 
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TRβ1 accounts for 30% of total TR.  Since TRα2 activity antagonizes T3-dependent activity and is 
only weakly activated by T3, TRα1 (hereafter referred to as TRα) is responsible for the bulk of T3-
dependent activities in the cardiomyocyte34.  In the absence of T3 stimulation, a transcriptional 
corepressor, such as nuclear receptor corepressor (NCoR), binds to and inhibits TRα (Figure 1).  A 
conformational change induced by T3 causes the corepressor to dissociate, releasing TRα inhibition 
and allowing the recruitment coreceptors, such as retinoid X receptor α (RXRα), and coactivators, 
such as peroxisome proliferator-activated receptor γ coactivator 1 (PGC1) (Figure 1).  Together, the 
TRα complex binds the thyroid response element (TRE) in the promoter region of TH-regulated 
genes, activating or inhibiting transcription (Figure 1)11.  Genes regulated by TRα include SERCA2a 
and PLN, which are activated and inhibited, respectively (Figure 1)39.  The transcriptional profile 
promoted by TRα in its entirety is associated with favorable cardiac hypertrophy, where cardiac 
function is at least maintained, if not improved, and does not progress to heart failure (the primary 
characteristics of physiological growth34). 
TRα has several extranuclear actions which have significant effects on cardiomyocyte 
metabolism and growth11, 39, 40.  A truncated form of TRα, a 43kD protein (TRαp43) the translation of 
which is initiated by an internal methionine residue, localizes to the cardiomyocyte mitochondria 
where it activates transcription of mitochondrial genes (Figure 1); thereby promoting the activity of 
the respiratory chain and mitochondrial oxygen consumption11, 41, 42.  Another truncated form of TRα 
is also localized to the mitochondria (TRαp28), but it lacks the DNA-binding region and does not act 
as a mitochondrial transcription factor11, 41.  Instead, TRαp28 binds to and activates adenine 
nucleotide translocator (ANT)11, 41, 43, the protein responsible for passage of ADP into the 
mitochondrial matrix, at the inner mitochondrial membrane.  Via this interaction with ANT, TRαp28 
instantaneously increases respiratory chain flux by feeding ADP substrate to ATP synthase (Figure 
1)40.  The overall effect of mitochondrial TRα isoforms (TRαp48 and TRαp28) is the increase in ATP 
production via oxidative phosphorylation that generates a greater pool of hydrolysable ATP within 
the cardiomyocyte.  By doing so, the processes that promote physiological cardiac growth and 
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contractility (transcription, translation, and excitation-contraction coupling) proceed at a greater rate 
because of the readiness of energy substrates.  
In addition to being localized to the cardiomyocyte nucleus and mitochondrion, active TRα is 
localized to the cytoplasm where its activity also promotes physiological growth as well40.  TRα 
interacts with the p85 subunit of PI-3K, promoting the activation of PI-3K and the downstream IGF-1 
signaling cascade (including Akt, mTOR, and p70S6K) (Figure 1)44.  As described above, activation 
of this signaling cascade activates both transcription and translation, therefore providing a mechanism 
by which TRα activates overall transcriptional processes (independent of the activation of its own 
target genes) and protein synthesis (Figure 1)44.  Furthermore, activation of PI-3K by TRα is a direct 
example of crosstalk between the IGF-1 and TH signaling pathways and represents the importance of 
comprehending these cascades not as distinct, but jointly promoting the final outcome of cardiac 
growth without pathological remodeling. 
The ubiquitin proteasome system1 
The conjugation of ubiquitin is unique among post-translational modifications in that it involves the 
attachment of another polypeptide, the 76-amino acid polypeptide, ubiquitin45, 46, instead of the 
addition of a functional group, such as a phosphate, acetate, lipid, or carbohydrate.  In the first step of 
the ubiquitin conjugation cascade, free ubiquitin is covalently linked to the ubiquitin-activating 
enzyme (E1) in an ATP-dependent reaction (Figure 2, far left)45, 46.  Next, ubiquitin is transferred 
from the E1 enzyme to the ubiquitin-conjugating enzyme (E2) (Figure 2, middle). Finally, the 
interaction between the E2 and the ubiquitin ligase enzyme (E3) allows the E3 to initiate the transfer 
of ubiquitin or SUMO from the E2 to a lysine residue on the substrate (Figure 2, middle)45, 46.  The 
E3 is the pivotal component in both the ubiquitin conjugation pathways since it confers specificity to 
the system by directly interacting with the substrate. Therefore, identifying ubiquitin ligase-substrate 
pairs is integral to understanding the cellular functions affected by ubiquitin conjugation45.  The most 
                                                     
1This section has previously appeared in American Journal of Physiology Heart and Circulatory Physiology.  
The original citation for the publication which includes this excerpt is as follows: Am J Physiol Heart Circ 
Physiol 2012 Feb 1;302(3):H515-26.       
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commonly described ubiquitination pattern is poly-ubiquitination, where the initial ubiquitin molecule 
is conjugated to the substrate, followed by the addition of subsequent ubiquitin molecules linked by 
their lysine located in the 48th amino acid position (Figure 2, right)45-47.  When the lysines are 
serially connected to each other by this canonical lysine number 48, it is referred to as a K48 (K = 
lysine) poly-ubiquitin chain. This canonical K48 ubiquitination pattern is recognized by the 26S 
proteasome, targeting the modified protein for degradation (Figure 2, right)47-49.  Other recognized 
ubiquitination patterns include mono-ubiquitination (the placement of only 1 ubiquitin on a 
substrate)46 and poly-ubiquitination via atypical [non-K48 linked (K63)] ubiquitin chains (Figure 2, 
right)46, 50.  Mono-ubiquitination and poly-ubiquitination via atypical ubiquitin chains have a wider 
effect on cellular function than polyubiquitination via K48, including translation, cell cycle 
regulation, signal transduction, protein trafficking, and protein-protein interactions45, 46, 51-53.  
Muscle RING Finger 1 (MuRF1): the discovery of a striated muscle-specific ubiquitin ligase  
 Discovery of MuRF proteins.  MuRF1 was initially identified in a yeast-two-hybrid screen 
using the transcription factor serum response factor (SRF) as bait54.  Subsequent studies by this group 
illustrated that MuRF1 was exclusively expressed in striated muscle (skeletal and cardiac) and co-
localized with sarcomeres in the mouse quadriceps54.  Further work by another group identified other 
MuRF1 family members, MuRF2 and MuRF3, via a yeast-two-hybrid screen using MuRF1 as bait55.  
All MuRF family members are part of subclass of RING proteins called RING-B-box-coiled-coil54, 
containing an N-terminal RING domain, a MuRF family-specific conserved region, Zn-binding B-
box motif, leucine-rich coiled coil motifs, and an acidic tail at the C-terminus, the last of which varies 
in length for each member55.  MuRF1, MuRF2, and MuRF3 co-segregate into the same subgroup in 
an evolutionary tree comparison with other members of the RING protein family, despite being 
encoded by different genes on different chromosomes (mouse chromosome 1, 8, and 2, 
respectively)55.  While expression patterns of each MuRF family member differ slightly, for instance, 
MuRF1 has been shown to be expressed in uterine smooth muscle56 and MuRF2 is expressed at low 
levels in the liver55, MuRF1, MuRF2, and MuRF3 are primarily expressed (and studied, for that 
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matter) in striated muscle.  Of all the family members, MuRF1’s activity in both skeletal and cardiac 
muscle is most established.   
Discovery of MuRF1’s connection to muscle atrophy.  The first direct evidence of the 
importance of MuRF proteins to muscle physiology came about soon after their discovery, where it 
was shown that the transcript coding for MuRF1 was one of two transcripts most highly expressed 
after induction of skeletal muscle atrophy in vivo57.  Unexpectedly, MuRF1-/- mice did not show any 
differences in skeletal muscle and heart weights at baseline57.  However, cutting the sciatic nerve of 
MuRF1-/- animals, thereby causing denervation of the tibialis anterior and gastrocnemius muscles, 
showed that MuRF1-/- skeletal muscles were heavier (+36%) compared to wildtype animals 
following this atrophy-inducing stimulus57.  The sparing of MuRF1-/- animals from denervation-
induced skeletal muscle atrophy suggested that MuRF1’s expression was not merely correlative with 
atrophy induction but that MuRF1’s activity as a putative ubiquitin ligase was significant in the 
development of muscle atrophy57.     
 MuRF1’s interacting partners and substrates originally characterized in striated 
muscle. The first proteins identified to interact with MuRF1 include an array of sarcomeric proteins, 
including titin, myosin heavy chain (MHC), myosin binding protein-C (MyBP-C), myosin light chain 
(MyLC), troponins, nebulin, myotilin, and telethonin55, 58.  Comparison of immunoblot data for 
troponin T, MyLC 1, and MyLC2 between wildtype and MuRF1-/- in cardiac tissue showed that 
higher molecular weight species (presumed to be ubiquitinated forms for these proteins) were reduced 
in MuRF1-/-58.  While MuRF1’s homology to RING-domain-containing monomeric ubiquitin ligases 
suggested that it ubiquitinates proteins, the decrease of the potential ubiquitinated species of these 
sarcomeric proteins in MuRF1-/- tissue provided evidence, albeit indirect, that MuRF1 is indeed a 
functional ubiquitin ligase58.  The primary consequence of a protein’s ubiquitination is its degradation 
by the proteasome, by which 80-90% of intracellular proteins undergo proteolysis59.  Therefore, 
further studies of MuRF1-dependent activity in muscle cells focused on determining the degree to 
which MuRF1 promotes the degradation of sarcomeric proteins.  Indeed, denervation atrophy-
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dependent decreases in MyBP-C, MyLC1, and MyLC2 protein levels were restored in the 
gastrocnemius of animals expressing MuRF1 without its RING domain (the region of MuRF1 
conferring its potential ubiquitin ligase activity)60.  These data supplied further evidence to support 
the hypothesis that MuRF1 was an operating ubiquitin ligase, in addition to suggesting that the 
MuRF1-dependent degradation of sarcomeric proteins plays a role in the development of muscle 
atrophy.  Confirmation of MuRF1’s ubiquitin ligase activity was secured when Kedar et al.61 showed 
that MuRF1 directly ubiquitinates cardiac troponin I (using in vitro ubiquitination assays).  This study 
not only provided definitive evidence of MuRF1’s activity as an ubiquitin ligase, but also showed that 
MuRF1 inhibits contraction of neonatal rat ventricular myocytes (NRVM), where maximal shortening 
and rate of shortening were decreased 25% in cardiomyocytes with increased expression of MuRF161.  
These closing data are especially important because they introduced MuRF1’s significance in 
cardiomyocyte function and laid the groundwork for the study of MuRF1 in cardiac physiology.           
MuRF1 activity in the cardiomyocyte 
As described above, MuRF1 plays an active role in protein quality control for the sarcomere 
in striated muscle.  In the cardiomyocyte specifically, MuRF1 targets troponin T, MyLC 1, MyLC2, 
troponin I, MyBP-C, βMHC, MHCIIa, and tropomyosin58, 61-64, suggesting that it may maintain 
overall sarcomeric performance by directing degradation of proteins which become damaged during 
continuous cycles of excitation-contraction coupling.  In addition to localizing to the sarcomeric M- 
and Z-lines54, 55, MuRF1 localizes to multiple other regions of the cardiomyocyte and targets 
substrates that are imperative for metabolism, transcription, and growth signaling.   
MuRF1 and cardiomyocyte metabolism.  The amount of ATP required to sustain 
excitation-contraction coupling during each heartbeat is vast65.  The rapid movement of ATP 
throughout the cell in striated muscle is achieved by creatine kinase (CK) via a phosphotransferase 
system that transfers ATP from the mitochondrion to sites of utilization, maintaining cardiac 
function66.  MuRF1 ubiquitinates CK67 and mice with cardiac-specific transgenic expression of 
MuRF1 (MuRF1 Tg+) have decreased CK activity68—showing that MuRF1 limits ATP 
11 
 
bioavailability in the cardiomyocyte.  A recent study has also identified ATP synthase β and a 
mitochondrial specific heat shock protein (Hspd1) as MuRF1 ubiquitin substrates in 
cardiomyocytes64,  illustrating MuRF1’s importance to mitochondrial function and suggesting that 
MuRF1 can localize to the mitochondrion. Moreover, MuRF1 affects cardiomyocyte metabolism at 
the transcriptional level.  Peroxisome proliferator-activated receptor (PPAR) family of NRs regulate 
the transcription of genes involved in lipid metabolism and promote fatty acid uptake and oxidation69.  
Since fatty acid oxidation is the primary source of ATP for the heart, PPARs are crucial for energy 
production in the cardiomyocyte69.  MuRF1 has been found to mono-ubiquitinate PPARα, inhibiting 
PPARα transcriptional activity by nuclear export (instead of promoting PPARα degradation)70-72. 
These results were consistent with the observation that MuRF1 Tg+ hearts are deficient in fatty acid 
oxidation68 and further work showed that PPARα transcriptional activity was inhibited by MuRF1 in 
vivo70.   
MuRF1 regulates transcription factors.  In addition to targeting PPARα, MuRF1 
ubiquitinates multiple other transcription factors.  As described above, MuRF1 was first identified in 
a screen for SRF-binding proteins54.  The direct effect of MuRF1 on SRF was discovered by our 
laboratory, where we showed that SRF-dependent luciferase activity was significantly decreased in 
cells expressing increased MuRF173.  We have also shown that MuRF1 interacts with the 
transcription factor c-Jun and specifically promotes the degradation of phospho-c-Jun upon 
ischemia/reperfusion injury74.  Finally, we have recently reported that both MuRF1 and MuRF2 
promote the transcriptional activity of E2F1 in vivo75.  Direct chromatin immunoprecipitation of E2F1 
from cardiac tissue show that E2F1 promoter occupancy was decreased in MuRF1-/-//MuRF2-/- 
double knockout mice, but not in single knockout mice, suggesting that MuRF1 and MuRF2 promote 
E2F1 activity redundantly; likely via the ubiquitination and proteasomal degradation of an inhibitor of 
E2F175.  Another essential finding from this study was the spontaneous hypertrophic cardiomyopathy 
observed in MuRF1-/-//MuRF2-/- animals75.  Since these animals were born with this hypertrophic 
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defect, these data implicate MuRF1 and MuRF2 in developmental heart growth75—providing initial 
evidence for MuRF1’s role in physiological hypertrophy.   
MuRF1 and cardiomyocyte hypertrophy.  MuRF1’s further role in growth signaling is 
illustrated via its interaction with receptor for activated protein C kinase 1 (RACK1).  Upon 
activation of GPCRs by phenylephrine (PE), MuRF1 and RACK1 colocalize in the perinuclear region 
of the cardiomyocyte76.  MuRF1’s interaction with RACK1 inhibits the translocation of protein kinase 
C ε (PKCε) to the sarcolemma.  This action of MuRF1 stops PKCε from interacting with focal 
adhesion kinase (FAK)76, a kinase which governs the cardiomyocyte’s response to extracellular 
biomechanical stress signals77.  Together, these data suggest that MuRF1 inhibits cardiomyocyte 
growth, since PKCε and FAK are pro-growth kinases76.  Indeed, increased expression of MuRF1 
inhibits growth induced by GPCR agonists PE, AngII, ET-1, and serum in NRVM76.  Since MuRF1 
hinders cardiomyocyte growth downstream of GPCRs76, most commonly associated with pathological 
growth signaling2, these data indicate that MuRF1 inhibits pathological cardiac hypertrophy.  Based 
on this evidence, our laboratory has shown that MuRF1-dependent inhibition of pathological cardiac 
hypertrophy is present in vivo by showing that MuRF1-/- mice have an exaggerated cardiac growth 
response to pressure-overload induced by transaortic constriction73.  These studies identify MuRF1 as 
a key regulator limiting cardiomyocyte growth in response to pathologic stimuli. 
Hypothesis for this dissertation work 
MuRF1 is known to inhibit pathological cardiac hypertrophy—shown both in isolated 
cardiomyocytes stimulated with GPCR agonists76 and in mice challenged with pressure overload73.  
Given that MuRF1’s inhibits this form of cardiac hypertrophy, and especially since mice lacking both 
MuRF1 and MuRF2 undergo exaggerated developmental cardiac growth (a type of hypertrophy 
known to be physiological in nature) without a precipitating challenge, the overarching hypothesis for 
this dissertation work is that MuRF1 also inhibits physiological hypertrophy.  IGF-1-, exercise-, and 
TH-dependent cardiac hypertrophy were chosen as models in to order to provide a thorough body of 
evidence for MuRF1-dependent effects on physiological hypertrophy.  In addition, a wide array of 
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methods were utilized in this work—including in vitro and in vivo models of cardiomyocyte 
hypertrophy, fluorescent imaging, and molecular biology—to demonstrate MuRF1-dependent 
inhibition of physiological hypertrophy, establish the molecular mechanisms by which MuRF1 
achieves limitation of this type of hypertrophy, and identify new substrates for MuRF1’s ubiquitin 
ligase activity. 
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CHAPTER 2: MUSCLE RING FINGER 1 ATTENUATES IGF-1-DEPENDENT 
CARDIOMYOCYTE HYPERTROPHY BY INHIBITING JNK SIGNALING2 
Introduction 
 MuRF1 is a muscle-specific ubiquitin ligase localized to multiple regions of the 
cardiomyocyte where it affects the function and stability of numerous proteins74, 76, 78-80.  MuRF1 
localized to the sarcomeric M-line polyubiquitinates and directs the proteasomal degradation of a 
number of proteins, including troponin I, βMHC, and MyBPC61, 63.  Cytoplasmic MuRF1 in 
cardiomyocytes interacts with the transcription factor c-Jun and specifically promotes the degradation 
of phospho-c-Jun upon ischemia/reperfusion injury74.  MuRF1 also localizes to the perinuclear region 
of the cardiomyocyte, where it interacts with RACK1 inhibiting the translocation of PKCε to focal 
adhesions following stimulation with GPCR agonists76.  In the nucleus, MuRF1 interacts with 
glucocorticoid modulatory element binding protein 1 (GMEB1), a nuclear transcriptional regulator78. 
  These studies illustrate MuRF1’s widespread effect on cardiomyocyte structure, gene 
expression, and signaling. Our laboratory has further conveyed MuRF1’s key role in the myocardium 
by showing that MuRF1 inhibits pathological cardiac hypertrophy induced by pressure-overload in 
vivo73.  Mechanistically, we established that MuRF1 achieves hypertrophy attenuation by binding to 
and inhibiting the transcription factor SRF, an inducer of pro-hypertrophic gene expression73.  In 
addition, we have found that MuRF1 loss in the mouse heart blocks hypertrophy regression following 
the reversal of transaortic constriction (TAC)—indicating that MuRF1 is required for induction of 
cardiac atrophy81.  Furthermore, increased expression of MuRF1 has been shown to inhibit growth 
and expression of pathological hypertrophy markers in response to PE, AngII, ET-1, and serum in 
                                                     
2As of this writing, this chapter appears as an Article in Press (published January 14, 2014) in American Journal 
of Physiology Endocrinology and Metabolism at the following website: 
http://ajpendo.physiology.org/content/early/2014/01/09/ajpendo.00326.2013 DOI:10.1152/ajpendo.00326.2013 
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NRVM76.  Together, these studies have identified MuRF1 as a key regulator limiting cardiomyocyte 
growth in response to pathologic stimuli. 
 We hypothesized that MuRF1 also inhibits physiological cardiac hypertrophy, which is a 
process mediated by IGF-1 signaling.  Physiological cardiac hypertrophy, such as that which occurs 
in an athlete’s heart in response to repetitive exercise, develops in response to IGF-1, a ligand 
synthesized and secreted by the liver in response to GH, that subsequently targets the cardiomyocyte3.  
IGF-1 binds to its RTK receptor (IGF-1R) on the surface of cardiomyocytes, leading to the activation 
of the PI3K/Akt signaling cascade2.  Akt is a serine/threonine kinase central to the kinase cascade 
activated by IGF-119.  Knockout of Akt inhibits cardiac hypertrophy in response to exercise20, 
illustrating Akt’s importance in promoting physiological hypertrophy. Conversely, acute cardiac-
specific transgenic expression of Akt has been shown to induce hypertrophy without dysfunction21. 
Together, these studies show that Akt expression itself, in addition to its activation by through IGF-1 
signaling, are imperative for the development physiological cardiac hypertrophy. 
 In this study, we examine the role of MuRF1 in physiological cardiomyocyte growth. We 
show that MuRF1 inhibits IGF-1-dependent growth in cardiomyocytes and limits the total protein 
expression of Akt, GSK3β, and mTOR. We go on to illustrate that the attenuation of IGF-1 signaling 
by MuRF1 requires c-Jun — where c-Jun activity is necessary for enhanced IGF-1 signaling observed 
when MuRF1 is knocked down. These data show for the first time that c-Jun can be regulated in an 
IGF-1-dependent manner in cardiomyocytes and provide new evidence supporting the role of c-Jun 
N-terminal kinase (JNK) signaling in cardiomyocyte growth and survival.  Importantly, we establish 
that MuRF1 limits this newfound activity of c-Jun. Finally, we go on to show that MuRF1 acts to 
limit cardiac hypertrophy induced by voluntary wheel running exercise in the mouse—indicating that 
MuRF1-dependent limitation of IGF-1 signaling is applicable in vivo. 
Materials and Methods 
 Cell culture, adenovirus transduction, and IGF-1 treatment. HL-1 cells, a continuously 
proliferating cardiomyocyte cell line derived from atrial tumors, were maintained as previously 
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published82, 83.  Before culturing cells, tissue culture vessels were coated with a mixture of 0.02% 
gelatin (w/v)/0.5% fibronectin (v/v) for at least 30 minutes.  HL-1 cells were trypsinized using 0.05% 
trypsin with EDTA, seeded on the gelatin/fibronectin-coated dishes at a dilution between 1:5 to 1:2, 
and allowed to adhere overnight in Claycomb media (Sigma-Aldrich, St. Louis, MO) supplemented 
with 10% fetal bovine serum, 1% penicillin/streptomycin, 1% norepinephrine, and 1% L-glutamine.  
After culturing for at least 24 hours, media was changed to serum-free Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 1% penicillin/streptomycin and HL-1 cells were treated with 
adenovirus at the multiplicity of infections (MOIs) and for the times indicated.  Transient knock-
down of MuRF1 was achieved using recombinant adenoviruses expressing scrambled shRNA control 
(Adshscrambled) or shRNA-MuRF1 custom made by Vector Biolabs (Philadelphia, PA).  shRNA 
sense sequence used for MuRF1 knockdown was GATCC-GCTCTGATCCTCCAGTACA-
TTCAAGAGATGTACTGGAGGATCAGAGC-TTTTTTAGATCTA.  Increased MuRF1 expression 
was achieved using previously described adenoviruses expressing GFP or myc-tagged 
MuRF1/bicistronic GFP61.  Following adenovirus transduction, cells were treated with IGF-1 
(suspended in PBS) which was then added to serum-free DMEM at a final concentration of 10 nM. 
 Isolation and culturing of NRVM. NRVM were isolated using the Worthington Neonatal 
Cardiomyocyte Isolation System (Worthington Biochemical Corporation, Lakewood, NJ) according 
to manufacturer’s protocol.  Briefly, dissected hearts were minced and digested using the provided 
trypsin solution overnight at 4°C.  The next day, the digested tissue was oxygenated and warmed to 
30°C, at which time trypsin inhibitor was added and incubated for 5 min.  Cells were released using a 
standard plastic sterological pipette and triturate supernatant was filtered through the cell strainer 
provided.  The filter was then washed twice with L15 media containing collagenase (provided), where 
filtrate was collected in the same tube as strained cells.  Collagenase digestion was allowed to occur 
for 20 minutes at RT, after which cells were collected by centrifugation.  Cardiomyocytes were 
reconstituted in Medium 199 (M199) supplemented with 15% FBS and 0.5% penicillin/streptomycin 
and seeded on 6-well dishes, coated with 40µg/mL fibronectin, at a concentration of 5x10^5 cells per 
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well.  Cells were cultured for 48 hours, after which media was changed to M199 without serum.  
After 24 hours starvation, increased MuRF1 expression was achieved using previously described 
adenoviruses expressing GFP or myc-tagged MuRF1/bicistronic GFP61 in serum-free M199.  
Following adenovirus transduction, cells were treated with 10nM IGF-1 in PBS in serum-free M199. 
 JNK Inhibitor treatment.  HL-1 cardiomyocytes were treated with the JNK inhibitor 
SP600125 as described previously74.  Briefly, cardiomyocytes were transduced with adenovirus, 
treated with SP600125 for 30 minutes, then challenged with IGF-1. At the concentration and the 
times indicated, SP600125 did not elicit any visible cell death or changes in cell density.   
 Fluorescence microscopy.  HL-1 cells were cultured on optically active flexible membrane 
6-well culture plates (Flexcell International, Hillsborough, NC) coated with gelatin/fibronectin.  
Following transduction with GFP-expressing adenovirus and IGF-1 stimulation, cells were fixed in 
4% formaldehyde in PBS, membranes cut into 1 x 1 cm sections, and mounted onto glass slides with 
media containing DAPI.  Fluorescent imaging was carried out using a Leica DMIRB Inverted 
fluorescence microscope (Leica Microsystems, Buffalo Grove, IL) and a Hamamatsu Orca ER 
camera (Bridgewater, NJ) with a 40X objective lens.  Pixel/mm scale was set in ImageJ using an 
image of a 1mm graticule taken with the Hamamatsu Orca ER camera under the 40X objective lens of 
the Leica DMIRB Inverted fluorescence microscope.  Cardiomyocyte area was determined using 
Image J software, in which a minimum of 200 cells in replicate wells in each experimental group 
were measured. 
 RT-PCR determination of mRNA expression. Total RNA was isolated from cells using 
the RNeasy kit according to the manufacturer’s protocols (Qiagen Valencia, CA).  cDNA was made 
using the High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA).  One µl of cDNA 
product was then amplified on an ABI Prism 7500 Sequence Detection System in 12 µl final volume 
using the TaqMan® Universal PCR Master Mix.  The PCR reaction mix included 0.6 µl of mouse 
specific Taqman® probes (Applied Biosystems) for MuRF1 (Mm01185221_m1), RYR1 
(Mm01175211_m1), Igfbp5 (Mm00516037_m1), and MAPK13 (Mm00442488_m1).  18S 
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(Hs99999901_s1) was used as a reference gene.  Raw CT values were analyzed using the ΔΔCt 
method, where CT values were first normalized to 18S and then normalized to either vehicle control 
(RYR1, Igfbp5, and MAPK13) or adenovirus control (MuRF1).  Fold change values (calculated by 
the formula 2(-ΔΔCT)) were used as final expression data. 
 Antibodies and Immunoblot.  Cells were lysed in the presence of 2x protease inhibitor 
cocktail Roche Applied Science, Indianapolis, IN), 1x phosphatase inhibitor cocktail Roche Applied 
Science), and 0.2M glycerol-2-phosphate Sigma-Aldrich) and stored at -80C.  Fifteen to twenty-five 
µg of protein was resolved on either 4-12% or 10% NuPAGE® gels (Life Technologies, Carlsbad, 
CA), transferred to Immobilon®-PVDF membrane (Millipore, Billerica, MA), blocked in 2% ECL-
blocking reagent (GE Healthcare Amersham™, Buckinghamshire, UK) in 1x TBST for 30 minutes, 
and incubated with primary antibody overnight at 4ºC.  After washing, HRP-linked secondary 
antibody was added to the PVDF membranes for 1 hour at RT.  Signal was detected using ECL 
Prime, GE Healthcare Amersham™) and final immunoblot results were acquired using hyperfilm 
(GE Healthcare Amersham™).  Densitometry analysis was performed using Quantity One 1-D 
Analysis Software (BioRad, Hercules, CA).  Antibodies recognizing Akt, p-Akt (S473 and T308) 
(Catalog #9272, 9271, and 9275, respectively, 1:1000) and c-Jun, pc-Jun (S63, S73, and T91) were 
obtained from Cell Signaling Technology, Inc. (Catalog #9165, 9261S, 9164S, and 2303S, 
respectively, at 1:500).  Antibodies recognizing GSK3α/β and pGSK3β (S9) (Catalog #44-610 and 
44-600G, Invitrogen, Inc., Camarillo, CA) were used at 1:4000 and 1:1000 dilutions, respectively. 
Anti-MuRF1 was purchased from R&D Systems, Inc. (Catalog #AF5366, 1:250 dilution, 
Minneapolis, MN) and anti-β-actin was purchased from Sigma-Aldrich (Catalog #A5441, 1:4000). 
 Animals. MuRF1-/- mice (129S/C57BL6) and α-MHC–MuRF1 (cardiac-specific) 
transgenic mice (DBA/C57BL6) ages 8-16 weeks were used as described68, 73.  After 5 weeks of 
monitored wheel running exercise (or sham exercise), mice were euthanized, hearts flash frozen and 
stored at -80ºC or perfusion fixed in 4% paraformaldehyde.  All animal studies were approved by the 
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institutional care and use committee (IACUC) for animal research at the University of North Carolina 
at Chapel Hill. 
 Unloaded voluntary wheel running and conscious echocardiographic analysis.  Female 
mice were assigned to either unloaded (no-resistance) wheel running or sedentary control groups as 
previously described84.  Mice were randomly assigned to running or sham control groups and 
monitored in parallel by echocardiography on conscious mice using a Visual Sonics Vevo 770 and 
2100 ultrasound biomicroscopy system at baseline, 2 weeks, and 5 weeks, as described previously68, 
81.   
 Histology and cross-sectional cardiomyocyte area analysis.  Fixed cardiac tissue was 
processed for paraffin-embedding, sectioned, and stained with standard hematoxylin and eosin 
(H&E).  H&E-stained slides were scanned using an Aperio Scanscope and exported using Aperio 
Imagescope software (Aperio Technologies, Vista, CA).  Paraffin-embedded cardiac sections were 
stained with a TRITC-labeled lectin as previously described73 and cardiomyocyte cross-sectional area 
was measured using Image J software.  A minimum of 15 random fields at 200X magnification in the 
left ventricle were imaged via fluorescent microscopy from at least 3 different hearts. 
 Measurement of exercise statistics.  Exercise wheel use was measured using a Mity 8 
Cyclocomputer (model CC-MT400), recording running time, average speed, and distance.  Running 
statistics were recorded daily. 
 RNA isolation and RT-PCR determination of mRNA expression from heart tissue. 
Whole heart tissue was homogenized in RLT Plus Lysis buffer, containing β-mercaptoethanol at a 
1:100 dilution, from Qiagen’s RNeasy Kit (Valencia, CA).  Total RNA was isolated from whole heart 
lysate using the RNeasy kit according to the manufacturer’s protocols.  cDNA was made using High 
Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA).  One µl of cDNA product was 
then amplified on an ABI Prism 7500 Sequence Detection System in 12 µl final volume using the 
TaqMan® Universal PCR Master Mix.  The PCR reaction mix included 0.6 µl of mouse specific 
Taqman® probes (Applied Biosystems) for either BNP (Mm00435304_g1), ANF 
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(Mm01255747_g1), skeletal muscle actin (Mm00808218_g1), Tbp (Mm00446971_m1), or Hprt 
(Mm01545399_m1).  Raw CT values were analyzed according to the ΔCt method using multiple 
reference genes (Tbp and Hprt).  ΔCt values for each gene were calculated by normalizing to the 
average CT value over all experimental groups.  Reference gene correction factors for each animal 
were calculated by taking the geometric mean of Tbp and Hprt ΔCt values for that animal.  Final 
expression data for each target gene was calculated by dividing the ΔCt value by the reference gene 
correction factor.  Expression data for BNP, ANF, and skeletal muscle actin were averaged over three 
animals per experimental group. 
 Statistics.  All statistical analysis was performed using Sigma Plot software (Systat 
Software, Inc., Chicago, IL).  A two-way ANOVA test was used to determine the source of variation 
when data included two independent variables.  For in vivo studies, the two variables were defined as 
genotype and exercise assignment group (sedentary or running).  For in vitro studies, the two 
variables were defined as adenovirus and treatment.  Interactions between the two variables were 
reported when significant (p<0.05) and the F-statistic (regression variable from the dependent 
variable mean/residual regression variation) and degrees of freedom (DF) were reported.  Differences 
between specific groups were determined using a multiple comparison post-test via the Holm-Sidak 
method using the all-pairwise procedure.  Significance level for all statistical analysis was set at 
p<0.05.  For experiments using JNK inhibitor pre-treatment, a three-way ANOVA test was used to 
determine the source of variation because three independent variables (adenovirus, pre-treatment, and 
treatment) were identified.  Interactions between all three variables, as well as pairwise interactions 
between variables, were reported when significant.  When appropriate, the results of a Student’s t-test 
was performed to express differences between groups within one variable.  
 For in vitro cardiomyocyte area experiments, n-values were defined as the total number of 
measured cells from at least two separate slides from three independent wells where at least 200 
cardiomyocytes in total were measured per treatment group. For in vitro RT-PCR experiments, n-
values were defined as expression data for each gene within each treatment group from three 
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independent experiments. For in vitro immunoblot experiments, each treatment group is represented 
in three lanes, each lane from one independent experiment and n=1 was defined as one lane.  For in 
vivo cardiomyocyte area experiments, n-values were defined as the total number of measured cells 
from separate 200X images, at least 2 slides per animal, where there were three animals per 
experimental group.  A minimum of 180 cardiomyocytes in total over all three animals per 
experimental group were measured.  For in vivo RT-PCR experiments, n-values were defined as 
expression data for three separate animals per each treatment group.  Significance level for all 
statistical analysis was set at p<0.05. 
Results 
 MuRF1 inhibits IGF-1-dependent cardiomyocyte hypertrophy by its effects on Akt 
signaling in vitro. To determine MuRF1’s role in IGF-1 induced cardiomyocyte growth, HL-1 
cardiomyocytes were transduced with a GFP-adenovirus expressing scrambled shRNA 
(Adshscrambled) or shRNA specific for MuRF1 (AdshMuRF1) and challenged with IGF-1 (Figure 
3A).  Analysis of cellular surface area after IGF-1 challenge revealed that decreasing MuRF1 
(AdshMuRF1) enhances cell growth compared to vehicle-treated controls cells (49.6% vs. 30.1%) 
(Figure 3B).  In addition, there was a significant interaction between the adenovirus and treatment 
variables (F=3.879, DF=1), providing evidence that knockdown of MuRF1 (AdshMuRF1) and IGF-1 
is required for this enhanced growth (Figure 3A).  Conversely, increasing MuRF1 inhibits IGF-1 
cardiomyocyte hypertrophy (Figure 3C).  Compared to IGF-1-treated vehicle-treated cells (areas of 
which increased with IGF-1), IGF-1 stimulation did not result in significant growth in 
cardiomyocytes when MuRF1 expression was increased (AdMuRF1) (Figure 3D).  In the same 
manner as HL-1 cardiomyocytes, we identified that increasing MuRF1 in NRVMs also completely 
inhibited IGF-1-dependent cardiomyocyte growth (Figure 3E), where statistical analysis showed that 
there was a significant interaction between variables (F=4.152, DF=1) (Figure 3F).  Taken together, 
these studies illustrate MuRF1-dependent inhibition of IGF-1-dependent growth in both cardiac-
derived cells and primary cardiomyocytes in vitro. 
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 Since Akt is central in IGF-1 signal transduction in vivo, we investigated MuRF1’s 
regulation of Akt-associated regulated genes by qRT-PCR analysis.  Mitogen activated kinase 13 
(MAPK13), ryanodine receptor 1 (RYR1), and the insulin-like growth factor binding protein-5 
(Igfbp5) mRNA levels were assayed (Figure 4) based on their differential expression in transgenic 
cardiac Akt mice at 14 days of age21.  After 18 hours of IGF-1 stimulation, a ~2 fold increase in 
MAPK13 and RYR1 expression was seen in HL-1 cells when MuRF1 expression was decreased 60% 
using AdshMuRF1 (Figure 4A).  Specifically, statistical analysis showed that enhanced RYR1 
expression required the interaction between MuRF1 knockdown (AdshMuRF1) and IGF-1 treatment 
(F=13.693, DF=1) (Figure 4A).  Conversely, increased MuRF1 expression resulted in decreased 
MAPK13 expression (40%) and complete inhibition of IGF-1-driven RYR1 expression in HL-1 cells 
(Figure 4B).  Furthermore, the combined effects of increased MuRF1 expression (AdMuRF1) and 
IGF-1 treatment led to significantly decreased Igfbp5 expression (F=5.576, DF=1) (Figure 4B). 
Together, these data support our proposed model that MuRF1 regulates IGF-1-dependent 
cardiomyocyte growth by regulating Akt activity. 
 MuRF1 inhibits total Akt, GSK3β, and mTOR protein levels in IGF-1 induced 
cardiomyocyte hypertrophy.  Since the fully active form of Akt is dually phosphorylated at 
threonine-308 (T308) and serine-473 (S473) and phosphorylates downstream effector proteins2, we 
first investigated how MuRF1 regulates Akt phosphorylation (Figure 5 and 6). We found that 
increasing MuRF1 resulted in a significant decrease in total Akt protein levels in vehicle-and IGF-1-
treated cells, but not phosphorylated Akt (T308 and S473) (Figure 5A). Phosphorylation of Akt at 
T308 was also unaffected by increased MuRF1 expression (AdMuRF1) in the presence of IGF-1 in 
NRVM (Figure 6). While inhibition of phosphorylation of Akt at S473 in the presence of IGF-1 was 
observed with increased MuRF1 expression (F=14.887, DF=1) in NRVM (Figure 6), unchanged 
phosphorylation of Akt at T308 suggests that MuRF1’s primary role in inhibiting Akt activity is not 
via Akt’s phosphorylation.  Similar to the inhibition of total Akt protein expression by MuRF1, the 
total protein expression of GSK3β, an immediate downstream effector of Akt2, was significantly 
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decreased in vehicle-treated cells (Figure 4A).  Phosphorylation (at S9) of GSK3β was also inhibited, 
where a significant interaction between increased MuRF1 expression and IGF-1 treatment was 
observed (F=12.258, DF=1) (Figure 5A), showing that signaling downstream of Akt is limited by 
MuRF1.  Increased MuRF1 expression in NRVM was also required for inhibition of IGF-1-dependent 
phosphorylation of GSK3β at S9 (F=10.405, DF=1) (Figure 6), showing that MuRF1-dependent 
inhibition of Akt activity occurs both in cardiac-derived cells and primary cardiomyocytes. 
 We next investigated how decreasing MuRF1 affects total and phosphorylated Akt and 
GSK3β proteins in IGF-1 stimulated HL-1 cells. Surprisingly, we only identified a significant 
increase in p-Akt S473, where knockdown of MuRF1 was required for enhanced phosphorylation of 
Akt at S473 in the presence of IGF-1 (F=11.801, DF=1) (Figure 5B).  p-Akt-T308 remained 
unchanged with MuRF1 knockdown in HL-1 cardiomyocytes stimulated with IGF-1 (Figure 5B), 
suggesting that the enhanced IGF-1-induced cardiomyocyte growth was not due to differences in the 
fully phosphorylated (active) form of Akt. Changes in only the S473-phosphorylated form of Akt in 
the presence of IGF-1, led us to hypothesize that the total protein expression of mTOR was being 
altered when MuRF1 is decreased, since mTOR complex 2 (mTORC2) phosphorylates Akt at S47319.  
Furthermore, inhibition of mTOR phosphorylation by increasing MuRF1 expression under basal 
conditions has been shown to occur in cardiomyocytes85.  We found that IGF-1 treatment increased 
total protein levels of mTOR only in the presence of decreased MuRF1 (AdshMuRF1) (F=5.922, 
DF=1) (Figure 7).  Interestingly, while MuRF1 knockdown induced increased mTOR 
phosphorylation at S2481 in vehicle-treated cardiomyocytes, IGF-1 treatment induced p-mTOR to be 
significantly decreased (F=21.990, DF=1) with the concomitant increase in total mTOR (Figure 7).  
Since phosphorylated mTOR is part of mTOR complex 1 (mTORC1)19, these data suggest that 
MuRF1 inhibits mTORC1 basally, consistent with recently published reports85, but that IGF-1 
treatment may shift MuRF1’s inhibitory activity of mTOR from mTORC1 to mTORC2.  Finally, 
immunoblot analysis of GSK3β showed that decreasing MuRF1 expression increased total protein 
expression of GSK3β in vehicle-treated cardiomyocytes, but neither GSK3β nor p-GSK3β S9 were 
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different between AdshMuRF1 and its control after IGF-1 stimulation (Figure 5B). Together, our 
protein expression findings suggest that increasing MuRF1 expression may be inhibiting IGF-1 
growth by its effects on total Akt and GSK3β , while MuRF1 knockdown releases this inhibition of 
IGF-1 signaling by promoting total protein expression of mTOR, and by extension, mTORC2.   
 MuRF1 inhibits c-Jun protein expression and phosphorylation in the presence of IGF-
1.  Recent studies have implicated that the sirtuin SIRT6 inhibits IGF-1-Akt signaling and the 
development of cardiac hypertrophy by targeting c-Jun22.  The authors of this study show that c-Jun 
promotes the mRNA expression of numerous proteins involved in IGF-1 signaling, including Akt, 
GSK3β, and mTOR; therefore, they demonstrated that inhibition of c-Jun by SIRT6 inhibited the 
expression of key components of IGF-1 signaling22.  We have recently discovered that c-Jun is a 
MuRF1 substrate74.  In these previous studies, we identified that MuRF1 inhibited ischemia-
reperfusion induced cell death (apoptosis) by preventing JNK signaling. MuRF1 preferentially 
recognized phospho-c-Jun, it was able to bind activated c-Jun, direct its polyubiquitination, which 
then was recognized by the 26S proteasome and degraded74.  This known MuRF1-dependent 
degradation of phospho-c-Jun led to our investigation the role of c-Jun in IGF-1 signaling in 
cardiomyocytes in the current study. 
 We first identified that MuRF1 inhibits total and phosphorylated c-Jun (p-S63-c-Jun and p-
S73-c-Jun) expression levels in IGF-1 stimulated HL-1 cells (Figure 8A).  These data are consistent 
with MuRF1’s inhibition Akt, GSK3β, and mTOR expression after IGF-1 stimulation (Figures 5-7) 
since c-Jun promotes the expression of the genes that code for all three of these proteins.  Similarly, 
increasing MuRF1 in NRVM resulted in a decrease in phosphorylated c-Jun (S63, S73, and T91) in 
vehicle-treated cardiomyocytes and p-T91-c-Jun specifically in the presence of IGF-1 (Figure 9).  
Conversely, when MuRF1 was decreased in HL-1 cardiomyocytes total c-Jun expression was 
significantly increased in the presence of IGF-1 (Figure 8B).  This is consistent with MuRF1’s ability 
to bind and poly-ubiquitinate c-Jun, targeting c-Jun it for proteasome-dependent degradation74.  Since 
c-Jun is a transcription factor that drives expression of Akt, GSK3β, and mTOR22, our observation 
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that Akt, GSK3β and mTOR total protein levels are inhibited by MuRF1 is suggest that MuRF1-
dependent limitation of c-Jun in IGF-1-stimulated cardiomyocytes is the mechanism by which 
MuRF1 inhibits IGF-1-dependent cardiomyocyte growth. 
 MuRF1-dependent regulation of IGF-1-dependent cardiomyocyte growth is JNK-
dependent.  To further support our the hypothesis that MuRF1 inhibits IGF-1 signaling in a c-Jun-
dependent manner, we next determined if inhibiting JNK, a kinase well-known to phosphorylate and 
activate c-Jun86, blocks MuRF1’s ability to inhibit IGF-1-induced cardiomyocyte growth (Figure 10).  
First, we identified that the JNK inhibitor SP600125 was able to prevent the exaggerated 
cardiomyocyte hypertrophy stimulated by IGF-1 that is observed when MuRF1 is transiently knocked 
down (Figure 10).  Importantly, JNK inhibitor treatment only acted to limit IGF-1-dependent growth 
(decreasing area by 27.1%) in cardiomyocytes with decreased MuRF1 (AdshMuRF1), having no 
effect on the IGF-1-dependent growth on control cells (Adshscrambled) (Figure 10).  In addition, 
decreased MuRF1 expression (AdshMuRF1), JNK inhibitor pre-treatment, and IGF-1 treatment 
together were required to produce these results (F=11.146, DF=1) (Figure 10). Consistent with these 
data, MAPK13 expression was inhibited in cardiomyocytes treated with JNK inhibitor only in cells 
with decreased MuRF1 (AdshMuRF1) (Figure 11).  Furthermore, IGF-1-dependent enhancement of 
RYR1 by knockdown of MuRF1 was lost with JNK inhibition (Figure 11), abrogating AdshMuRF1’s 
augmentation of RYR1 expression seen in Figure 4.  Together, these data illustrate that MuRF1’s 
regulation of IGF-1induced growth and Akt-specific gene expression are dependent on JNK 
signaling. Overall, these data illustrate a role for MuRF1 in regulating IGF-1-induced cardiac 
hypertrophy through its regulation of JNK/c-Jun activity.  In the context with our previous studies 
that show that MuRF1 inhibits JNK signaling by directly interacting and ubiquitinating cardiac c-Jun 
to target it for proteasome-dependent degradation74, the present data illustrates a role for this 
mechanism in IGF-1-induced cardiac hypertrophy as well. 
 MuRF1 inhibits exercise-induced cardiac hypertrophy in vivo. Since MuRF1 inhibits 
IGF-1 signaling in both cardiac-derived and primary cardiomyocytes in vitro, we next determined if 
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MuRF1 similarly inhibits IGF-1 signaling in vivo. The development of physiological cardiac 
hypertrophy in response to regular exercise occurs through IGF-1 signaling2.  So we next challenged 
MuRF1-/- and MuRF1 Tg+ mice and their sibling-matched wildtype controls to voluntary unloaded 
wheel running for 5 weeks to understand the role of MuRF1-dependent inhibition of IGF-1 signaling 
in vivo.  Echocardiographic analysis performed at baseline and 5 weeks of voluntary running revealed 
that MuRF1 -/- hearts exhibited significant increases in LV anterior and posterior wall thickness and 
LV mass compared to wildtype control and sham animals (Table 1, Figure 12A-B).  Indicators of 
systolic function (EF% and FS%) did not change over the course of the experiment (Table 1).  
Consistent with an exaggerated cardiac hypertrophy, MuRF1-/- hearts exhibited a significant increase 
in LV mass/tibia length and cardiomyocyte cross-sectional area (Figure 12C-D). In contrast, the 
anterior and posterior wall thickness of MuRF1 Tg+ hearts did not increase in size, by 
echocardiographic analysis of wall thickness, after 5 weeks of voluntary running compared to 
matched wildtype control hearts (Table 2, Figure 13A-B).  In addition, MuRF1 Tg+ cardiomyocyte 
cross-sectional areas exhibiting significantly less cardiomyocyte hypertrophy compared to wildtype 
controls (Figure 13C-D).  These echocardiographic and histological analyses illustrate MuRF1’s 
negative regulation of physiological hypertrophy after 5 weeks of voluntary running at the level of the 
whole heart and cardiomyocyte. 
 To further analyze the type of cardiac hypertrophy the MuRF1-/- and MuRF1 Tg+ hearts 
were undergoing, we quantified the expression of genes up-regulated in cardiac pathological 
hypertrophy.  Brain natriuretic peptide (BNP), atrial natriuretic peptide (ANF), and smooth muscle 
actin (SM actin) were unchanged by qRT-PCR in cardiac tissue from sham and running mice. Neither 
MuRF1-/- nor MuRF1 Tg+ hearts demonstrated significant increases in gene expression after running 
(Figure 12E and 13E, respectively).  No inflammatory or fibrotic remodeling was identified by 
histological analysis of MuRF1-/- or MuRF1 Tg+ hearts (Figure 14A, 14B, respectively).  Both the 
lack of pathological cardiac hypertrophy makers and the absence of any histological pathology 
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illustrate that both MuRF1 -/and MuRF1 Tg+ hearts respond to voluntary running by undergoing 
physiological hypertrophy, a process driven by IGF-1 mediated cell signaling in vivo. 
 Daily analysis of the running time, average speed, and total distance was collected for each 
of the groups.  Interestingly, both the MuRF1 -/and MuRF1 Tg+ mice ran the same amount of time as 
did their strain-matched controls (Tables 3 and 4, respectively).  Interestingly, the MuRF1-/- mice 
ran significantly farther than their matched control wildtype littermates for the entire 5-week duration 
of the study (Table 3).  Consistent with these findings, MuRF1-/- mice ran farther for the entire 5-
week duration of the study (Table 3).  In contrast, MuRF1 Tg+ mice ran the same speed and distance 
compared to their wild type controls.  Together, these data suggest that absence of MuRF1 enhances 
the function of the cardiovascular system due effects on cardiac and/or skeletal muscle (Table 4).  
Since MuRF1 Tg+ mice, where MuRF1 is specifically expressed in the heart, were not exercise 
inhibited, these studies suggest that skeletal muscle may be, in part, responsible for our finding that 
global MuRF1-/- mice have enhanced exercise performance. 
Discussion 
 Increases in cardiac workload induce the mammalian heart to grow by a process called 
cardiac hypertrophy, that can be induced by either pathological or physiological stimulation.  The 
ability of the muscle-specific ubiquitin ligase MuRF1 to inhibit pathological cardiac hypertrophy has 
been shown73, 76.  Growth of primary NRVM with PE, AngII, ET-1, or NE (activators of signaling 
pathways which drive pathological hypertrophic remodeling), has been reported to be inhibited by 
MuRF1 by virtue of MuRF1-dependent inhibition of PKCε76.  In vivo, TAC, a method used to mimic 
the pressure overload observed during chronic hypertension, of MuRF1-/- mice resulted in 
exaggerated cardiac hypertrophy73.  Furthermore, increased activity of the transcription factor SRF, 
was observed with increased MuRF1 expression in cardiomyocytes, showing that MuRF1 inhibition 
of SRF contributes to MuRF1’s effect on cardiac growth following TAC73.  We have recently 
reported that MuRF1 and MuRF2 are functionally redundant in regulating developmental cardiac 
hypertrophy by regulating E2F1-mediated gene expression75.  These reports establish MuRF1’s 
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widespread inhibitory effect on pathological myocardial growth signaling on the level of both protein 
kinases (PKCε) and transcription factors (SRF).  Due to this broad activity of MuRF1 in limiting 
these signal transduction cascades, we posited that MuRF1 would also inhibit the signal transduction 
cascades distinctly activated by physiologic cardiac stimuli. 
 Cardiomyocyte growth induced by physiologic stimuli, such as repetitive exercise and 
pregnancy, is beneficial because the changes in size and strength, enhanced vascular perfusion, and 
metabolism associated with cardiac hypertrophy occur without the adverse long term effects seen in 
pathologic hypertrophy5.  Physiological stimuli trigger the release of GH that subsequently induces 
the production of IGF-1 in the liver.  At the molecular level, elevated circulating GH and IGF-1 drive 
physiological cardiac hypertrophy87.  Considerable effort has been made to delineate pro-hypertrophic 
IGF-1 signaling pathways in the myocardium.  Circulating IGF-1 is the main source of IGF-1 for the 
cardiomyocyte.  While it has been shown that cardiomyocytes themselves transiently release IGF-1 in 
response to exercise, this pool of IGF-1 contributes to the hypertrophy effect at a much lesser extent 
than circulating IGF-114-16.  At the cardiomyocyte plasma membrane, IGF-1 binds to and activates the 
IGF-1R and IR RTKs, which subsequently activate PI3K3.  PI3K catalyze the formation of PIP3, 
inducing PDK1 translocation to the plasma membrane.  The crucial step in IGF-1 signaling 
transduction is PDK1-dependent phosphorylation of Akt1, the main isoform of Akt in the heart (Akt2 
is also present, but to a lesser extent) at T30817, 18.  This hypophosphorylated form of Akt is fully 
activated by phosphorylation at S473 by mTORC219.  Akt promotes protein translation by 
phosphorylating and inhibiting GSK3β, an inhibitor of the translation elongation eIF2Bε15, 18, 25 and 
phosphorylating mTOR, promoting the formation of mTORC1 and subsequent mTORC1-dependent 
activation of ribosome biosynthesis and protein translation19. 
 In the present study, we detail, for the first time, the ability of MuRF1 to inhibit 
physiological cardiomyocyte hypertrophy by acting on a novel regulator of IGF-1 signaling, the 
transcription factor c-Jun.  We show that when MuRF1’s expression is knocked-down, cardiomyocyte 
hypertrophy is enhanced, while increases in MuRF1 inhibited cardiomyocyte hypertrophy (Figure 3). 
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To date, only a few endogenous molecular inhibitors of IGF-1 signaling in cardiomyocytes have been 
described: phosphatase and tensin homolog (PTEN), which acts as a phosphatase for PIP3 and Akt88, 
89 and FOXO3a, which activates transcription of genes involved in cardiac atrophy, including 
MuRF123; therefore inhibition of IGF-1 signaling by MuRF1 in the myocardium is a novel finding.  
We expanded on MuRF1’s role in inhibiting IGF-1-dependent hypertrophy by showing that MuRF1 
inhibits Akt-associated gene expression (Figure 4).  If MuRF1 acts at the level of Akt or higher in the 
signaling pathway, we expected that MuRF1 would limit Akt phosphorylation; however, our findings 
suggested that Akt phosphorylation was not the main method by which MuRF1 inhibited Akt activity 
(Figure 5 and 6), despite the observation that phosphorylation of GSK3β, a direct target of Akt, was 
inhibited by MuRF1 (Figure 5 and 6). These findings are consistent with the findings of Chen et 
al.85, who demonstrated that increased MuRF1 expression in adult mouse cardiomyocytes did not 
alter basal levels of phosphorylated Akt.  Instead, we observed that MuRF1 inhibited total Akt, 
GSK3β (Figure 5 and 6) and mTOR (Figure 7) expression in the presence of IGF-1.  In addition, 
IGF-1-dependent MuRF1 regulation of mTOR suggested that IGF-1 switches MuRF1-dependent 
inhibition from mTORC1 to mTORC2 (Figure 7). Together, MuRF1’s regulation of three 
independent proteins involved in the IGF-1 pathway indicated that MuRF1-dependent inhibition of 
IGF-1-dependent hypertrophy and signaling was independent of Akt activation and likely involved 
transcriptional regulation. 
 Since a recently published study identified Akt1, GSK3β, and mTOR in a number of cardiac 
genes the promoter regions of which are bound and activated by c-Jun22 we hypothesized that MuRF1 
achieves its limitation of Akt, GSK3β, and mTOR protein levels by inhibiting c-Jun in the presence of 
IGF-1. We were especially interested in c-Jun-dependent regulation of IGF-1 signaling since our 
laboratory recently identified MuRF1’s ability to inhibit JNK signaling through MuRF1’s direct 
interaction with, and degradation of, c-Jun74.  In that study, we showed that, in the context of ischemia 
reperfusion injury, increased c-Jun degradation (by MuRF1) resulted in the inhibition of I/R-induced 
cell death and cardiomyocyte dysfunction74.  In the present study, we found that increasing MuRF1 
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expression decreased total c-Jun levels when cardiomyocytes were stimulated with IGF-1; in parallel, 
MuRF1 reduced the amount of phosphorylated c-Jun present (S73 and T91) (Figure 8 and 9). 
Conversely, we found that total c-Jun protein levels were increased in the presence of IGF-1 when 
MuRF1 was knocked down (Figure 8B). Using a c-Jun N-terminal kinase (JNK) inhibitor, we then 
demonstrated that JNK (an activator of c-Jun) activity is required for the exaggerated IGF-1 mediated 
cardiomyocyte growth and Akt-associated gene expression observed when MuRF1 is knocked-down 
(Figure 10 and 11). Taken together, these studies suggest that MuRF1 limits IGF-1 cardiomyocyte 
hypertrophy and signaling, in part, by its inhibition of JNK signaling. This mechanism is likely 
through MuRF1dependent proteasome degradation of phosphor-c-Jun, newly identified as a 
transcription factor responsible for transcription of multiple genes in the myocardium involved in the 
IGF-1 pathway22.  c-Jun’s importance in MuRF1-dependent regulation of IGF-1 hypertrophy is not 
altogether surprising since IGF-1-induced JNK activation has previously been reported in 
cardiomyocytes90 and in the maintenance of cardiac hypertrophy91. 
 There are a growing number of ubiquitin ligases that regulate JNK signal transduction in 
multiple cells types by recognizing phosphorylated substrates92. These ubiquitin ligases include 
MEKK1 (NIH3T3 cells), FBw7 (neurons), DCXhDET1-hCOP1 (U2Os, HEK293T cells), and itch (T 
cells)93-99.  Interestingly, MEKK1, a MAPK3K in the JNK signaling pathways that phosphorylates 
MAP2K (one kinase that phosphorylates JNK), acts as an ubiquitin ligase that preferentially poly-
ubiquitinates phospho-c-Jun and target c-Jun for proteasomal degradation100-102.  Showing that poly-
ubiquitination of phospho-c-Jun specifically is induced by ubiquitin ligases other than MuRF1.  
While the mechanism by which MuRF1 regulates c-Jun to inhibit IGF-1-dependent cardiomyocyte 
growth is novel, given that ubiquitin ligase-dependent inhibition of JNK signaling is being identified 
in a growing number of cell types and disease processes, it is likely that the mechanism we describe 
here occurs more commonly than has been reported.  
 Exercise training induces the release of IGF-1 from the liver, leading to activation of IGF-1 
signaling in the myocardium and cardiac growth with limited adverse effects on cardiac function4.  In 
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an effort to understand MuRF1-dependent regulation of endogenous IGF-1 signaling in the 
myocardium in vivo, we submitted MuRF1-/- and MuRF1Tg+, and their littermate controls 
(MuRF1+/+ and WildtypeMuRF1Tg+, respectively) to voluntary wheel running exercise to increase 
circulating IGF-1 in these animals by natural means. We discovered that loss of MuRF1 (MuRF1-/-) 
caused exercise-induced cardiac hypertrophy to be exaggerated, without provoking pathological 
remodeling (Figure 12).  Conversely, exaggerated cardiac growth in response to exercise was lost in 
MuRF1 Tg+ animals and blunted on the level of cardiomyocyte-specific growth (Figure 13).  These 
data confirm that MuRF1-dependent regulation of IGF-1 signaling is applicable in whole animal 
models and provide additional evidence for the importance of the ubiquitin proteasome system (UPS) 
in the heart.   
 Our current study showing that MuRF1 regulates IGF-1 signaling in the myocardium in vivo 
is latest in the growing literature implicating the UPS in maintenance of cardiac function92, 103.  Mice 
lacking the ubiquitin ligase and protein chaperone carboxyl terminus of Hsp70-interacting protein 
(CHIP) exhibit an exaggerated cardiac hypertrophy in as little as 1 week and as much as 5 weeks of 
running, which parallels increases in increased phosphorylated Akt after IGF-1 stimulation in vitro84.  
While these studies suggest an inhibitory role of CHIP in Akt activation, Akt was not found to be a 
direct CHIP substrate103. The ubiquitin ligase MAFbx/Atrogin-1 has recently been found to regulate 
physiological cardiac hypertrophy induced by both IGF-1/GH injections and wheel running exercise.  
MAFbx/Atrogin-1 achieves this inhibition by ubiquitinating and activating of Forkhead proteins 
(FOXO1 and FOXO3a)52.  Interestingly, another recent study identified that aging MuRF1-/- mice 
exhibit a spontaneous cardiac hypertrophy, lacking observable pathological remodeling, after 6 
months of age, with parallel increases in phosphorylated Akt104.  The mechanism underlying these 
spontaneous changes in the MuRF1-/- mouse hearts remains unknown, but the mechanistic 
relationship between MuRF1 and Akt activation was implicated in that model104.  In contrast, we 
found that increased phosphorylated Akt was not evident over the transient knock-down periods used 
in the current study, we did observed increases in cardiac size in MuRF1-/- compared to MuRF1+/+ 
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in our sedentary controls (Figure 12) and incremental, spontaneous increases in cardiomyocyte size 
with transient MuRF1 knockdown in vitro (Figure 3); the latter indicating how closely the cultured 
cells parallel in vivo findings in this study.   
 Regulation of cardiac growth by MuRF1 has recently been identified to contribute to cardiac 
disease in humans.  Patients with hypertrophic cardiomyopathy were found to have 3 MuRF1 
variants, including two missense and one deletion, which produce MuRF1 protein with impaired 
sarcomeric localization and ability to auto-ubiquitinate and ubiquitinate multiple substrates85.  
Mechanistic studies showed that mTOR signaling is specifically altered in cardiomyocytes expressing 
these MuRF1 variants85—confirming that the effect we observed in IGF-1-dependent regulation of 
mTOR signaling by MuRF1 in this study.  Taken together, these emerging studies implicate the UPS 
and ubiquitin ligases, such as MuRF1, as critical regulators of IGF-1 signaling, with additional 
components likely to be found.  Our current study, as well as recently published reports, illustrate the 
importance of studying the mechanisms by which ubiquitin ligases limit pro-hypertrophic signaling in 
the heart, especially for development of therapies for hypertrophic cardiomyopathy and heart failure. 
Figure Legends 
 Figure 3. Knockdown of MuRF1 enhances and increased expression of MuRF1 
represses IGF-1-induced cardiomyocyte hypertrophy A. MuRF1 was knocked down using 
AdshMuRF1, with Adshscrambled as control, at MOI 60 for 24 hours in serum-free DMEM followed 
by treatment with 10nM IGF-1 for 18 hours. Cells were fixed and observed with a fluorescent 
microscope using a 40X objective lens. Shown are representative images of vehicle or IGF1-treated 
HL-1 cardiomyocytes transduced with either Adshscrambled or AdshMuRF1. B. Cardiomyocyte area 
(mm2) measurements of vehicle or IGF1-treated HL-1 cardiomyocytes transduced with either 
Adshscrambled or AdshMuRF1, averaged over at least 200 cardiomyocytes. Black bars represent 
vehicle and gray bars represent IGF-1-treated cells C. MuRF1 was increased in expression using 
AdMuRF1, with AdGFP as a control, at MOI 25 for 24 hours in serum-free DMEM followed by 
treatment with IGF-1 for 18 hours. Shown are representative fluorescent images of vehicle or IGF1-
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treated HL-1 cardiomyocytes transduced with either AdGFP or AdMuRF1. D. Cardiomyocyte area 
(mm2) measurements of vehicle or IGF1-treated HL-1 cardiomyocytes transduced with either AdGFP 
or AdMuRF1. Black bars represent vehicle-and gray bars represent IGF-1-treated cells. 
Cardiomyocyte area measurements are represented as mean area ± SEM. E. MuRF1 was increased in 
expression in NRVM using AdMuRF1, with AdGFP as a control, at MOI 25 for 24 hours in serum-
free M199 followed by treatment with IGF-1 for 18 hours. Shown are representative fluorescent 
images of vehicle or IGF1treated cardiomyocytes transduced with either AdGFP or AdMuRF1. F. 
Cardiomyocyte area (mm2) measurements of vehicle or IGF1-treated NRVM transduced with either 
AdGFP or AdMuRF1. Black bars represent vehicle-and gray bars represent IGF-1-treated cells. 
Cardiomyocyte area measurements are represented as mean area ± SEM. A two-way ANOVA test 
was used to determine statistical significance. *indicates significance on level of adenovirus group, 
**indicates significance on level of treatment group. %indicates a significant interaction between 
adenovirus and treatment groups. The F statistic and degrees of freedom (DF) were reported when 
dependence between groups was found to be a significant source of variation.  Significance between 
groups is represented as #P< 0.05, ##P< 0.001 as determined using a pairwise post-test. 
 Figure 4. IGF-1-dependent expression of genes associated with Akt activity is inhibited 
by MuRF1. A. AdshMuRF1 and control Adshscrambled were used at MOI 60 for 24 hours in serum-
free DMEM to knockdown MuRF1 in HL-1 cardiomyocytes and transduced cells were treated with 
10nM IGF-1 for 18 hours. RNA was isolated and cDNA generated for use in measuring expression of 
MuRF1, MAPK13, RYR1, Igfbp5, and 18S (reference gene). Shown are RTPCR data for each of 
these genes in vehicle or IGF-1-treated HL-1 cardiomyocytes transduced with either Adshscrambled 
or AdshMuRF1. B. AdMuRF1 and control AdGFP were used at MOI 25 for 24 hours in serum-free 
DMEM to increase MuRF1 and transduced cells were treated with 10nM IGF-1 for 18 hours. Shown 
are RT-PCR data for MuRF1, MAPK13, RYR1, and Igfbp5 in cardiomyocytes transduced with either 
AdGFP or AdMuRF1 and treated with either vehicle or IGF-1. Raw CT values from three 
independent experiments were normalized to their respective 18S values, averaged over experimental 
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group, and subsequently normalized to either to vehicle control (MAPK13, RYR1, and Igfbp5) or 
adenovirus control (MuRF1). Final data is represented as mean fold change ± SEM. A two-way 
ANOVA test was used to determine statistical significance. * indicates significance on level of 
adenovirus group. **indicates significance on level of treatment group. % indicates a significant 
interaction between adenovirus and treatment groups. The F statistic and degrees of freedom (DF) 
were reported when dependence between groups was found to be a significant source of variation. 
Significance between groups are represented as #P< 0.05, ##P< 0.001 as determined using a pairwise 
post-test.  $ indicates significance (p<0.05) between groups within the treatment group, as measured 
by a Student’s t-test. 
 Figure 5. MuRF1 inhibits protein expression of Akt and GSK3β in IGF-1 stimulated 
HL-1 cardiomyocytes. A. HL-1 cells were transduced with AdMuRF1 or control AdGFP at MOI 25 
for 24 hours in serum-free DMEM to increase MuRF1 expression, followed by treatment with 10nM 
IGF-1 for 30 minutes. Immunoblots using whole cell lysates from three independent experiments are 
shown for p-Akt S473, p-Akt T308, Akt, GSK3β, and p-GSK3β S9. Primary antibody against myc 
was used to assess adenovirus-dependent expression of myc-MuRF1 and immunoblot for MuRF1 was 
done to determine endogenous protein levels. β-actin was used as a loading control. Densitometry 
analysis of Akt, p-Akt S473, p-Akt T308, GSK3β, and p-GSK3β S9 are shown for vehicle or IGF-1-
treated cardiomyocytes transduced with either AdGFP or AdMuRF1. Total protein levels were 
normalized to β-actin and phospho-protein levels were normalized first to β-actin and then to total 
protein levels. B. HL-1 cardiomyocytes were transduced with either AdshMuRF1 or control 
Adshscrambled at MOI 30 for 48 hours in serum-free DMEM, followed by treatment with 10nM 
IGF-1 for 30 minutes. Akt and GSK3β expression and phosphorylation in whole cell lysates from 
three independent experiments was assessed by immunoblot using primary antibodies raised against 
total Akt or GSK3β and p-Akt S473, p-Akt T308, and p-GSK3β S9, as indicated. Primary antibody 
against MuRF1 was used to confirm knockdown. β-actin was used as a loading control. Densitometry 
analysis of Akt, p-Akt S473, p-Akt T308, GSK3β, and p-GSK3β S9 are shown for vehicle or IGF-1-
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treated cardiomyocytes transduced with either Adshscrambled or AdshMuRF1. Densitometry analysis 
is represented as means ± SEM. A two-way ANOVA test was used to determine statistical 
significance. * indicates significance on level of adenovirus group. ** indicates significance on level 
of treatment group. % indicates a significant interaction between adenovirus and treatment groups. 
The F statistic and degrees of freedom (DF) were reported when dependence between groups was 
found to be a significant source of variation. Significance between groups are represented as #P< 
0.05, ##P< 0.001 as determined using a pairwise post-test. 
 Figure 6. MuRF1 inhibits protein expression of Akt and GSK3β in IGF-1 stimulated 
NRVM. NRVM were transduced with AdMuRF1 or control AdGFP at MOI 25 for 24 hours in 
serum-free M199 to increase MuRF1 expression, followed by treatment with 10nM IGF-1 for 30 
minutes. Immunoblots using whole cell lysates from three independent experiments are shown for p-
Akt S473, p-Akt T308, Akt, GSK3β, and p-GSK3β S9. Primary antibody against myc was used to 
assess adenovirus-dependent expression of myc-MuRF1. β-actin was used as a loading control. 
Densitometry analysis of Akt, p-Akt S473, p-Akt T308, and p-GSK3β S9 are shown for vehicle or 
IGF-1-treated cardiomyocytes transduced with either AdGFP or AdMuRF1. Total protein levels were 
normalized to β-actin and phospho-protein levels were normalized first to β-actin and then to total 
protein levels.  Densitometry analysis is represented as means ± SEM. A two-way ANOVA test was 
used to determine statistical significance. * indicates significance on level of adenovirus group ** 
indicates significance on level of treatment group. % indicates a significant interaction between 
adenovirus and treatment groups. The F statistic and degrees of freedom (DF) were reported when 
dependence between groups was found to be a significant source of variation. Significance between 
groups are represented as #P< 0.05, ##P< 0.001 as determined using a pair-wise post-test. 
 Figure 7. MuRF1 knockdown in HL-1 cardiomyocytes induces total mTOR protein 
levels to increase upon IGF-1 stimulation.  HL-1 cardiomyocytes were transduced with either 
AdshMuRF1 or control Adshscrambled at MOI 30 for 48 hours in serum-free DMEM, followed by 
treatment with 10nM IGF-1 for 30 minutes. Total and phosphorylated (S2481) mTOR was measuring 
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by immunoblot of whole cell lysates from three independent experiments. β-actin was used as a 
loading control. Densitometry analysis of mTOR and p-mTOR S2481 are shown for vehicle or IGF-
1-treated cardiomyocytes transduced with either Adshscrambled or AdshMuRF1. Total protein levels 
were normalized to β-actin and phosphor-protein levels were normalized first to β-actin and then to 
total protein levels. Densitometry analysis is represented as means ± SEM. A two-way ANOVA test 
was used to determine statistical significance.  *indicates significance on level of adenovirus group. 
**indicates significance on level of treatment group. %indicates a significant interaction between 
adenovirus and treatment groups.  The F statistic and degrees of freedom (DF) were reported when 
dependence between groups was found to be a significant source of variation. Significance between 
groups are represented as #P< 0.05, ##P< 0.001 as determined using a pairwise post-test. 
 Figure 8. MuRF1 inhibits HL-1 cardiomyocyte c-Jun protein levels and 
phosphorylation in the presence of IGF-1. A. MuRF1 expression was increased in HL-1 cells using 
AdMuRF1 and control AdGFP at MOI 25 for 24 hours in serum-free DMEM followed by treatment 
with 10nM IGF-1 for 30 minutes. c-Jun expression and phosphorylation in whole cell lysates from 
three independent experiments was assessed by immunoblot using primary antibodies raised against 
total c-Jun, p-c-Jun S63, p-c-Jun S73, and p-c-Jun T91, as indicated. Primary antibody against myc 
was used to confirm adenovirus-dependent expression of myc-MuRF1. β-actin was used as a loading 
control. Densitometry analysis of c-Jun, p-c-Jun S63, p-c-Jun S73, and p-c-Jun T91 are shown for 
vehicle or IGF-1-treated cardiomyocytes transduced with either AdGFP or AdMuRF1. Total protein 
levels were normalized to β-actin and phospho-protein levels were normalized first to β-actin and 
then to total protein levels. B. AdshMuRF1 and control Adshscrambled were used at MOI 30 for 48 
hours in serum-free DMEM to knockdown MuRF1 in HL-1 cardiomyocytes followed by IGF-1 
treatment for 30 minutes. Immunoblot using whole cell lysates from three independent experiments 
are shown for c-Jun, p-c-Jun S63, p-c-Jun S73, and p-c-Jun T91. MuRF1 primary antibody was used 
to confirm knockdown. β-actin was used as a loading control. Densitometry analysis of c-Jun, p-c-Jun 
S63, p-c-Jun S73, and p-c-Jun T91 are shown for vehicle or IGF-1-treated cardiomyocytes transduced 
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with either Adshscrambled or AdshMuRF1. Total protein levels were normalized to β-actin and 
phospho-protein levels were normalized first to β-actin and then to total protein levels.  Densitometry 
analysis is represented as means ± SEM. A two-way ANOVA test was used to determine statistical 
significance. * indicates significance on level of adenovirus group ** indicates significance on level 
of treatment group. % indicates a significant interaction between adenovirus and treatment groups. 
The F statistic and degrees of freedom (DF) were reported when dependence between groups was 
found to be a significant source of variation. Significance between groups are represented as #P< 
0.05, ##P< 0.001 as determined using a pair-wise post-test. 
 Figure 9. MuRF1 inhibits NRVM c-Jun protein levels and phosphorylation in the 
presence of IGF-1. NRVM were transduced with AdMuRF1 or control AdGFP at MOI 25 for 24 
hours in serum-free M199 to increase MuRF1 expression, followed by treatment with 10nM IGF-1 
for 30 minutes. Immunoblots using whole cell lysates from three independent experiments are shown 
for c-Jun, p-c-Jun S63, p-c-Jun S73, and p-c-Jun T91. Primary antibody against myc was used to 
assess adenovirus-dependent expression of myc-MuRF1. β-actin was used as a loading control. 
Densitometry analysis of c-Jun, p-c-Jun S63, p-c-Jun S73, and p-c-Jun T91 are shown for vehicle or 
IGF-1-treated cardiomyocytes transduced with either AdGFP or AdMuRF1.  Densitometry analysis is 
represented as means ± SEM. A two-way ANOVA test was used to determine statistical significance. 
* indicates significance on level of adenovirus group ** indicates significance on level of treatment 
group. % indicates a significant interaction between adenovirus and treatment groups. The F statistic 
and degrees of freedom (DF) were reported when dependence between groups was found to be a 
significant source of variation. Significance between groups are represented as #P< 0.05, ##P< 0.001 
as determined using a pair-wise post-test. 
 Figure 10. Exaggerated IGF-1-dependent cardiomyocyte growth with MuRF1 
knockdown requires JNK activity A. MuRF1 was knocked down using AdshMuRF1, with 
Adshscrambled as control, at MOI 60 for 24 hours in serum-free DMEM followed by pre-treatment 
with 10µM SP600125 (JNK inhibitor) for 30 minutes.  Cardiomyocytes were subsequently treated 
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with 10nM IGF-1 for 18 hours. Cells were fixed and observed using with a fluorescent microscope 
using a 40X objective lens. Shown are representative images and quantification of cardiomyocyte 
area (mm2) averaged over at least 200 cells per group. Cardiomyocyte area measurements are 
represented as mean area ± SEM. A three-way ANOVA test was used to determine statistical 
significance. * indicates significance on level of adenovirus group ** indicates significance on level 
of pre-treatment group. % denotes significant interactions between either the adenovirus, pre-
treatment, or treatment groups, as indicated. %%% indicates a significant interaction between all 
three groups. The F statistic and degrees of freedom (DF) were reported when dependence between 
groups was found to be a significant source of variation. Significance between groups are represented 
as #P< 0.05, ##P< 0.001 as determined using a pairwise post-test. 
 Figure 11. Exaggerated IGF-1-dependent Akt-associated gene expression with MuRF1 
knockdown requires JNK activity.  AdshMuRF1 and control Adshscrambled were used at MOI 60 
for 24 hours in serum-free DMEM to knockdown MuRF1 in HL-1 cardiomyocytes. Transduced cells 
were pre-treated with 10µM SP600125 (JNK inhibitor) for 30 minutes, followed by treatment with 
10nM IGF-1 treatment for 18 hours. RNA was isolated and cDNA generated for use in measuring 
expression of MuRF1, MAPK13, RYR1, and 18S (reference gene). Raw CT values from three 
independent experiments were normalized to their respective 18S values, averaged over experimental 
group, and subsequently normalized to either vehicle control (MAPK13, RYR1, and Igfbp5) or 
adenovirus control (MuRF1). Final data is represented as mean fold change ± SEM. Shown are RT-
PCR data for each of these genes in cardiomyocytes transduced with either Adshscrambled or 
AdshMuRF1 and treated with vehicle or both JNK inhibitor and IGF-1.  A three-way ANOVA test 
was used to determine statistical significance. * indicates significance on level of adenovirus group ** 
indicates significance on level of pre-treatment group. % denotes significant interactions between 
either the adenovirus, pre-treatment, or treatment groups, as indicated. %%% indicates a significant 
interaction between all three groups. The F statistic and degrees of freedom (DF) were reported when 
39 
 
dependence between groups was found to be a significant source of variation. Significance between 
groups are represented as #P< 0.05, ##P< 0.001 as determined using a pairwise post-test.      
 Figure 12. MuRF1 regulates physiological cardiac hypertrophy induced by exercise 
training in MuRF1-/- mice. MuRF1-/- and sibling-matched wildtype control mice (MuRF1 +/+) 
were randomly assigned to either sedentary or running groups, where running groups were provided 
with an in-cage exercise wheel for 5 weeks and sedentary groups were not. Cardiac growth and 
function were measured by echocardiography. A. Representative M-mode images, containing at least 
10 waveforms, from echocardiography of sedentary and running MuRF1+/+ and MuRF1-/-. B. LV 
mass measurements, as measured by echocardiography, normalized to tibia length (TL) for 
MuRF1+/+ and MuRF1-/- mice assigned to either sedentary or running groups were also analyzed. C. 
Perfused and fixed paraffin-embedded heart sections from sedentary and running MuRF1-/- and wild 
type control mice were stained with Lectin-TRITC, imaged using fluorescent microscopy to visualize 
cardiomyocytes, and cross-sectional area analyzed from >180 cardiomyocytes from at least three 
animals per group. D. Histological analysis of hematoxylin and eosin (HE) was also performed. E. 
RNA was isolated from whole heart tissue from sedentary and running MuRF1+/+ and MuRF1-/-, 
cDNA generated, and BNP, ANF, skeletal muscle actin, TATA box-binding protein (Tbp), and 
hypoxanthine phosphoribosyltransferase (Hprt) expression determined, where both Tbp and Hprt 
were used as reference genes. Raw CT values were normalized to the average Ct value over all 
groups within each genotype pair to calculate ΔCT values. ΔCT values for each animal were then 
divided by their respective reference gene correction factor (geometric mean of Tbp and Hprt ΔCT 
values) to obtain final expression data for target genes (BNP, ANF, and skeletal muscle actin). Three 
animals (n=3) were used per group. A two-way ANOVA test was used to determine statistical 
significance. A two-way ANOVA test was used to determine statistical significance. * indicates 
significance on level of genotype group. ** indicates significance on level of exercise (sedentary or 
running) group. % indicates a significant interaction between genotype and exercise groups. The F 
statistic and degrees of freedom (DF) were reported when dependence between groups was found to 
40 
 
be a significant source of variation. Significance between groups are represented as #P< 0.05, ##P< 
0.001 as determined using a pair-wise post-test. 
 Figure 13. MuRF1 regulates physiological cardiac hypertrophy induced by exercise 
training in MuRF1Tg+ mice.  MuRF1 Tg+ and sibling-matched wildtype control mice 
(WildtypeMuRF1Tg+) were randomly assigned to either sedentary or running groups, where running 
groups were provided with an in-cage exercise wheel for 5 weeks and sedentary groups were not. 
Cardiac growth and function were measured by echocardiography.  A. Representative M-mode 
images, containing at least 10 waveforms, from echocardiography of sedentary and running MuRF1 
Tg+ and WildtypeMuRF1Tg+ B. LV mass measurements, as measured by echocardiography, normalized 
to TL for MuRF1 Tg+ and WildtypeMuRF1Tg+ mice assigned to either sedentary or running groups were 
also analyzed. C. Perfused and fix paraffin-embedded heart sections from sedentary and running 
MuRF1 Tg+ and WildtypeMuRF1Tg+ control mice were stained with Lectin-TRITC, imaged using 
fluorescent microscopy to visualize cardiomyocytes, and cross-sectional area analyzed from >180 
cardiomyocytes from at least three animals per and cross-sectional area analyzed from >180 
cardiomyocytes from at least three animals per group. D. Histological analysis of HE was also 
performed. E. RNA was isolated from whole heart tissue from sedentary and running 
WildtypeMuRF1Tg+ and MuRFTg+ mice cDNA generated and BNP, ANF, skeletal muscle actin, Tbp, 
and Hprt expression determined, where both Tbp and Hprt were used as reference genes (described 
above).      
 Figure 9. High power histological analysis of MuRF1-/-, MuRF1 Tg+, and sibling 
wildtype control hearts. Top: HE staining of representative cardiac sections from A. MuRF1-/- and 
B. MuRF1 Tg+ mice after 5 weeks sham or running challenge. Bottom: Masson's trichrome (MT) 
staining of representative cardiac sections from C. MuRF1-/- and D. MuRF1 Tg+ mice after 5 weeks 
sham or running challenge. 
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CHAPTER 3: MURF1 INHIBITS CARDIAC THYROID HORMONE SIGNALING BY 
LOCALIZING TRα to CAP350 
Introduction 
 TH plays a critical role in the homeostasis of the heart.  Biologically active T3 regulates 
most of the enzyme systems involved in Ca2+ and ion fluxes in the heart.  T3 regulates sarcoplasmic 
Ca2+ via by controlling the expression of SERCa2 and PLN105, 106.  In addition to regulating 
cardiomyocyte Ca2+, T3 modulates K+ availability by regulating voltage-gated K+ channels, affecting 
cardiomyocyte excitation at the plasma membrane107, 108.  At the tissue level, T3 maintains myocyte 
alignment, ventricular geometry109 and function110, the turnover of the extracellular matrix111, and the 
progression of heart failure112, 113.  T3 has also been implicated in restoration of heart function, 
reducing susceptibility to heart failure after infarction114 and converting pathological cardiac 
hypertrophy to physiological hypertrophy under certain conditions115, 116. 
 At the molecular level, T3 exerts its activity by binding to TRs, a group of NR transcription 
factors including TRα and TRβ117.  Activation of TRα or TRβ induces their dimerization with another 
NR, retinoid X receptor (RXR).  Together, the NR transcription factor complex binds to thyroid 
response elements (TREs) and regulate gene expression118.  The regulation of TRs by post-
translational modifications is just beginning to be elucidated.  Recent studies in kidney-derived 
HEK293T cells have demonstrated that SIRT1 deacetylates TRβ, inhibiting TRβ activity by 
promoting ubiquitin-dependent turnover of TRβ119.  Phosphorylation of TRβ by MAPK in CV-1 cells, 
inhibits TRβ activity by recruiting transcriptional co-repressors120, 121.  The small ubiquitin-like 
modifier (SUMO) has recently been reported to regulate TH-dependent gene regulation122; using the 
liver HepG2 cell line, it was shown that the SUMO ligase PIASxβ specifically SUMOylates TRα, 
while PIAS1, PIAS3 and PIASy all can SUMOylate TRβ122.  Poly-ubiquitination of the ligand
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binding domain has been reported for TRα in CV-1 cells, where T3 treatment induces TRα poly-
ubiquitination and subsequent TRα degradation by the proteasome123.  Degradation of the TRβ by the 
proteasome pathway has been reported in QBI-HEK 293A cells; however, no direct measurements of 
TRβ poly-ubiquitination were made in this study124.  While these studies show that TRs can be 
regulated by post-translational modifications, these modifications have not been reported in the heart. 
Especially absent are investigations of the molecular mechanisms by which cardiac ubiquitin ligases 
might regulate TRs and downstream TH activity. 
 In the present study, the cardiac ubiquitin ligase MuRF1 is identified as an inhibitor of T3-
induced physiological cardiac hypertrophy in vivo. We identified, for the first time, the role of mono-
ubiquitination in regulating TRα activity.  Specifically, we show that T3-dependent mono-
ubiquitination targets TRα to centrosome-associated protein 350 (CAP350), a protein that has 
recently been identified to interact with other NR transcription factors (including PPARs (α, β/δ, γ) 
and the liver X receptor (LXR)) in cancer cell lines125.  The present study confirms the expression of 
CAP350 in cardiomyocytes, which has only been alluded to by microarray results available on Gene 
Expression Omnibus (GEO), and establishes CAP350’s involvement in a novel mechanism by which 
non-canonical ubiquitination regulates TRα.  
Materials and Methods 
 Cell culture, adenovirus transduction, and T3 treatment. The cardiac-derived HL-1 cell 
line was maintained as previously described82, 83.  Briefly, cells were grown in Claycomb media 
(51800C, Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, 1% norepinephrine, and 1% L-glutamine on dishes coated with 0.02% gelatin 
(w/v)/0.5% fibronectin (v/v). COS-7 (CRL-1651™, ATCC®, Manassas, VA) cells were cultured 
according to the manufacturer’s protocols in DMEM-10 and 1% penicillin/streptomycin.  Control 
GFP (AdGFP) or myc-tagged MuRF1/bicistronic GFP (AdMuRF1) were transduced in both HL-1 
and COS-7 cells, as previously described61.  MuRF1 was transiently knocked down using the 
adenovirus shRNA-MuRF1 or control adenovirus expressing scrambled shRNA (Adshscrambled) 
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(Vector Biolabs, Inc., Philadelphia, PA) as previously described126. Following adenovirus 
transduction, either HL-1 or COS-7 cells were treated with 3,3’,5-triiodo-L-thyronine (T3) 
(Cat.#T2877, Sigma-Aldrich, Inc., St. Louis, MO) at a final concentration of 1µM in PBS in serum-
free DMEM supplemented with 1% penicillin/streptomycin. 
 Animals. MuRF1-/- mice and α-MHC–MuRF1 (cardiac-specific) transgenic mice and 
strain-matched wildtype mice (MuRF1+/+ and WildtypeMuRF1Tg+, respectively) ages 8-16 weeks were 
used as previously described68, 73.  Mice were randomly assigned to treatment with triiodothyronine 
(T3) or vehicle control groups (10-12 mice per group), followed by daily 1mg/kg T3 (dissolved in 
PBS) or PBS alone intraperitoneal injection for two weeks.  Conscious echocardiography analysis 
was performed at baseline, one week, and two weeks.  After two weeks of vehicle- or T3-treatment, 
mice were anesthetized to collect retro-orbital blood, then euthanized.  Hearts were flash frozen and 
stored at -80°C.  Blood was collected in Microtainer SST-Amber tubes (Cat.# 365978, BD 
Biosciences, San José, CA), allowed to clot at room temperature, centrifuged at 1,300xg; the 
remaining serum aliquoted and stored at -80°C. Randomly assigned mice were euthanized for cardiac 
fixation in 4% paraformaldehyde via perfusion for use in histological studies.  All animal studies 
were approved by the institutional care and use committee (IACUC) for animal research at the 
University of North Carolina at Chapel Hill. 
 Conscious echocardiographic analysis.  A Vevo 770 and 2100 ultrasound biomicroscopy 
system (FUJIFILM VisualSonics, Toronto, ON Canada) was used to perform echocardiography on 
conscious mice, at baseline, one week, and two weeks of T3 (or control) treatment, as previously 
described68, 81. 
 Histological determination of cardiomyocytes cross-sectional area. Fixed cardiac tissue 
was processed for paraffin-embedding, sectioned, and stained with standard HE or MT. Slides were 
scanned using an Aperio Scanscope (Aperio Technologies, Vista, CA) analyzed for fibrosis (MT 
stained), and images exported in Aperio Imagescope (Aperio Technologies). Cardiomyocyte cross- 
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sectional area was determined on MT-stained slides using ImageJ software on a minimum of 6 
random sections per image (100 X magnification) from three different hearts per group. 
 Analysis of T3 and T4 in serum. T3 and T4 measurements from serum was completed 
using the Luminex MAGPIX® system (EMD Millipore, Billerica MA) utilizing the MILLIPLEX® 
MAP magnetic bead-based Multi-Species Steroid/Thyroid Hormone assay (Cat# STTHMAG-21K) 
analyzed on the MAGPIX® Multiplexing instrument.  Serum from at least three animals per 
experimental group was used for the final analyte analysis. 
 Plasmid constructs and transfection protocols.  The pGL4 luciferase mammalian 
expression vector with the growth hormone (GH) thyroid response element (TRE) driving luciferase 
expression was used as described previously122.  The pcDNA™3.1 (V790-20, Life Technologies 
Invitrogen™, Carlsbad, CA).  The pcDNA™3.1 β-galactosidase vector was described previously74.  
Mouse TRα cDNA sequence was subcloned into the p3XFLAG®-CMV-14 expression vector 
(Cat.#E4901, Sigma-Aldrich, Inc.) at EcoRI and BamHI.  A pcDNA™3.1 (V790-20, Life 
Technologies Invitrogen™, Carlsbad, CA) expression vector containing DNA coding for 
hemagglutinin (HA)-ubiquitin, as described previously127.  Mutation strategies for the lysine to 
arginine (K to R) residue changes within specific TRα domains were devised by identifying all 
lysines within each domain (A/B, C, D, and E/F) and synthesizing DNA sequences replacing all 
lysine codons with arginine codons within a single domain with the remaining domains left intact (as 
shown in Figure 20).  The four DNA sequences (A/B K to R, C K to R, D K to R, and E/F K to R) 
were then subcloned into the p3xFLAG®-CMV-14 expression vector at its EcoRI and BamHI sites. 
 HL-1 cells were transfected with plasmids using Lipofectamine® LTX with PLUS™ 
(Cat.#15338030, Life Technologies, Inc., Grand Island, NY ) and transfection experiments in Cos-7 
cells were carried using the Lipofectamine®2000 reagent (Cat.#11668019, Life Technologies, Inc.), 
according to the manufacturer’s protocols.  Plasmid DNA and Lipofectamine® reagents for were 
diluted in OPTI-MEM® I Reduced Serum Medium (Cat.#31985070, Life Technologies, Inc.). DNA 
complexes were applied to cells (4 hours) and cells recovered overnight Claycomb Media 
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supplemented with 10% FBS, 1% pen/strep, 1% norepinephrine, and 1% L-glutamine (HL-1 cells) or 
DMEM-10 with 10% FBS and 1% pen/strep (Cos-7 cells).  When adenoviruses were used in 
conjunction with transfection, cells were then transduced with adenovirus and treated with T3 
(described above). 
 Isolation and culturing of NRVM.  NRVMs were isolated as previously described using a 
commercial kit according to the manufacturer’s protocols (Cat.#LK003300, Worthington 
Biochemical Corporation, Lakewood, NJ)126.  NRVMs were cultured in 6-well plates coated with 
40µg/mL fibronectin, at a concentration of 5x10^5 cells per well in Medium 199 (M199) 
supplemented with 15% FBS and 0.5% penicillin/streptomycin. After 48 hours, cells were placed in 
M199 media. Twenty four hours later, AdGFP or AdMuRF1 (described above) were added in M199 
media.  Following adenovirus transduction, cells were treated with T3 in PBS in serum-free M199 
(described above). 
 Fluorescent microscopy and cardiomyocyte size analysis.  Optically active flexible 
membrane 6-well culture plates (Flexcell International, Hillsborough, NC) were used to culture either 
HL-1 cells or NRVM, as described previously126.  Cells were transduced with AdGFP and AdMuRF1, 
treated with T3, fixed membranes were prepared to be mounted onto glass slides, as described 
previously126.  A Leica DMIRB inverted fluorescence microscope (Leica Microsystems, Buffalo 
Grove, IL) at 400X with a Hamamatsu Orca ER camera (Bridgewater, NJ) was used.  As previously 
described126, cell area was measured using ImageJ software.  At least 200 cells in replicate wells were 
analyzed in each experimental group. 
 Total RNA isolation from tissue and qPCR analysis of mRNA.  Ventricular tissues was 
homogenized using the TissueLyser LT (Cat.#85600, Qiagen, Valencia, CA), according to the 
manufacturer’s protocols.  Briefly, two 5mm stainless steel beads (69989, Qiagen, Inc.) were used to 
~5mg of apical ventricles were homogenized in 1mL of TRIzol® (Cat.#15596-026, Life 
Technologies Invitrogen™, Grand Island, NY).  Total RNA was isolated and purified from the 
homogenized tissue according to the manufacturer’s protocols.  cDNA was generated from 1µg RNA 
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using a High Capacity cDNA Archive kit (Cat.#4374967, Life Technologies Invitrogen™).  One µl of 
cDNA product was then amplified on a Lightcycler® 480 Sequence Detection System (Roche, 
Indianapolis, IN) in 10 µl final volume using the Lightcycler® 480 Probes Master Mix 
(Cat.#04707494001, Roche).  The PCR reaction mix included 0.5 µl of mouse-specific 20x Taqman® 
probes (Life Technologies Applied Biosystems®) for either BNP (Mm00435304_g1), ANF 
(Mm01255747_g1), skeletal muscle actin (Mm00808218_g1), monocarboxylate transporter 8 
(MCT8) (Mm01232724_m1), or monocarboxylate transporter 10 (MCT10) (Mm00661045_m1).  Tbp 
(Mm00446971_m1) was assayed as a reference gene.  The ΔΔCt method was used to analyze raw CT 
values. Final expression data for each target gene was calculated normalizing all groups to the sham 
wildtype group.  Expression data for BNP, ANF, skeletal muscle actin, MCT8, and MCT10 were 
averaged over three animals per experimental group. 
 TRE luciferase assay. Cos-7 cells were co-transfected with plasmids expressing β-
galactosidase, growth hormone (GH) thyroid response element (TRE) luciferase reporter, and either 
empty p3XFLAG®-CMV-14 or FLAG-TRα expression vectors.  Following transfection, cells were 
transduced with AdGFP or AdMuRF1, treated with either vehicle or T3 and luciferase activity was 
detected using the Dual-Light® Luciferase & β-galactosidase Reporter Gene Assay Kit (T1003, 
Applied Biosystems), as described previously74.  Assays were run in quadruplicate normalized to β-
galactosidase expression. 
 Immunoblot and antibodies. Cells were lysed in Cell Lysis Buffer (Cat.#9803S, Cell 
Signaling, Danvers, MA), supplemented with protease inhibitor cocktail (Cat.#11697498001, Roche), 
phosphatase inhibitor cocktail (Cat.#04906845001, Roche), and 0.2M glycerol-2-phosphate (Sigma-
Aldrich) and resolved on NuPAGE® gels (Cat.#s NP0321 and NP0301, Life Technologies Novex®). 
Protein was transferred to PVDF (Cat.#IPVH00010, EMD Millipore), blocked in 2% Amersham™ 
ECL™ Prime Blocking Reagent (Cat.#RPN418, GE Healthcare Life Sciences, Pittsburgh, PA), and 
incubated with primary antibody overnight at 4ºC. Membranes were washed, in HRP-linked 
secondary antibody for one hour at RT. Amersham™ ECL™ Prime or ECL™ Select (Cat.#s 
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RPN2232 and RPN2235, respectively, GE Healthcare Life Sciences) was used to detect signal and 
final immunoblot results were acquired using Amersham™ Hyperfilm ECL™ (Cat.# 28-9068-38, GE 
Healthcare Life Sciences). Densitometry analysis was performed using Quantity One 1-D Analysis 
Software (Bio-Rad, Hercules, CA). 
 Primary antibodies for TRα (PA1-211A, Thermo Scientific, Inc., Rockford, IL, 1:500 
dilution), FLAG-TRα (anti-FLAG Cat.# F7425, Sigma-Aldrich, 1:1000), MuRF1 (Cat.#AF5366, RD 
Systems, Minneapolis, MN, 1:250), β-actin and GAPDH (Cat.#s A5441 and G8795, Sigma-Aldrich, 
Inc., 1:4000 dilution), p-Rb (Cat.#sc-50, Santa Cruz Biotechnology, Dallas, TX), myc-tagged MuRF1 
(anti-myc [Cat.#C4439, Sigma Aldrich, 1:4000] or [anti-myc-HRP-linked primary [Cat.#A5598, 
1:10,000]), glutathione-S-transferase (GST)-tagged TRα (anti-GST [Cat.#G1160], Sigma Aldrich, 
Inc., 1:10,000), HA-ubiquitin (anti-HA [Cat.#sc-57592], 1:1000) or anti-HA-HRP-linked primary 
[Cat.#12013819001], Roche, 1:500) were used.  HRP-linked secondary antibodies against mouse 
(Cat.# NA931V, GE Healthcare Life Sciences, 1:10,000), rabbit (Cat.#A9169, Sigma Aldrich, 
1:20,000) and goat (Cat.#A5420, Sigma Aldrich, 1:10,000) were used.        
 Cytoplasmic and nuclear fractionation.  Cellular fractionation was carried out using the 
Nuclear Extraction Kit (Cat.#AY2002) purchased from Panomics (Fremont, CA) according to the 
manufacturer’s protocol. 
 Confocal immunofluorescence and quantitative colocalization analysis.  HL-1 cells 
grown on Flexcell plates (Cat.# BF-3001U, Flexcell International, Hillsborough, NC) were 
transfected with the plasmids indicated, transduced with 25 MOI AdGFP or AdMuRF1, treated with 
vehicle or 1µM T3 for two hours, then fixed in 4% formaldehyde in PBS, cut into 1 x 1 cm sections 
and blocked in 0.4% TritonX100/5% FBS.  Membranes were exposed to primary antibody overnight 
and signal was detected using the appropriate AlexaFluor® secondary antibodies.  After washing, 
membranes were mounted onto glass slides using a Fluoro-Gel II Mounting Media containing DAPI 
(17985-50, Electron Microscopy Services, Hatfield, PA).  Samples were observed via confocal 
microscopy using the FV1000 MPE SIM Laser Scanning Confocal Microscope (Olympus, Center 
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Valley, PA) and the 60X objective lens.  Final images were taken at 2X magnification.  FLAG-TRα 
was detected using either a rabbit anti-FLAG antibody (F7425) or mouse anti-FLAG antibody 
(F1804), both purchased form Sigma-Aldrich, at 1:100 dilution.  myc-MuRF1 was detected using 
either a rabbit anti-myc (C3956) or mouse anti-myc (C4439), both purchased from Sigma-Aldrich, at 
1:100 dilution.  Endogenous CAP350 was detected using an anti-CAP350 antibody (sc-161481) 
purchased from Santa Cruz Biotechnology at 1:50 dilution. Secondary AlexaFluor® anti-goat 488 
(Cat.#11055), anti-rabbit 568 (Cat.#11011), and anti-mouse 568 (Cat.#110040) antibodies from Life 
Technologies Molecular Probes® were used as were anti-rabbit 647 (Cat.#A21443) and anti-mouse 
647 (Cat.#A21463) from Life Technologies Invitrogen™.  Colocalization analysis was performed by 
determining the coefficient values representing the degree in which two different fluorescence 
channels (450, 488, 568, or 647) overlap in isolated regions of the cardiomyocyte using Volocity® 
3D Images Software Quantitation  (PerkinElmer, Waltham, MA), as described previously by other 
groups128, 129.  Measurements were made using the Costes’ Pearson’s Coefficient correlation statistics 
function provided within the software which uses the threshold values for each channel to adjust the 
final coefficient data. 
 Coimmunoprecipitation. Cos-7 cells were transduced with either AdGFP or AdMuRF1 and 
subsequently treated with either vehicle or T3, lysed (50 mM Tris, pH 7.5, 30mM NaCl, 1mM EDTA, 
0.5% (v/v) Triton X100) supplemented with 2x protease inhibitor cocktail (Roche) and 1x 
phosphatase inhibitor cocktail (Roche).  Lysates were precleared with 5 µg rabbit IgG (I5006, Sigma-
Aldrich) and 2% (v/v) Protein A/G PLUS Agarose beads (sc-2003, Santa Cruz Biotechnology) per 1 
mg of protein lysate for one hour at 4ºC with rotation.  Myc-MuRF1 was immunoprecipitated using 
5% (v/v) EZ View™ Red Anti-c-Myc Affinity Gel (E6654, Sigma-Aldrich) by incubating precleared 
lysates with equilibrated anti-c-myc beads overnight at 4ºC with rotation. Beads were then washed 
seven times with the lysis buffer (12.5x bead volume) and eluted with 20 µg myc peptide (M2435, 
Sigma-Aldrich).  Immunoprecipitated proteins were analyzed by immunoblot. 
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 In vivo ubiquitination assay. Cos-7 cells were transfected with either empty p3XFLAG®-
CMV-14 or FLAG-TRα and subsequently transduced with either AdGFP or AdMuRF1.  Cells were 
lysed using 50mM Tris, pH 7.5, 30mM NaCl, 1mM EDTA, 0.5% (v/v) Triton X100 supplemented 
with 2x protease inhibitor cocktail (Roche) and 1x phosphatase inhibitor cocktail (Roche).  Prior to 
immunoprecipitation, 1mg of protein lysates was precleared using 5µg mouse IgG (Cat.#I5381, 
Sigma-Aldrich) and 2% (v/v) Protein A/G PLUS Agarose beads (Cat.#sc-2003, Santa Cruz 
Biotechnology) for one hour at 4ºC with rotation.  FLAG-TRα was immunoprecipitated using 5% 
(v/v) EZ View™ Red Anti-FLAG Affinity Gel (Cat.#F2426, Sigma-Aldrich).  Precleared lysates 
were then incubated with equilibrated anti-c-myc beads overnight at 4ºC with rotation. Beads were 
then washed seven times with the lysis buffer (12.5x bead volume) and eluted using 20µg FLAG 
peptide (Cat.#F3290, Sigma-Aldrich).  Immunoprecipitated proteins were analyzed by immunoblot. 
 Statistics.  SigmaPlot software (Ver. 11, Systat Software, Inc., Chicago, IL) was used for all 
statistical analyses. When data included two independent variables, a two-way ANOVA test was used 
to determine the source of variation. Interactions between the two variables were reported when 
significant (p<0.05) and the F-statistic (regression variable from the dependent variable mean/residual 
regression variation) and degrees of freedom (DF) were reported. A Holm-Sidak post-test method 
using the all-pairwise procedure was used to determine differences between specific groups.  For in 
vivo studies, the two variables were defined as genotype and treatment assignment group (vehicle or 
T3).  For in vitro studies, the two variables were defined as adenovirus/plasmid expression and 
treatment. Since only one independent variable was present in the quantitative coimmunofluorescence 
experiments using TRα K to R domain mutants, a one-way ANOVA test was used to determine 
significance with an all pairwise post-test to determine differences between specific groups.  
 For in vitro cardiomyocyte area experiments, n-values were defined as the total number of 
measured cells from at least two separate slides from three independent wells where at least 200 
cardiomyocytes in total were measured per treatment group.  For in vivo cardiomyocyte area 
experiments, n-values were defined as the total number of measured cells in three random fields from 
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four separate 100X images, at least four image per animal, where there were three animals per 
experimental group. A minimum of 500 cardiomyocytes in total over all three animals per 
experimental group were measured. For luciferase assays, n-values were defined as a single well in 
three independent experiments.  For quantitative coimmunofluorescence experiments, n-values were 
defined as the total number of measured cells from at least two separate slides from three independent 
wells where at least 15 cardiomyocytes in total were measured per treatment group. For in vitro 
immunoblot experiments, each treatment group is represented in three lanes, each lane from one 
independent experiment and n=1 was defined as one lane. Significance level for all statistical analysis 
was set at p<0.05. 
Results 
 MuRF1 inhibits T3-dependent cardiac hypertrophy.  Previous studies have indicated that 
MuRF1 regulates transcription factors in the cardiomyocytes, including SRF and the nuclear receptor 
PPARα70-73, critical for the adaptions needed for cardiac hypertrophy/pathological heart failure and 
fatty acid metabolism, respectively.  Moreover, we have identified that MuRF1 inhibits processes in 
physiological hypertrophy126, thereby illustrating MuRF1’s regulation of both pathological and 
physiological hypertrophy in vivo.  In the present study, we hypothesized that MuRF1 regulates TH-
induced physiological hypertrophy in vivo by acting on the primary TR in cardiomyocytes, the TRα34.  
To determine MuRF1’s role in regulating cardiomyocytes, we stimulated the HL-1 cardiac-derived 
cell line and NRVMs with 1μM triiodothyronine (T3). T3 uniformly increased the size of both cell 
types (Figure 15 A-C); knock-down of MuRF1 by 50% resulted in an exaggerated increased in 
cardiomyocyte area in HL-1 cells (Figure 15A). Increasing MuRF1 expression in HL-1 and NRCM 
inhibited T3-induced cardiomyocyte hypertrophy, preventing the growth response (Figure 15B and 
C). 
 With experimental evidence for MuRF1’s regulation of cardiomyocyte hypertrophy in vitro, 
we next tested the hypothesis that MuRF1 regulates cardiomyocyte hypertrophy in vivo.  We 
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challenged the recently described MuRF1 -/-73, 75, 81 and cardiomyocyte-specific MuRF1 Tg+ mice68, 74 
with daily intraperitoneal injections of 1 mg/kg T3 (or PBS vehicle alone) for 14 days and followed 
the cardiac phenotype by conscious echocardiography and histology.  After 2 weeks, T3 treatment 
induced significant growth in MuRF1+/+ hearts compared to sham controls (Figure 16A).  MuRF1-/- 
hearts were found to exhibit an exaggerated heart weight, significantly larger than that of T3-treated 
MuRF1+/+ hearts (Figure 16A).  In contrast, the MuRF1 Tg+ mice had significantly attenuated T3-
dependent increases in heart weight (36.0%) compared to sibling-matched wildtype controls (47.9%) 
(Figure 16B).  Consistent with these findings, T3 treatment of wildtype mice significantly increased 
both anterior and posterior wall thickness, as measured by echocardiography, versus sham-treated 
mice (detailed echocardiographic analysis in Tables 5-8).  Histological analysis of both MuRF1 -/- 
and MuRF1 Tg+ perfused hearts confirmed these differences in size (Figure 16C), while detailed 
analysis of  cross-sectional areas demonstrated that MuRF1-/- cardiomyocytes exhibited an 
exaggerated hypertrophy (Figure 16D) while parallel studies of MuRF1 Tg+ cardiomyocytes 
demonstrated inhibition of cardiomyocyte hypertrophy in response to T3 treatment (Figure 16E).  
QPCR analysis of genes associated with pathological cardiac hypertrophy (BNP, ANF, and skeletal 
muscle actin) illustrated that challenging MuRF1-/- and MuRF1 Tg+ mice with T3 did not result in 
pathological hypertrophy (Figure 17A and B). 
 Since the T3-induced hypertrophy response is dose dependent, we measured circulating T3 
and T4 levels in serum at the time of harvest to determine if the significant changes in cardiac 
hypertrophy seen in our mouse models were due to differences in T3 and T4. Circulating levels of T3 
was significantly increased in T3-treated MuRF1 Tg+, but were unchanged in MuRF1-/- (Figure 18A 
and B).  Consistent with these finding, T4 was also increased in MuRF1 Tg+ serum, while being 
decreased in MuRF1-/- (sham-treated animals) (Figure 18A and B).  These data show that the 
exaggerated hypertrophic response to T3 in MuRF1-/- mice was not merely a result of increased 
circulating T3/T4.  In addition, these data also suggested to us that T3/T4 tissue uptake is impaired in 
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MuRF1 Tg+ animals.  While it was previously believed that T3/T4 freely diffuse across the plasma 
membrane, more recent reports have shown that plasma membrane transporters are required for the 
movement of T3/T4 into the cell from the circulation36, 130.  The most well-studied transporters 
responsible for the passage of T3/T4 across the plasma membrane include two members of the 
monocarboxylate transporter (MCT) family, MCT8 and MCT1036.  Recent studies have shown that 
MCT8 and 10 expression in the heart are transcriptionally regulated by T338.  Consequently, we 
measured mRNA expression of MCT8 and MCT10 by qPCR in the hearts of sham- and T3-treated 
MuRF1-/- and MuRF1 Tg+ mice and their respective wildtype controls.  Significant differences in 
expression were only observed for MCT10; however, this result was not altogether surprising since 
T3-dependent regulation of MCT10 is more robust than MCT8 in the heart38.  MuRF1-/- animals had 
increased MCT10 expression approaching significance (p=0.052) (Figure 19A) and T3-dependent 
expression of MCT10 was inhibited in MuRF1 Tg+ animals (Figure 19B).  These data provide an 
explanation for the differences observed for serum T3/T4 (Figure 18A and B) in these animals: 
decreased T4 in MuRF1-/- is a result of increased movement of TH into cardiomyocytes via MCT10 
and, conversely, increased T3/T4 in MuRF1 Tg+ is a result of  inhibition of TH movement into 
cardiomyocytes because of decreased expression  MCT10.  Since MCT10 is a T3-dependent gene in 
the cardiomyocyte38, these data illustrate that MuRF1’s inhibition of cardiomyocyte hypertrophy in 
vivo is a result of MuRF1’s regulation of T3/T4 molecular signaling, most likely via transcriptional 
pathways. 
 MuRF1 inhibits TRα transcriptional activity without affecting TRα total protein levels. 
While thyroid hormone signals through TRα and TRβ receptors, recent studies have demonstrated 
that TRα is specifically responsible for the effects of TH in the heart.  Mice lacking TRα exhibit the 
contractile abnormalities associated with thyroid hormone depletion, while mice lacking TRβ do 
not131, 132. These in vivo studies reflect the contrary functions of TRα and TRβ at the molecular level: 
TRβ inhibits TH signaling via recruitment of transcriptional co-repressors133, while TRα, the 
predominant cardiac TR representing 70% of TR at the mRNA and protein level, stimulates TH 
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signaling34. We therefore focused our studies on how MuRF1 regulates TRα.   First, we measured 
MuRF1’s effect on TRα transcriptional activity using luciferase reporter assays.  In the presence of 
1μM T3, increasing TRα expression in the presence of T3 increased TRE-driven luciferase activity 
>6 fold (Figure 20A).  Increasing MuRF1 expression significantly inhibited TRα activity (Figure 
20A), indicating that MuRF1’s inhibition of thyroid hormone activity occurs at the level of TRα’s 
transcriptional activity.  As a ubiquitin ligase, MuRF1’s regulation of transcriptional activity has been 
associated with both proteasome-mediated degradation (e.g. c-Jun)74 and non-degradation-associated 
inhibition (e.g. SRF, PPARα)70-73.  We next determined how MuRF1 expression affects steady state 
levels of TRα in cardiomyocytes.  Knocking down endogenous MuRF1 expression by shMuRF1 did 
not affect endogenous TRα levels (Figure 20B); similarly, increasing MuRF1 in cardiomyocytes also 
did not affect endogenous TRα levels (Figure 20C). These studies suggest that MuRF1 inhibits T3-
dependent cardiac hypertrophy by inhibiting TRα transcriptional activity but without affecting the 
TRα protein levels; indicating that MuRF1’s inhibition of T3-mediated signaling in the 
cardiomyocyte occurs through mechanisms independent of proteasome-mediated degradation of TRα. 
 MuRF1 causes TRα to accumulate in the nucleus.  To provide more detail on MuRF1-
dependent regulation of TRα activity, we performed immunofluorescence confocal analysis of TRα to 
determine how MuRF1 affects TRα localization in the cardiomyocyte.  HL-1 cardiomyocytes were 
transfected with a plasmid expressing TRα (for empty vector see Figure 22) and transduced with 
AdMuRF1 or empty control adenovirus, with and without T3.  Cells expressing TRα (transduced with 
control adenovirus) had significantly more TRα localized to the nucleus in the presence of T3 (Figure 
21A, column 2 vs. column 1).  These data are consistent with previously published reports in Xenopus 
oocytes showing that T3 induces TRα nuclear retention134. Unexpectedly, increasing MuRF1 
expression increased TRα localization to the nucleus (Figure 21A, column 3 vs column 1), despite 
our data showing MuRF1’s inhibitory effect on TRα (Figure 20A). MuRF1 co-localized with TRα in 
the nucleus (Figure 21B), which was significantly enhanced in the presence of T3 (Figure 21B, 
column 4 vs column 3). Compared to secondary antibody controls (Figure 21C), these studies 
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identified that MuRF1 both increased TRα levels in the nucleus and co-localized with TRα in a 
distribution around the periphery of the nucleus. 
 Since it was unexpected that MuRF1 increases nuclear localization of TRα, while decreasing 
TRα activity, we sought to quantify this relationship using a second method.  Immunoblot analysis 
was performed to determine if MuRF1 affected the localization of endogenous TRα in nuclear- and 
cytoplasmic-enriched fractions of cardiomyocytes transduced with adenovirus driving MuRF1 
expression (AdMuRF1).  In the presence of T3, we found that MuRF1 significantly increases the 
levels of endogenous TRα in the nucleus (Figure 23). Increasing MuRF1 expression in the presence 
of T3 does not significantly alter the cytoplasmic localization for the cytoplasm compared to vehicle 
controls (Figure 23). These studies confirm our unanticipated finding that increasing cardiomyocyte 
MuRF1 expression enhances endogenous TRα localization to the nucleus, despite simultaneous 
MuRF1-dependent inhibition of T3-driven TRα activity. 
 MuRF1 interacts with and mono-ubiquitinates TRα.  To determine if MuRF1 regulates 
TRα activity by interacting with TRα, we performed immunoprecipitation assays.  In cells transduced 
with AdMuRF1, we immunoprecipitated MuRF1 and found that it bound to endogenous TRα 
specifically in the presence of T3 (Figure 24).  To identify how MuRF1 posttranslationally modifies 
TRα, we performed in vivo ubiquitination assays in COS-7 cells.  Using exogenously transfected HA-
tagged ubiquitin, we identified that immunoprecipitated TRα exhibited both poly-ubiquitination and 
mono-ubiquitination (Figure 25).  A mono-ubiquitinated species (~52kDa, see asterisk) of TRα was 
present with increased MuRF1 (which was absent in adenovirus control), while poly-ubiquitinated 
TRα appeared to be unaffected by MuRF1 (Figure 25A).  Additional studies revealed that the 
background poly-ubiquitination of immunoprecipitated TRα was actually inhibited in the presence of 
increased MuRF1 expression (Figure 25B).  Together, these data show that MuRF1 increases TRα 
mono-ubiquitination while concomitantly decreasing TRα poly-ubiquitination, suggesting that mono-
ubiquitination of TRα by MuRF1 competes with poly-ubiquitination of TRα by another, yet to be 
identified, ubiquitin ligase(s) and possibly for the same residue (lysine) to modify with ubiquitin. 
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 MuRF1 promotes the interaction between TRα and CAP350.  We next searched for 
further mechanisms that have been implicated in inhibiting NR activities and share the characteristics 
of enhancing nuclear localization.  To our surprise, we found a study from 2005 that identified that 
centrosome-associated protein 350 (CAP350) is a negative regulator of PPARα in NIH3T3 cancer 
cells125.  This study found that increasing CAP350 expression caused PPARα to localize to a discrete 
peri-nuclear region, where CAP350 also co-localized with PPARα125.  The authors went on to show 
that PPARα’s capture within the nucleus by CAP350 prevents PPARα transcriptional activity125.  
CAP350 has neither been identified nor implicated in the regulation of nuclear receptors in 
cardiomyocytes, but based on our data showing that MuRF1 co-localizes with TRα in the peri-nuclear 
region of the cardiomyocyte, we hypothesized that CAP350 is involved in TRα’s accumulation to this 
region.  To test this hypothesis, we performed immunofluorescence confocal analysis of endogenous 
CAP350 and TRα in cardiomyocytes (Figure 26). We found the increasing MuRF1 expression 
significantly increased the co-localization of CAP350 and TRα in cardiomyocytes (Figure 26A, right 
two columns vs. left two columns).  In addition, the co-localization of CAP350 and TRα (Figure 
26A, yellow, right-most column) had a distinctly perinuclear distribution and appeared to have extra-
nuclear connections just adjacent to the nucleus.  
 CAP350 is known to interact with intermediate filaments125, 135-137 and has a role in 
microtubule stability in association with the Golgi complex135-137.  Therefore, we were interested to 
see if co-localization of TRα and CAP350 at the nuclear membrane involved any cytoskeletal proteins 
in that region of the cardiomyocyte.  Two intermediate filament proteins localized to the nuclear 
membrane in cardiomyocytes are desmin and laminβ1, which are both imperative for contractile 
function138.  To determine if MuRF1 promotes the interaction of TRα and either of these intermediate 
filament proteins, we performed immunofluorescence confocal analysis of TRα and endogenous 
desmin or laminβ1.  Indeed, we found that MuRF1 promotes the interaction between TRα and desmin 
at the nuclear membrane, specifically in the presence of T3 (Figure 27A, column 4 vs. column 2 and 
3).  Compared to secondary antibody controls (Figure 27B), these data suggest both that the MuRF1-
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dependent complex of TRα and CAP350 includes desmin and that this complex is localized on the 
outer face of the nuclear membrane of cardiomyocytes (where TRα does not have access to DNA) 
since desmin is a cytoplasmic intermediate filament protein139.  Conversely, MuRF1 inhibits the T3-
dependent interaction of TRα and laminβ1 at the nuclear membrane (Figure 28A, column 2 vs. 
column 4), compared to secondary antibody controls (Figure 28B).  A recent study has shown that 
lamins, by virtue of their presence directly within the nuclear membrane bilayer and interaction with 
chromatin140, promote the activity of the mechanosensitive transcription factor megakaryoblastic 
leukemia 1 (MLK1) (a transcriptional co-activator for SRF) in the heart141.  Interestingly, interaction 
between TRα and laminβ1 was increased in T3-treated cells transduced with AdGFP (Figure 28A, 
column 1 vs. column)—suggesting that this newfound lamin-dependent mechanism of promoting 
transcriptional activity could apply to TRα’s interaction with laminβ1.  Since increasing MuRF1 
expression interrupts the interaction between TRα and laminβ1, these data could explain how MuRF1 
inhibits TRα-dependent transcription.  Taken together, these studies identify for the first time that 
CAP350 is expressed in the heart and is localized adjacent to the connecting intermediate filaments 
(desmin) peripheral to the nucleus and suggest that CAP350 interacts specifically with mono-
ubiquitinated TRα. 
 As an ubiquitin ligase, MuRF1’s activity has been found to depend on its post-translational 
modification of protein substrates.  We identified that MuRF1 mono-ubiquitinates endogenous TRα 
in vivo (Figure 26A), while promoting the co-localization of TRα and CAP350 in the nucleus 
(Figure 26) and inhibiting TRα activity (Figure 20).  We next sought to determine the specific 
regions of TRα that are important for MuRF1’s regulation of TRα nuclear activity in cardiomyocytes.  
Since MuRF1 places ubiquitin on lysine residues of substrates, as do all ubiquitin ligases, full-length 
TRα constructs with lysines mutated to arginine (K to R) in each of the four functional domains (A/B, 
C, D, E/F) were created to prevent ubiquitination of TRα in those individual regions (amino acid 
sequences of these mutants shown in Figure 29).  We transfected cardiomyocytes with these each of 
these mutants, increased MuRF1, treated all groups with T3 (since these are the experimental 
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conditions under which TRα nuclear accumulation and interaction with CAP350 was most robust 
(Figure 21 and Figure 25) and measured TRα nuclear localization using immunofluorescence 
confocal analysis (Figure 30).  Like cells transfected with the full-length wild type TRα, 
cardiomyocytes expressing A/B (N-terminal), C (DNA Binding domain), and D (Hinge region) 
domain lysine mutants did not differ in their nuclear localization (Figure 30A).  In contrast, the 
nuclear localization of the TRα E/F domain lysine mutant was significantly decreased (Figure 30A).  
This result was not merely due to MuRF1’s lack of binding to the E/F mutant, since the mutant co-
localized with MuRF1 to the same degree as wildtype TRα, despite the dispersion of MuRF1 and the 
TRα E/F mutant throughout the nucleus (Figure 30B).  These data indicate that MuRF1’s activity in 
relation to TRα is dependent upon ubiquitination of lysines in the E/F (ligand binding) domain of 
TRα (Figure 30A).  Our finding was not altogether surprising since the E/F region/ligand binding 
domain of TRα has previously been shown to be poly-ubiquitinated123 and SUMOylated122.  These 
data are also consistent with our data showing that MuRF1 inhibits the poly-ubiquitination of TRα 
(Figure 25B)—since the lysine responsible for MuRF1’s regulation of TRα is within the same 
domain that is known to be poly-ubiquitinated123.  Co-localization of CAP350 with the E/F mutant in 
the nucleus was significantly decreased compared with wildtype TRα (Figure 30C).  Furthermore, 
CAP350 staining was diffuse throughout the nucleus, instead of localized to the nuclear membrane, in 
the presence of the TRα E/F domain lysine mutant (Figure 30C). These data suggest the lysines 
within the E/F region of TRα are important for the interaction between TRα and CAP350; by 
extension, these results also suggest that mono-ubiquitination of TRα at a lysine residue within its E/F 
region by MuRF1 promotes the binding of TRα and CAP350.   Furthermore, intra-nuclear 
localization of both CAP350 and MuRF1 is impacted by the expression of the TRα E/F domain lysine 
mutant, in that they were dispersed throughout the nucleus rather than being localized to the nuclear 
membrane; therefore these data suggest that intra-nuclear trafficking of CAP350 and MuRF1 is 
dependent upon ubiquitination of TRα by MuRF1. 
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Discussion 
 Increasing attention has recently been given to the role of TH in cardiac disease—focusing 
specifically on the beneficial effects of TH on patients with heart failure.  Specifically, TH is known 
to enhance contractile and relaxation properties of the heart, while preserving cardiac structure and 
performance under basal conditions and in response to injury.  Consequently, negative regulation of 
TH signaling, even at low levels, is associated with worsening prognosis for heart failure patients112.  
While the study of the systemic importance of TH has been ongoing, work on the specific regulation 
of TH signaling at the molecular level is just beginning.  Importantly, these new mechanistic studies 
may offer us a more precise picture of how to regulate the beneficial effects of TH on the 
myocardium, especially in heart failure.  For example, recent studies have identified that TRα is 
down-regulated in the heart post-ischemia—potentially causing cardiac-specific decreases in the 
efficacy of TH, termed “tissue hypothyroidism”142, 143.  Like TH deficiency at the systemic level, 
cardiac “tissue hypothyroidism” can potentially result in decreased contractility (by decreasing the 
expression levels of SERCa2 and PLN) and alterations in MHC isoform expression34.   
 In the current study we show that the striated muscle-specific ubiquitin ligase MuRF1 
inhibits T3-dependent cardiac hypertrophy in vivo (Figure 16)—implicating MuRF1 as a master 
regulator of TH signaling in the cardiomyocyte.  We also found that MuRF1 causes TH accumulate in 
serum (Figure 18A and B) limiting the access of the heart to TH.  Indicating that MuRF1, despite 
being expressed in skeletal and cardiac muscles (and at low levels in smooth muscle), can affect 
systemic circulation.  Furthermore, we found that MuRF1 inhibits of the expression of MCT10, a 
well-established plasma membrane TH transporter, in cardiac tissue (Figure 19A and B).  Showing 
that MuRF1 limits the ability of TH to enter the cardiomyocyte and consequently, TH-dependent 
signaling in the myocardium.  Recent studies have shown that MCT10 gene expression is regulated 
by T3 in the myocardium38, therefore we hypothesized that MuRF1 enacts it limitation of T3-
dependent physiologic cardiac hypertrophy by limiting TH-dependent transcription. 
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 It has been recognized for some time that regulation of cardiac function by TH occurs 
predominantly through transcriptional activation via TRs131-133.  The activity of TRα, especially, is 
most frequently studied in the heart since it is the main form of TR that is positively regulated by T3 
in cardiomyocytes34.  In the presence of hormone, TRα binds to TRE DNA sequences in gene 
promoter sequences (as a monomer, homodimers, or heterodimers with RXR or TRβ) and acts to 
enhance gene expression.  In the absence of T3, TRα forms a complex with co-repressor proteins11.   
 How post-translational modification regulates TRα, especially via the ubiquitin proteasome 
system (UPS), is just beginning to be understood.  Poly-ubiquitination of TRα at its ligand binding 
domain has been shown in kidney fibroblasts123.  Indirect regulation of TRα activity by the UPS has 
also been reported.  Recent studies have shown that the ubiquitin ligase mSiah2 positively regulates 
the process of T3-driven adipogenesis in PV cells144.  This study found that mSiah2 enhanced T3 
activity by targeting the transcriptional co-repressor NCoR for degradation, releasing NCoR’s 
inhibition of TRα and resulting in enhanced TRα transcriptional activity144.  TRα is SUMOylated 
(closely associated with ubiquitination) at lysines 283 and 389, both of which are found in the ligand 
binding/E/F domain, by PIASxβ in HepG2 (liver) cells122.  These investigators did show that 
SUMOylated TRα is present in cardiac tissue, but the impact of SUMOylation on TRα (inhibition) 
was only shown in HepG2 cells122.  Together, these studies show that ubiquitination and 
SUMOylation regulate TRα activity, but the impact of these post-translational mechanisms has yet to 
be understood in the heart.  By understanding the role of post-translational regulation of TRα, 
especially in beneficial TH-induced physiological cardiac hypertrophy, novel ways to potentiate 
cardiac function at the molecular level may be identified.  
 In the present study, we show that TRα is mono-ubiquitinated by MuRF1, a striated muscle 
specific ubiquitin ligase (Figure 25A).  We also show that mono-ubiquitination of TRα by MuRF1 
inhibits T3-dependent TRα transcriptional activity (Figure 20A), suggesting that T3-induced 
conformational changes in TRα may be necessary for MuRF1 to gain access to and ubiquitinate TRα.  
MuRF1 also causes TRα to accumulate in the nucleus of cardiomyocytes (Figure 23A and Figure 
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21).  Specifically, MuRF1-dependent localization of TRα to the nucleus in the presence of T3 relies 
on the lysines located in the TRα E/F domain (Figure 30A).  Interestingly, the TRα lysines 
previously shown to be ubiquitinated and SUMOylated are also located to the E/F domain122, 123, 
therefore it is possible that other ligases compete with MuRF1 for the specific lysines in this region.  
This competition may explain our findings that increasing MuRF1 expression enhances TRα mono-
ubiquitination while at the same time decreases TRα poly-ubiquitination (Figure 25A and B).   
 We also extend our knowledge of TH signaling in the cardiomyocyte by illustrating, for the 
first time, that TRα is targeted to CAP350 in a T3-dependment manner (Figure 25 and Figure 29C).  
CAP350 has been identified to be expressed in cardiomyocytes in GEO.  Our query made in January 
2014 for “CEP350 cardiomyocytes” yielded 24 results.  The studies found in the show that octanoic 
acid (GEO Accession #GDS3648) and mechanical stretch (GEO Accession #GDS3117) increase 
expression of CAP350 in cardiomyocytes.  Conversely, polyunsaturated fatty acids (GEO Accession 
#GDS2607) decrease expression of CAP350 in cardiomyocytes.  To our knowledge our current study 
is the first to determine the effect of CAP350 specifically on cardiomyocyte function.  CAP350’s link 
to NRs, however, has already been established.  A previous study identified that CAP350 interacts 
with and inhibits PPARα activity by localizing it to the perinuclear region of NIH3T3 cells125.  
Parallel studies by this group showed that TRα localization was not altered by co-expression of 
CAP350, but the investigators did not assay the effect of T3 on this interaction125.  The latter is a 
critical point, because in our current study the enhanced TRα-CAP350 perinuclear localization was 
observed only in the presence of T3 (Figure 25). 
 MuRF1-dependent regulation of has cardiomyocyte transcription factors in cardiomyocytes 
has become a specific mechanistic pattern by which MuRF1 effect cardiac function.  MuRF1 inhibits 
the SRF to attenuate pressure overload-induced cardiac hypertrophy 73.  Like the current study, 
MuRF1 inhibits SRF activity without degrading SRF 73.   In contrast, MuRF1 poly-ubiquitinates and 
degrades phospho-c-Jun following ischemia reperfusion injury, thereby inhibiting AP-1-dependent 
transcription downstream apoptotic cell death74.  Recent studies from our laboratory have identified 
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that MuRF1 regulates other NRs transcription factors in addition to TRα.  MuRF1 mono-ubiquitinates 
PPARα, targeting PPARα nuclear export by altering PPARα’s ability to interact with CRM1 (main 
mediator of nuclear export machinery)70-72.  While these studies and the current study were carried out 
under dynamically different conditions, MuRF1 appears to interact and regulate multiple transcription 
factors via ubiquitination, albeit by different mechanisms.  Taken together, these investigations 
provide evidence for the universality of MuRF1-dependent ubiquitination as a regulator of 
transcription factor complexes in the cardiomyocyte.  In the current context, the present studies may 
elucidate the first steps in determining how the UPS (via MuRF1) can be harnessed to enhance TH’s 
beneficial effect on the heart during health and disease states. 
Figure Legends 
 Figure 15. MuRF1 inhibits T3-induced cardiomyocyte hypertrophy in vitro and in vivo. 
A. MuRF1 was knocked down in HL-1 cardiomyocytes using AdshMuRF1, with Adshscrambled as 
control, at MOI 60 for 24 hours in serum-free DMEM followed by treatment with 1µM T3 for 18 
hours.  Shown are representative fluorescent images and area analysis for vehicle-and T3-treated 
cardiomyocytes transduced with either Adshscrambled or AdshMuRF1.  B. MuRF1 was increased in 
expression in HL-1 cardiomyocytes using AdMuRF1, with AdGFP as a control, at MOI 25 for 24 
hours in serum-free DMEM followed by treatment with 1µM T3 for 18 hours. Shown are 
representative fluorescent images and area analysis of vehicle- or T3-treated HL-1 cardiomyocytes 
transduced with either AdGFP or AdMuRF1. C. MuRF1 was increased in expression in NRVM using 
AdMuRF1, with AdGFP as a control, at MOI 25 for 24 hours in serum-free M199 followed by 
treatment with 1µM T3 for 18 hours.  Shown are representative fluorescent images and area analysis 
of vehicle- or T3-treated NRVM transduced with either AdGFP or AdMuRF1.  Data are represented 
as mean ± SEM.  Black bars represent vehicle and gray bars represent T3-treated cells or animals.  A 
two-way ANOVA test was used to determine statistical significance. *indicates significance on level 
of adenovirus or genotype group, **indicates significance on level of treatment group.  %indicates a 
significant interaction between adenovirus and treatment groups. The F statistic and degrees of 
62 
 
freedom (DF) were reported when dependence between groups was found to be a significant source 
of variation.  Significance between groups is represented as #P< 0.05, ##P< 0.001, as determined 
using a pairwise post-test. 
 Figure 16. MuRF1 inhibits T3-induced cardiomyocyte hypertrophy in vivo.  MuRF1-/-, 
MuRF1 Tg+, and sibling-matched wildtype control mice (MuRF1 +/+, WildtypeMuRF1Tg+) were 
randomly assigned to either vehicle or T3 groups, where T3 groups were injected with 1mg/kg T3 and 
vehicle groups were injected with PBS intraperitoneally each day for 14 days. A.  Heart weight (HW) 
measurements normalized to body weight (BW) for MuRF1+/+ and MuRF1-/- vehicle and T3 groups.  
B.  Heart weight (HW) measurements normalized to body weight (BW) for WildtypeMuRF1Tg+ and 
MuRF1 Tg+ vehicle and T3 groups.  C. Representative images of histological analysis of perfused 
and fixed heart sections stained with hemotoxylin and eosin (HE) from T3-treated MuRF1+/+, 
MuRF1 -/-, WildtypeMuRF1Tg+, and MuRF1 Tg+.  D. Representative 100x images of histological 
analysis of perfused and fixed heart sections stained with Masson’s Trichrome (MT) from vehicle- 
and T3-treated MuRF1+/+ and MuRF1-/- used for cardiomyocyte area measurements.  Analysis of 
cardiomyocyte area of vehicle- and T3-treated MuRF1+/+ and MuRF1-/-.  E.  Representative 100x 
images of histological analysis of perfused and fixed heart sections stained with MT from vehicle- 
and T3-treated WildtypeMuRF1Tg+ and MuRF1 Tg+ used for cardiomyocyte area measurements.  
Analysis of cardiomyocyte area of vehicle- and T3-treated WildtypeMuRF1Tg+ and MuRF1 Tg+.  Data 
are represented as mean ± SEM.  Black bars represent vehicle and gray bars represent T3-treated cells 
or animals.  A two-way ANOVA test was used to determine statistical significance. *indicates 
significance on level of adenovirus or genotype group, **indicates significance on level of treatment 
group.  %indicates a significant interaction between adenovirus and treatment groups. The F statistic 
and degrees of freedom (DF) were reported when dependence between groups was found to be a 
significant source of variation.  Significance between groups is represented as #P< 0.05, ##P< 0.001, 
as determined using a pairwise post-test. 
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 Figure 17.  Gene expression associated with pathological hypertrophy is not altered in 
MuRF1-/- and MuRF1Tg+ mice treated with T3.  A. RNA was isolated from whole heart tissue 
from vehicle- and T3-treated MuRF1+/+ and MuRF1-/-, cDNA generated, and BNP, skeletal muscle 
actin, ANF, and TATA box-binding protein (Tbp) expression determined, where Tbp was used as a 
reference gene. B. RNA was isolated from whole heart tissue from vehicle- and T3-treated 
WildtypeMuRF1Tg+ and MuRF1 Tg+, cDNA generated, and BNP, skeletal muscle actin, ANF, and 
TATA box-binding protein (Tbp) expression determined, where Tbp was used as a reference gene.  In 
vitro cardiomyocyte area measurements were averaged over at least 200 cardiomyocytes.  In vivo 
cardiomyocyte area measurements were averaged over at least 400 cardiomyocytes from three 
different animals per group.  RT-PCR analysis was carried out using the ΔΔCT method, where raw 
CT values were first normalized to Tbp (ΔCT values) and then to vehicle-treated wildtype groups 
(ΔΔCTvalues).  RT-PCR data were averaged over 3 animals per group.  Data are represented as mean 
± SEM.  Black bars represent vehicle and gray bars represent T3-treated cells or animals.     
 Figure 18. MuRF1 inhibits TH cardiac uptake.  A. Serum T3 and T4 analysis of MuRF1-
/- and sibling-matched wildtype control mice (MuRF1 +/+) injected with either 1mg/kg T3 or vehicle 
(PBS) intraperitoneally each day for 14 days.  Black bars represent MuRF1+/+ and gray bars 
represent MuRF1-/-.  B. Serum T3 and T4 analysis of MuRF1 Tg+ and sibling-matched wildtype 
control mice (WildtypeMuRF1Tg+) injected with either 1mg/kg T3 or vehicle (PBS) intraperitoneally 
each day for 14 days.  Black bars represent WildtypeMuRF1Tg+ and gray bars represent MuRF1 Tg+.  
Data are represented as mean ± SEM.  A two-way ANOVA test was used to determine statistical 
significance. *indicates significance on level of adenovirus group, **indicates significance on level of 
treatment group %indicates a significant interaction between adenovirus and treatment groups. The F 
statistic and degrees of freedom (DF) were reported when dependence between groups was found to 
be a significant source of variation.  Significance between groups is represented as #P< 0.05, ##P< 
0.001 as determined using a pairwise post-test. 
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 Figure 19. MuRF1 inhibits cardiac MCT10 gene expression.  A. RNA was isolated from 
whole heart tissue from vehicle- and T3-treated MuRF1+/+ and MuRF1-/-, cDNA generated, and 
monocarboxylate transporter 8 (MCT8), MCT10, and Tbp expression determined, where Tbp was 
used as a reference gene. Black bars represent MuRF1+/+ and gray bars represent MuRF1-/-. B.  
RNA was isolated from whole heart tissue from vehicle- and T3-treated WildtypeMuRF1Tg+ and MuRF1 
Tg+, cDNA generated, and monocarboxylate transporter 8 (MCT8), MCT10, and Tbp expression 
determined, where Tbp was used as a reference gene.  Black bars represent WildtypeMuRF1Tg+ and gray 
bars represent MuRF1 Tg+. RT-PCR analysis was carried out using the ΔΔCT method, where raw CT 
values were first normalized to Tbp (ΔCT values) and then to vehicle-treated wildtype groups 
(ΔΔCTvalues).  RT-PCR data were averaged over 3 animals per group.  Data are represented as mean 
± SEM.  A two-way ANOVA test was used to determine statistical significance. *indicates 
significance on level of adenovirus group, **indicates significance on level of treatment group 
%indicates a significant interaction between adenovirus and treatment groups. The F statistic and 
degrees of freedom (DF) were reported when dependence between groups was found to be a 
significant source of variation.  Significance between groups is represented as #P< 0.05, ##P< 0.001 
as determined using a pairwise post-test.     
 Figure 20. MuRF1 inhibits TRα transcriptional activity, but does not target TRα for 
proteasomal degradation.  A. To assess the role of MuRF1 on TRα transcriptional activity, Cos-7 
cells were co-transfected with luciferase plasmid driven by the thyroid response element (TRE) of the 
GH gene, as described previously122, β-galactosidase plasmid (for transfection control), and FLAG-
TRα plasmid, with empty FLAG as a control, transduced with AdMuRF1, with AdGFP as a control, 
at MOI 25 for 4 hours, and treated with 1µM T3 for 24 hours.  Parallel plates were used to confirm 
expression of FLAG-TRα and myc-MuRF1 by immunoblot using FLAG and myc antibodies, 
respectively.  Black bars represent AdGFP- and gray bars represent AdMuRF1-transduced cells.  B.  
MuRF1 was knocked down in HL-1 cardiomyocytes using AdshMuRF1, with Adshscrambled as 
control, at MOI 60 for 24 hours.  Immunoblot using whole cell lysates was used to access protein 
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expression of endogenous TRα.  MuRF1 antibody was used to confirm knockdown. β-actin was used 
as a loading control.  C.  MuRF1 was increased in expression in HL-1 cardiomyocytes using 
AdMuRF1, with AdGFP as a control, at MOI 25 for 24 hours.  Immunoblot using whole cell lysates 
was used to access protein expression of endogenous TRα.  Myc antibody was used to confirm 
expression of myc-MuRF1.  β-actin was used as a loading control.  Luciferase data is representative 
of three independent experiments.  Data are represented as mean ± SEM.  A two-way ANOVA test 
was used to determine statistical significance. *indicates significance on level of plasmid group.  
%indicates a significant interaction between adenovirus and treatment groups. The F statistic and 
degrees of freedom (DF) were reported when dependence between groups was found to be a 
significant source of variation.  Significance between groups is represented as #P< 0.05 as determined 
using a pairwise post-test. 
 Figure 21. Localization of TRα in the nucleus of cardiomyocytes is increased by 
MuRF1. HL-1 cardiomyocytes were transfected with FLAG-TRα plasmid, or with empty FLAG as a 
control (see Figure 14), transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours, 
and treated with 1µM T3 for 2 hours.  A. Nuclear localization of TRα was assessed using confocal 
microscopy, immunofluorescent staining of TRα (anti-FLAG, red) and nuclei (DAPI, blue), and 
quantitatively evaluated by determining the degree of TRα (red) and DAPI (blue) overlap via 
correlation coefficient measurements.  B. The co-localization of MuRF1 and TRα in the nucleus was 
assessed using confocal microscopy, immunofluorescent staining of MuRF1 (anti-myc, green) and 
TRα (anti-FLAG, red), and quantitatively evaluated by determining the degree of MuRF1 (green) and 
TRα (red) overlap, isolated to the nucleus, via correlation coefficient measurements. C. Control 
confocal analysis of immunofluorescent staining with secondary antibodies (568 for TRα and 647 for 
MuRF1) alone.  Quantitative immunofluorescence measurements were made using Volocity imaging 
software.  For correlation coefficients, numeric range is from 0 to 1, where 0 indicates no correlation 
and 1 indicated perfect correlation. Data are represented as mean ± SEM.  For TRα/DAPI co-
immunofluorescence, a two-way ANOVA test was used to determine statistical significance. 
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*indicates significance on level of adenovirus group, **indicates significance on level of treatment 
group.  Significance between groups is represented as ##P< 0.001 as determined using a pairwise 
post-test.  For TRα/MuRF1 coimmunofluorescence, a Student’s t-test was used to measure statistical 
significance where $ indicates P<0.001 between groups. 
 Figure 22. Empty FLAG vector controls for FLAG-TRα immunofluorescence.  HL-1 
cardiomyocytes were transfected with empty FLAG as a control, transduced with AdMuRF1, with 
AdGFP as a control, at MOI 25 for 4 hours, and treated with 1µM T3 for 2 hours.  Control confocal 
analysis of immunofluorescent staining with anti-FLAG (red) and nuclei (DAPI, blue). 
 Figure 23. Endogenous TRα accumulates in the nucleus in a MuRF1- and T3-
dependent manner.  MuRF1 was increased in expression in HL-1 cardiomyocytes using AdMuRF1, 
with AdGFP as a control, at MOI 25 for 24 hours in serum-free DMEM followed by treatment with 
1µM T3 for 2 hours.  Immunoblot using nuclear- and cytoplasmic-enriched fractions was used to 
access nuclear localization of endogenous TRα.  p-Rb was used as a nuclear marker and GAPDH was 
used as a cytoplasmic marker.  Densitometry analysis of TRα is shown for AdGFP- and AdMuRF1-
transduced cardiomyocytes treated with vehicle (PBS) or T3.  Data are represented as mean ± SEM.  
A two-way ANOVA test was used to determine statistical significance. *indicates significance on 
level of adenovirus group, **indicates significance on level of treatment group %indicates a 
significant interaction between adenovirus and treatment groups. The F statistic and degrees of 
freedom (DF) were reported when dependence between groups was found to be a significant source 
of variation.  Significance between groups is represented as #P< 0.05 as determined using a pairwise 
post-test. 
 Figure 24. MuRF1 interacts with TRα specifically in the presence of T3. Cos-7 cells 
were transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 24 hours, and treated with 
1µM T3 for 2 hours.  To determine if MuRF1 physically interacts with TRα, whole cell lysates were 
submitted to specific immunoprecipitation of myc-MuRF1 followed by immunoblot of endogenous 
TRα.   
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 Figure 25.  MuRF1 mono-ubiquitinates TRα, inhibiting TRα’s poly-ubiquitination.  
Cos-7 cells were co-transfected with HA-Ub and FLAG-TRα plasmids, with empty HA and FLAG as 
controls, and transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours.  To assess 
the effect of MuRF1 expression on TRα mono-ubiquitination (B), whole cell lysates were submitted 
to specific immunoprecipitation of FLAG-TRα followed by immunoblot of HA using anti-HA-
horseradish peroxidase (HRP)-linked primary antibody (to prevent IgG heavy chain signal).  To 
assess the effect of MuRF1 expression on TRα poly-ubiquitination (C), whole cell lysates were 
submitted to specific immunoprecipitation of FLAG-TRα followed by immunoblot of HA using 
primary anti-HA and HRP-linked secondary antibody.    
 Figure 26. MuRF1 promotes the interaction of TRα and CAP350 in the nucleus.  HL-1 
cardiomyocytes were transfected with FLAG-TRα plasmid, or with empty FLAG as a control (see 
Figure 22), transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours, and treated 
with 1µM T3 for 2 hours.  A.  The co-localization of TRα and endogenous centrosome-associated 
protein 350 (CAP350) in the nucleus was assessed using confocal microscopy, immunofluorescent 
staining of TRα (anti-FLAG, red) and CAP350 (green), and quantitatively evaluated by determining 
the degree of TRα (red) and CAP350 (green) overlap, isolated to the nucleus, via correlation 
coefficient measurements. B. Control confocal analysis of immunofluorescent staining with 
secondary antibodies (568 for TRα and 488 for CAP350) alone.  Quantitative immunofluorescence 
measurements were made using Volocity imaging software.  For correlation coefficients, numeric 
range is from 0 to 1, where 0 indicates no correlation and 1 indicated perfect correlation. Data are 
represented as mean ± SEM.  A two-way ANOVA test was used to determine statistical significance. 
*indicates significance on level of adenovirus group, **indicates significance on level of treatment 
group.  Significance between groups is represented as ##P< 0.001 as determined using a pairwise 
post-test. 
 Figure 27. Interaction between desmin and TRα at the cardiomyocyte nuclear 
membrane is MuRF1- and T3-dependent.  HL-1 cardiomyocytes were transfected with FLAG-TRα 
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plasmid, or with empty FLAG as a control (see Figure 14), transduced with AdMuRF1, with AdGFP 
as a control, at MOI 25 for 4 hours, and treated with 1µM T3 for 2 hours.  A.  The co-localization of 
TRα and endogenous desmin at the nuclear membrane was assessed using confocal microscopy, 
immunofluorescent staining of TRα (anti-FLAG, red) and desmin (green), and quantitatively 
evaluated by determining the degree of TRα (red) and desmin (green) overlap, isolated to the nuclear 
membrane, via correlation coefficient measurements. B. Control confocal analysis of 
immunofluorescent staining with secondary antibodies (568 for TRα and 488 for desmin) alone.  
Quantitative immunofluorescence measurements were made using Volocity imaging software.  For 
correlation coefficients, numeric range is from 0 to 1, where 0 indicates no correlation and 1 indicated 
perfect correlation. Data are represented as mean ± SEM.  A two-way ANOVA test was used to 
determine statistical significance. *indicates significance on level of adenovirus group, **indicates 
significance on level of treatment group %indicates a significant interaction between adenovirus and 
treatment groups. The F statistic and degrees of freedom (DF) were reported when dependence 
between groups was found to be a significant source of variation.  Significance between groups is 
represented as #P< 0.05 as determined using a pairwise post-test. 
 Figure 28. T3 promotes the interaction between laminβ1 and TRα, which is inhibited by 
MuRF1.  HL-1 cardiomyocytes were transfected with FLAG-TRα plasmid, or with empty FLAG as a 
control (see Figure 14), transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours, 
and treated with 1µM T3 for 2 hours.  A.  The co-localization of TRα and endogenous laminβ1 at the 
nuclear membrane was assessed using confocal microscopy, immunofluorescent staining of TRα 
(anti-FLAG, red) and laminβ1 (green), and quantitatively evaluated by determining the degree of TRα 
(red) and laminβ1 (green) overlap, isolated to the nuclear membrane, via correlation coefficient 
measurements. B. Control confocal analysis of immunofluorescent staining with secondary antibodies 
(568 for TRα and 488 for laminβ1) alone.  Quantitative immunofluorescence measurements were 
made using Volocity imaging software.  For correlation coefficients, numeric range is from 0 to 1, 
where 0 indicates no correlation and 1 indicated perfect correlation. Data are represented as mean ± 
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SEM. A two-way ANOVA test was used to determine statistical significance. *indicates significance 
on level of adenovirus group, **indicates significance on level of treatment group %indicates a 
significant interaction between adenovirus and treatment groups. The F statistic and degrees of 
freedom (DF) were reported when dependence between groups was found to be a significant source 
of variation.  Significance between groups is represented as #P< 0.05, ##P< 0.001 as determined 
using a pairwise post-test. 
 Figure 29.  Amino acid sequences of mouse TRα domain lysine mutants.  Final amino 
acid sequences of TRα WT, TRα A/B KtoR, TRα C KtoR, TRα D KtoR, and TRα E/F KtoR, as 
expressed via the p3XFLAG®-CMV-14 vector.  Plasmid cloning described in data supplement. 
 Figure 30. Mutation of the lysine residues within the E/F region of TRα inhibits 
MuRF1-dependent TRα nuclear accumulation.  HL-1 cardiomyocytes were transfected with 
indicated FLAG-TRα domain lysine to arginine (KtoR) mutant plasmids, or with empty FLAG as a 
control (see Figure 22), transduced with AdMuRF1 at MOI 25 for 4 hours, and treated with 1µM T3 
for 2 hours.  A.  Nuclear localization of TRα was assessed using confocal microscopy, 
immunofluorescent staining of TRα (anti-FLAG, red) and nuclei (DAPI, blue), and quantitatively 
evaluated by determining the degree of TRα (red) and DAPI (blue) overlap via correlation coefficient 
measurements.  B. The co-localization of MuRF1 and TRα in the nucleus was assessed using 
confocal microscopy, immunofluorescent staining of MuRF1 (anti-myc, green) and TRα (anti-FLAG, 
red), and quantitatively evaluated by determining the degree of MuRF1 (green) and TRα (red) 
overlap, isolated to the nucleus, via correlation coefficient measurements.  C. The co-localization of 
TRα and endogenous CAP350 in the nucleus was assessed using confocal microscopy, 
immunofluorescent staining of TRα (anti-FLAG, red) and CAP350 (green), and quantitatively 
evaluated by determining the degree of TRα (red) and CAP350 (green) overlap, isolated to the 
nucleus, via correlation coefficient measurements.  Quantitative immunofluorescence measurements 
were made using Volocity imaging software.  For correlation coefficients, numeric range is from 0 to 
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1, where 0 indicates no correlation and 1 indicated perfect correlation.  Data are represented as mean 
± SEM.  A one-way ANOVA test was used to determine statistical significance. Significance between 
groups is represented as ##P< 0.001 as determined using a pairwise post-test. 
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CHAPTER 4: DISCUSSION AND PERSPECTIVES 
The ubiquitin proteasome system (UPS) and muscle atrophy 
 Diseases of skeletal muscle atrophy involve the UPS. The involvement of the UPS in the 
regulation of muscle atrophy was first discovered by David Glass and colleagues in 2001 (Bodine et 
al.)57.  In this study, the authors induced muscle atrophy in the hindlimb of rats by hindlimb 
suspension, immobilization or denervation, and analyzed gene expression levels.  The expression of 
two E3 ubiquitin ligases, MuRF1 and muscle atrophy F box (MAFbx), were found to be most highly 
upregulated in all the models of muscle atrophy57.  Knocking out either MuRF1 or MAFbx partially 
maintained muscle mass in response to denervation, suggesting that these ubiquitin ligases play a role 
in the induction of muscle atrophy57.  Consequently, ubiquitin ligases were presumed to be involved 
in muscle wasting diseases—leading to the study of the activity of the UPS and ubiquitin ligases in 
these diseases in hope of developing therapies effective in restoring muscle mass and function145.  The 
importance of ubiquitin ligases, especially MuRF1 and MAFbx, continues to be shown in 
immobilization- and starvation-induced atrophy, cachexia, and sarcopenia146-149.  The identification of 
new ubiquitin ligases involved in atrophy is ongoing: for instance, the expression and activity of 
tumor necrosis factor (TNF) receptor activated factor 6 (TRAF6), an ubiquitin ligase activated 
downstream of inflammatory cytokines, is increased following atrophic stimuli has recently been 
established150.  Together these studies demonstrate the significance of the UPS, especially ubiquitin 
ligases, in skeletal muscle atrophy.    
 The UPS in DMD. One of the most devastating diseases defined by loss of muscle mass is 
Duchenne muscular dystrophy (DMD)151.  Proteasome inhibition has been considered as possible new 
therapy for the treatment DMD152  because protein degradation has been shown to be increased 
overall in the mdx mouse model of DMD153 and proteasome expression is increased in human DMD 
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patients (Kumamoto et al.154, described in Table 7).  As shown in Table 7, multiple studies have 
tested the effectiveness of proteasome inhibitors to improve the pathophysiology of muscular 
dystrophy using the mdx mouse model of muscular dystrophy and human muscle explants from DMD 
patients. Overall, proteasome inhibition improves function and diminishes histological markers of 
dystrophy, while reducing molecular markers of inflammation and increasing expression of proteins 
within the dystrophin-glycoprotein complex (DGC) (Table 7).  While these reports provided evidence 
for improvement of dystrophic muscle disease by proteasome inhibitors, at that time, they did so only 
in the mouse, an animal for which loss of function mutations in dystrophin gene produces only mild 
myopathy155, 156, in only three types of skeletal muscle (Table 7), and not in cardiac muscle (likely 
because cardiomyopathy in the mdx mouse is delayed157).  (It is important to note that Gloria 
Bonuccelli and colleagues, authors of most of the studies described in Table 7, have since 
investigated the role of proteasome inhibition in Golden retriever muscular dystrophy (GRMD)158, the 
model of DMD used in our laboratory’s study159 described below)     
 To provide a more complete understanding of the regulation of the UPS in DMD, our 
laboratory undertook a comprehensive study of the activity of the proteasome and calpain 1 and 2 
(Ca2+-dependent cysteine proteases also involved in the pathogenesis of DMD160) and expression of 
multiple members of the UPS (including multiple E2 enzymes and ubiquitin ligases), proteasomal 
subunits, and calpain 1 and 2 in five different skeletal muscles and heart from dogs with GRMD159.  
We chose the GRMD model of DMD specifically because the severity of myopathy in these animals 
compares to that observed in humans155, 156.  The resulting study is reprinted in its entirety as the 
Appendix of this dissertation.  Overall, we did find significant differences the expression of E2 
enzymes, ubiquitin ligases, proteasomal subunits, and calpain 1 and 2 and the activity of the 
proteasome and calpain 1 and 2, but, unexpectedly, these metrics were not all increased, as would be 
expected based on the studies described in Table 7.  Instead, certain muscles displayed explicit 
patterns.  While expression of E2 enzymes, ubiquitin ligases, proteasomal subunits, and calpain 1 and 
calpain 2 were all increased overall in skeletal muscle (Figures 33-37 and Tables 9 and 10), these 
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increases did not translate to differences in protease activity in all these muscles—most notably 
protease activity was increased across the board in the long digital extensor, but remained unchanged 
in the cranial sartorius (Table 10).  Interestingly, protease activity correlated with the known 
phenotype for each of these muscles:  the long digital extensor undergoes severe atrophy and cranial 
sartorius undergoes hypertrophy (Table 10)161.  These data suggest that the UPS plays a role in the 
pathophysiology of DMD, but that the effects are specific to each muscle type and, possibly, use (the 
long digital extensor is an extensor muscle and cranial sartorius is a flexor muscle (Table 10).  Most 
importantly, these findings show that proteasome inhibition in GRMD may improve function for 
certain muscles for which proteasome activity is increased (e.g. long digital extensor), but worsen 
function for certain muscles for which proteasome activity is unchanged (e.g. cranial sartorius).  
Following the publication of Wadosky et al.159, Gloria Bonuccelli and colleagues showed that 
treatment of GRMD dogs with the proteasome inhibitor bortezomib did improve disease pathology 
via histology (increased fiber diameter, decreased lymphocytic invasion, and decreased collagen 
deposition) and immunohistochemistry (increased plasma membrane localization of DGC proteins), 
but these improvements did not translate to clinical progress since neither physical nor hematological 
signs of disease were improved in the two treated dogs158.  In addition, the particular skeletal muscle 
biopsied was never indicated in this study—so it is still unclear whether certain skeletal muscles (e.g. 
cranial sartorius) are adversely affected by proteasome inhibitor treatment in GRMD.       
 Neither the studies in the mdx mouse (Table 7) nor the recent study in GRMD dogs158 
assessed how proteasome inhibition treatment affects the heart of diseased animals.  Since dilated 
cardiomyopathy is a severe complication of DMD156, 162-164, this omission is considerable; therefore, 
we also measured the expression E2 enzymes, ubiquitin ligases, proteasomal subunits, and calpain 1 
and calpain and activity of the proteasome and calpain 1 and 2 in the hearts of GRMD and control 
animals (Figures 33-37 and Tables 9 and 10).  In contrast to skeletal muscle, expression of one E2 
enzyme (UNC4/5), two ubiquitin ligases (CHIP and MDM2), all three proteasomal subunits, and both 
calpain 1 and 2 where decreased in GRMD cardiac muscle (Figures 33-37 and Tables 9 and 10).  
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These data provide substantial evidence that proteasome inhibitor treatment would be detrimental to 
the DMD heart, which is already undergoing pathological remodeling.  Use of bortezomib is 
approved for treatment of multiple myeloma165 and has been linked to adverse cardiac outcomes166—
for instance, one patient with no previous history of cardiac disease underwent myocardial infarction 
only 5 days starting treatment with bortezomib and dexamethasone167.  In addition, studies have 
shown that the progression of cardiac dysfunction in general (not specific to DMD) decreases 
proteasome activity168-172.  Altogether these studies suggest that use of proteasome inhibitors in DMD 
patients could worsen their existing cardiomyopathy; therefore, identification of another way to target 
the UPS, perhaps one that can be injected in certain skeletal muscle rather than be administered 
systemically, would be a superior treatment option. 
The UPS in cardiac disease    
 The adverse effects of proteasome inhibition on the heart166, 167 and the endogenous 
decreases in proteasome activity in the myocardium during pathological remodeling168-172  illustrate 
the importance of the UPS to cardiac biology92, 173-175.  Since cardiomyocytes, the cell type that makes 
up 70-80% of the adult heart2, are post-mitotic, their post-damage repair relies on protein quality 
control mechanisms of which the UPS is one (in addition to molecular chaperones and autophagy)175.  
Continuous rounds of sarcomeric contraction and relaxation provokes protein wear and tear requires 
that the UPS is functioning properly.  Not surprisingly, cardiac disease states, such ischemic heart 
disease, certain cardiomyopathies, and pathological hypertrophy, are associated with altered UPS 
function and imbalance between protein synthesis and protein degradation92, 173-175.   
 Cardiac hypertrophy and ubiquitin ligases.  In cardiac hypertrophy, the balance between 
protein synthesis and protein degradation is skewed toward protein synthesis (Figure 31)175.  Since 
the purpose of hypertrophic remodeling is to increase the number of sarcomeres, making new and 
limiting the breakdown of sarcomeric proteins is required for the maintenance of heart function in the 
face of increased load2, 175.  Biasing this overall balance toward synthesis can involve increases in 
growth signaling or decreases degradation signaling, or both (Figure 31).  Signaling cascades can 
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even affect both protein synthesis and degradation.  Depending on which pathway is activated, 
shifting the balance toward protein synthesis can be good or bad for the myocardium2.  Pathological 
cardiac hypertrophy, induced by hypertension, aortic stenosis, and myocardial infarction, activates 
GPCRs and downstream MAPK signaling while physiological hypertrophy, induced by 
developmental growth, exercise, and pregnancy, activates RTKs and downstream PI-3K/Akt 
signaling2.  While distinct signaling cascades have been linked to each type of hypertrophy, why 
continued activation of MAPKs causes heart failure and RTKs do not, has yet to be established.  
Interestingly, decreased proteasome function and accumulation of ubiquitinated proteins has been 
shown to occur in cardiomyocytes during the development of pathological hypertrophy168, implicating 
the inhibition of the UPS in this maladaptive cardiac growth.  IGF-1/Akt signaling, activated 
downstream of physiologic growth activation, activates protein translation while inhibiting FOXO 
proteins, transcription factors that drive the expression of cardiac ubiquitin ligases (Figure 1)19; the 
latter of which again implicates inhibition of the UPS and ubiquitin ligases in this form of cardiac 
hypertrophy that occurs without pathological remodeling.  While these findings are in opposition—
inhibition of the UPS is involved in both pathological and physiological growth—they show that the 
study of the UPS and ubiquitin ligases is imperative to understanding what makes pathological 
hypertrophy “bad” and physiological hypertrophy “good” for the myocardium, and perhaps the key to 
converting improving function in heart failure patients by stimulate “physiologic” type growth. 
 Since the discovery that ubiquitin ligases regulate skeletal muscle atrophy57, these enzymes 
have been extensively studied in the context of cardiac hypertrophy176.  MAFBx/Atrogin-1 inhibits 
pressure overload-induced pathological cardiac hypertrophy by degrading calcineurin, a phosphatase 
that de-phosphorylates and activates the growth-promoting transcription factor NFAT177.  IGF-1- and 
exercise-induced physiological hypertrophy is also inhibited by MAFBx/Atrogin-1 via 
MAFBx/Atrogin-1-dependent ubiquitination of FOXOs, protecting FOXOs from Akt-dependent 
phosphorylation and inhibition52.  Another ubiquitin ligase, CHIP has been found to inhibit both 
pathological and physiological cardiac hypertrophy.  CHIP inhibits pathological hypertrophy by 
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promoting the activity of AMP activated kinase (AMPK), a metabolic sensor that orchestrates the 
cardiac stress response to increased ATP requirements178, and thereby retaining the availability of 
ATP to the myocardium179.  Our laboratory has shown that CHIP also inhibits physiological 
hypertrophy—where CHIP was found to inhibit beneficial autophagy in response to exercise84.  It has 
also been shown by our laboratory that MuRF1, but not MuRF2, inhibits pressure overload-induced 
cardiac hypertrophy by inhibiting the activity of the growth promoting transcription factor SRF73.  In 
contrast, recent studies by our laboratory have shown that both MuRF1 and MuRF2 inhibit 
developmental cardiac growth by regulating E2F1 promoter occupancy75.  Indicating that MuRF1 and 
MuRF2 inhibit physiological hypertrophy, at least during post-natal development.  A recent study has 
shown that MuRF1-/- animals undergo spontaneous age-dependent cardiac hypertrophy and have 
decreased phosphorylation of Akt and mTOR104, providing additional evidence for MuRF1’s 
inhibition of physiological hypertrophy.  A common theme which reveals itself in the studies 
described above is that ubiquitin ligases can inhibit both pathological and physiological hypertrophy.  
After the reviewing this body of work the paucity of investigations studying MuRF1’s regulation of 
physiological hypertrophy is also significant.  Therefore, the purpose of this dissertation is to fill that 
void by providing rigorous study of MuRF1 in the context of physiological cardiac hypertrophy 
induced by growth hormones and exercise.   
MuRF1 inhibits IGF-1- and exercise-dependent cardiac hypertrophy 
 Regulation of IGF-1/Akt pathway by ubiquitination and SUMOylation.  Ubiquitination 
regulates IGF-1/Akt signal transduction at multiple levels of the kinase cascade and Akt 
ubiquitination, specifically, has been the most well-studied.  The initial recruitment of Akt to the 
plasma membrane, where it is phosphorylated by PDK1 (Figure 1), requires poly-ubiquitination.  The 
ubiquitin ligase TRAF6, which interacts with IGF-1R, is activated by IGF-1 engagement of IGF1R180.  
TRAF6 then specifically polyubiquitinates unphosphorylated Akt via a K63 linkage (an atypical 
chain type (see Figure 2), which induces Akt membrane localization, promotes the interaction of Akt 
and PDK1, and subsequent phosphorylation of Akt at T308 by PDK1180.  This ubiquitin-dependent 
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mechanism of Akt by TRAF6 has been shown to be present in skeletal and cardiac muscle180.  In 
addition, new evidence has shown that TRAF4 can also ubiquitinate and activate Akt in the context of 
lung cancer181.  Akt nuclear localization, and thereby Akt-dependent phosphorylation and inhibition 
of FOXO transcription factors (Figure 1), is also dependent on ubiquitination.  Fully phosphorylated 
Akt (S473 and T308) is recognized by the ubiquitin ligase tetratricopeptide repeat domain 3 (TTC3), 
that polyubiquitinates Akt via a K48 linkage and promotes the nuclear localization of Akt182.  While 
nuclear-specific activity of Akt has been shown to be important for cardiomyocyte survival183 and 
Akt-dependent inhibition of pathological hypertrophic cardiac remodeling184, the role of TTC3-
dependent ubiquitination of Akt have yet to be studied in the heart.  Activation of Akt has also been 
shown to be dependent on SUMOylation by PIAS, where Akt kinase activity, cell proliferation, and 
tumorigenesis are inhibited when an Akt lysine mutant unable to be SUMOylated is expressed185.   
 Ubiquitination also plays a role in inhibiting Akt.  After passage to the nucleus Akt also 
recognized for degradation by the nuclear proteasome182, a negative feedback mechanism postulated 
to keep growth signaling in check by ensuring that activation of IGF-1 signaling originates via 
extracellular ligand and not by unrestrained activated Akt186.  Negative regulation of IGF-1 signaling 
by ubiquitination of Akt also occurs in the cytoplasm, where mTORC2-dependent phosphorylation of 
Akt at S473 has been shown to promote the degradation of Akt187 and at the outer mitochondrial 
membrane, where mitochondria-specific ubiquitin ligase mitochondrial ubiquitin ligase activator of 
NF-κB (MULAN)188 polyubiquitinates phosphorylated Akt via a K48 linkage, promoting the 
degradation of Akt189.  Together, these studies show that negative feedback control of IGF-1 signaling 
via proteasome-dependent degradation of Akt occurs by multiple mechanisms.   
 MuRF1 inhibits IGF-1 signaling by ubiquitin-mediated degradation of c-Jun.  The 
studies described above show that a ubiquitin/SUMO ligase network, in addition to the kinase 
network, regulates IGF-1/Akt signaling.  However, the majority of the studies investigating the 
regulation of IGF-1/Akt signaling by ubiquitination have been carried out in the context of cancer, not 
in cardiac hypertrophy.  The work shown in Chapter 2126 of this dissertation reveals that ubiquitin-
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dependent regulation of IGF-1/Akt signaling occurs in the myocardium.  In addition, the work 
presented also shows that this regulation occurs at a level that had yet to be discovered for IGF-1/Akt 
signaling in the heart—that of ubiquitination-dependent transcriptional regulation of the IGF-1 
pathway by the action of the ubiquitin ligase MuRF1.  MuRF1 limits the total protein expression of 
Akt, GSK3β, and mTOR (Figure 5-7) by reducing total and phosphorylated c-Jun (Figure 8 and 9), 
a transcription factor recently shown to regulate the transcription of multiple genes that code for 
proteins that make up the IGF-1 signaling cascade22 , via proteasome-dependent degradation upon 
poly-ubiquitination by MuRF174.  Inhibition of IGF-1-dependent cardiomyocyte hypertrophy (Figure 
1) was consequent upon MuRF1-dependent inhibition of IGF-1 pathway transcription via c-Jun 
(Figure 10 and 11).  Showing that MuRF1’s ubiquitination of c-Jun in the context of IGF-1 signaling 
has significance for growth on the cardiomyocyte level.   
 The next goal was to determine if MuRF1’s regulation of IGF-1 signaling applied 
systemically.  Indeed, we found that MuRF1 inhibits cardiac hypertrophy in response to running 
exercise in the mouse (Figure 12 and 13).  Importantly, the hypertrophy observed in these studies 
was without cardiac dysfunction (Tables 1 and 2) or markers of pathological remodeling (Figures 
12E, 13E, and 14), as we expected to be the case for cardiac hypertrophy induced by running 
exercise 21487028.  These data link MuRF1 activity to the inhibition of exercise-induced 
physiological hypertrophy for the first time.  MuRF1’s influence even has an effect on a mouse’s 
ability to exercise—in that, global knockout of MuRF1 increases the running speed and distance that 
a mouse can run (Tables 3 and 4).  One caveat of these findings, however, is that it cannot be 
determined from these data whether increased exercise performance is associated with MuRF1 
activity in the heart or the skeletal muscle, since is not expressed in either in this animal model57.   
 Altogether, Chapter 2126 has established, for the first time, that MuRF1 inhibits 
physiological cardiac hypertrophy stimulated by aerobic exercise.  In addition, the work in that 
chapter also established that MuRF1 can be listed among the ubiquitin/SUMO ligases, including 
TRAF6, TRAF4, TTC3, MULAN, and PIAS, that are part of a network that regulates IGF-1/Akt 
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growth signaling.  Interestingly, in regulating c-Jun, MuRF1 acts upstream of all of the other ligases 
within this network by regulating the transcription of gene which code for the proteins, namely Akt, 
that these ligases call substrates.  Since MuRF1’s inhibition of IGF-1/Akt signaling has a substantial 
effect on cardiac physiology in response to exercise, the novel mechanism detailed in Chapter 2126 
may prove to be useful in the development of therapies that interrupt MuRF1’s inhibition of IGF-1 
signaling for use in promoting beneficial cardiac remodeling in heart failure patients.         
MuRF1 inhibits TH-dependent cardiac hypertrophy 
 Ubiquitination of NRs.  Regulation of NRs by ubiquitination has been the subject of 
emerging research in the last several years in the study of NR regulation in multiple diseases190-192. 
The ubiquitin ligase RING finger protein 4 (RNF4) promotes the nuclear localization of androgen 
receptor (AR), thereby increasing testosterone-mediated transcription193, 194.  Another RING finger 
protein, RNF6, also positively regulates AR transcriptional activity by poly-ubiquitinating AR195.  
Canonical poly-ubiquitination and subsequent proteasomal degradation also plays a role in AR 
regulation: the ubiquitin ligases MDM2 and CHIP have both been shown to poly-ubiquitinate AR and 
promote AR degradation196, 197.  The UPS is also important for the regulation of ERα, in that 
proteasome-dependent degradation of ERα is implicated in maintaining estrogen-dependent 
transcription by promoting ERα turnover190.  In addition to targeting AR, MDM2 and CHIP also 
target ERα for poly-ubiquitination and subsequent proteasomal degradation198, 199.  ERα is targeted by 
a number of other ubiquitin ligases, including estrogen-responsive finger protein (EFP) and E6 
associated protein (E6AP)200-202.  Most notably, Breast cancer early onset 1 (BRCA1), a tumor 
suppressor coded for by a gene that commonly mutated in breast tumors203, complexed with BRCA1-
associated RING domain 1 (BARD1) monoubiquitinates ERα, inhibiting ERα-dependent 
transcription204.  Not surprisingly, BRCA1/BARD1 also poly-ubiquitinates and targets progesterone 
receptor (PR) for proteasome-dependent degradation205, inhibiting the action of progesterone (the 
dysregulation of which is also found in breast cancer206).  Liver X receptor α (LXRα), that regulates 
lipid homeostasis and inflammation in multiple tissues207, is also poly-ubiquitinated by 
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BRCA1/BARD1, promoting the LXRα degradation by the proteasome; illustrating that the activity of 
this ubiquitin ligase complex is important in tissues other than estrogen/progesterone target tissues.   
Finally, the UPS also regulates glucocorticoid receptor (GR)—where CHIP-dependent poly-
ubiquitination of GR promoting GR’s degradation by the proteasome208.  Like ERα, the regular 
turnover of GR via the UPS maintains GR function; therefore CHIP-mediated degradation of GR 
promoted, rather than inhibited, GR transcriptional activity208.  Altogether, these studies show that 
ubiquitination of NRs has a wide effect on numerous organ systems and thereby is involved in the 
pathogenesis of multiple disease, including prostate cancer (AR)191, breast cancer (ERα and PR)191, 206, 
inflammatory/auto-immune diseases (LXR and GR)207, type II diabetes (LXR, PPAR)207, obesity 
(LXR, PPAR)207, atherosclerosis (LXR, PPAR)207, and liver disease (LXR, PPAR)207.  Except for two 
recent studies linking AR and ERα to striated muscle function and growth7, 209, PPARs and TRs (and 
the co-receptor for both of these NRs, RXRα) are the NRs which have most well-studied in cardiac 
diseases; therefore the ubiquitin-dependent regulation of these NRs will be discussed in more detail 
below. 
 Regulation of PPARα by the UPS3.  Over the past 10 years, several lines of evidence have 
implicated the ubiquitin proteasome system (UPS) in the regulation of PPARα activity. In early 
studies, GFP- or HA-tagged PPARα expression vectors were transfected into HeLa cells and analyzed 
by Western blot analysis for PPARα. These studies revealed that PPARα protein stability is greatly 
affected by the presence or absence of a selective PPARα ligand210.  Similar observations have been 
reported in HepG2 cells transfected with PPARα211.   In these cells, cotransfection with PPARα and 
HA-tagged ubiquitin reveals that PPARα can be polyubiquitinated and that this post-translational 
modification is lost in the presence of multiple PPARα ligands. Likewise, increasing the expression of 
the RXRα and the CREB binding protein coactivator of PPARα (both PPARα coactivators) in HepG2 
cells leads to a decrease in PPARα ubiquitination. Finally, when these cells are treated with MG132, a 
                                                     
3 This section has previously appeared in American Journal of Physiology Heart and Circulatory Physiology.  
The original citation for the publication which includes this excerpt is as follows: Am J Physiol Heart Circ 
Physiol 2012 Feb 1;302(3):H515-26.       
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proteasome inhibitor, PPARα activity is increased, presumably because of the decrease in ubiquitin-
mediated proteasomal degradation of PPARα211.   
 Recently, additional molecular details surrounding PPARα ubiquitination and its effect on 
PPARα activity have been reported by Gopinathan et al.212.  In this study, an interesting relationship 
between PPARα activity and the ratio of PPARα to MDM2, was revealed.  MDM2 associates with 
PPARα through the A/B domain of PPARα and the coexpression of MDM2 increases PPARα 
ubiquitination212.  Increasing MDM2 levels relative to PPARα and PPARβ/δ, but not PPARγ, leads to 
a decrease in PPAR activity212, whereas knocking down MDM2 expression levels with small 
interfering RNA in rat hepatoma cells inhibits mRNA expression of several PPARα targets212.  
Increasing MDM2 levels in the presence of Wy-14643 (a PPARα selective agonist) leads to enhanced 
PPARα activity up to a ratio of MDM2 to PPARα <0.5 to 1; however, ratios of MDM2 to PPARα ≥ 1 
inhibits PPARα activity212.  In summary, these studies demonstrate the ubiquitination of PPARα in a 
ligand-dependent manner and that effect of ubiquitination on PPARα activity depends on the systems 
studied. 
 Regulation of PPARβ/δ by the UPS4.  Like PPARα, the mechanism by which 
ubiquitination affects PPARβ/δ activity and protein levels has been studied in different cell types. In 
U2OS human osteosarcoma cells expressing recombinant PPARβ/δ, PPARβ/δ is ubiquitinated and 
rapidly degraded in the absence of a ligand. However, the addition of PPARβ/δ-specific agonists such 
as L-165041, GW-501516, and the stable prostaglandin analog carbaprostacyclin PGI2 completely 
inhibit PPARβ/δ degradation, a process that is reliant on the DNA binding domain of PPARβ/δ213.  
When U2OS cells are treated with puromycin (an inhibitor of protein synthesis) and the proteasome 
inhibitor PS341, PPARβ/δ protein levels are stabilized to levels similar to what is seen with 
puromycin and L-165041 (a PPARβ/δ agonist) treatment, suggesting that L-165041 blocks 
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ubiquitination and degradation of PPARβ/δ in U2OS cells213.  Independent of basal levels of 
PPARβ/δ, ligand binding of PPARβ/δ prevents its ubiquitination and subsequent degradation213. 
 In contrast to the study described above, studies using mouse fibroblasts demonstrate that the 
ligand dependency of ubiquitination and degradation of PPARβ/δ is determined by PPARβ/δ protein 
levels. At low PPARβ/δ protein concentration, PPARβ/δ ubiquitination and degradation is not 
influenced by the synthetic agonist GW-501516214.  However, at high PPARβ/δ levels, GW-501516 
strongly inhibits the ubiquitination and degradation of PPARβ/δ214.  These findings have implications 
not only in the biological regulation of PPARβ/δ but also in the experimental design of 
overexpression systems used to determine the function and regulation of PPARβ/δ. 
 Regulation of PPARγ by the UPS5.  There are two forms of PPARγ that are generated from 
the same gene by alternative promoter usage, PPARγ1 and PPARγ2. PPARγ1 is found in most cell 
types, whereas PPARγ2 is found exclusively in adipose tissues215.  Ubiquitination of PPARγ has only 
been studied in adipocytes216-218, and therefore the knowledge of the regulation of PPARγ by the UPS 
is limited to the PPARγ2 moiety. Like other PPAR family members, the rate at which PPARγ2 is 
degraded is dependent on its interaction with ligands and appears to be mediated by an ubiquitin-
dependent mechanism. However, unlike PPARα and PPARβ/δ, ubiquitin-mediated regulation of 
PPARγ2 is enhanced rather than inhibited in the presence of PPARγ2-specific ligands. When 
differentiated adipocyte cells (3T3-F442A) are treated with the PPARγ2 ligand pioglitazone (or other 
thiazolidinediones), a dose-dependent increase in ubiquitination and a subsequent decrease in the 
PPARγ2 protein expression are observed217.  When the proteasome is inhibited in this adipocyte cell 
line, the degradation of PPARγ2 is also inhibited, indicating that the degradation of PPARγ2 in the 
presence of ligand occurs via proteasomal degradation. Interestingly, PPARγ2 constructs containing 
mutations in the activation function-1 domain, part of the ligand binding domain, are able to attenuate 
this ligand-dependent degradation of PPARγ2, supporting the theory that ligand binding to PPARγ2 is 
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necessary for its ubiquitin-mediated proteasomal degradation217.  In the context of the previous two 
sections, these findings demonstrate that all three members of the PPAR family are degraded by the 
UPS, albeit by different mechanisms. 
 Regulation of RXRα by the UPS6.  Ubiquitination of the PPAR/TR coreceptor RXRα has 
been reported, although there are a limited number of studies that address this particular post-
translational modification.  Since PPAR transcription factors work by dimerizing with RXRα, these 
studies likely have relevance to the post-translational regulation of PPARs. Recent studies have 
demonstrated that RXR homologs are ubiquitinated by ubiquitin ligases. However, it has not been 
determined whether this leads to degradation of RXR, which would be expected to inhibit PPAR 
activity overall. A yeast two-hybrid screen of the Schistosoma mansoni (Sm) cDNA library using 
SmRXR1 and SmRXR2 as bait identified the RING finger protein Sm seven in absentia (SmSINA) as 
a potential ubiquitin ligase specific for SmRXRs219.  In vitro ubiquitination assays demonstrated that 
SmSINA has ubiquitin ligase activity and can polyubiquitinate both SmRXR1 and SmRXR2, 
targeting them for proteasomal degradation219.  The DNA binding domain of SmRXRs shares 80% 
homology with mammalian RXRα, but the ligand-binding E domain of SmRXRs shares only 22–25% 
homology with mammalian RXRα220. Since SmSINA interacts with the E domains of SmRXR1 and 
SmRXR2, where S. mansoni and mammals share the least homology in RXR sequence, it is unclear 
whether SINA-dependent degradation of RXRα would occur in mammals. Another RING finger 
protein, RNF8, has also been identified as an RXRα-interacting protein using a yeast two-hybrid 
screen of a human liver cDNA library221.  Interestingly, increasing expression of RNF8 in COS7 cells 
has no effect on RXRα ubiquitination but increases its transactivation ability, a phenomenon that is 
enhanced by retinoic acid treatment221.  Although this pathway does not lead to RXRα ubiquitination, 
it is an interesting example of how interaction with an ubiquitin ligase can affect a protein's function 
in an ubiquitin-independent manner. 
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 Further studies aimed at determining the physiological relevance of RXRα ubiquitination 
have revealed that RXRα is polyubiquitinated in smooth muscle cells (SMCs) derived from the 
myometrium and that this ubiquitination is significantly inhibited in cells isolated from leiomyomas, 
a benign smooth muscle neoplasm of the uterus. Protein lysates from tissue samples from 
leiomyomas and healthy myometrium contain three RXRα immunoreactive bands: one at 54 kDa, 
representing the full-length RXRα, and two bands at lower molecular mass at 45 and 42 kDa. 
Interestingly, the lower molecular mass bands (presumably degradation products) are predominantly 
in protein lysates from healthy myometrium, whereas the single higher molecular mass band is 
predominant in protein lysates isolated from leiomyomas, suggesting that RXRα degradation is 
inhibited in leiomyomas222.  Interestingly, although degradation of RXRα is inhibited in SMCs 
derived from leiomyomas, it can be rescued by the addition of the RXR ligand 9-cis-retinoic acid, 
indicating that 9-cis-retinoic acid promotes the degradation of RXRα in leiomyomas222.  These results 
suggest that RXRα is poly-ubiquitinated and degraded by the proteasome in SMCs derived from the 
myometrium and that this process is inhibited during the pathogenesis of leiomyoma, leading to the 
accumulation RXRα. Furthermore, 9-cis-retinoic acid can attenuate RXRα protein accumulation by 
restoring RXRα's polyubiquitination and degradation to basal levels, showing the potential of 9-cis-
retinoic acid as an efficient treatment of leiomyomas. Since RXRα is the protein PPAR dimerizes 
with to enhance PPAR activity, it would not be surprising if PPAR activity was increased in 
leiomyomas, because of increased RXRα protein and activity levels. 
 Regulation of TRα by ubiquitination and SUMOylation.  Being that the UPS regulates a 
variety of other NRs, including its co-receptor RXRα, it is anticipated that TRs is also regulated by 
the UPS; especially because of its widespread effect on cardiomyocytes (Figure 1).  Surprisingly, 
there has been little work done to identify the role of the UPS in controlling TRs.  Both TRα and TRβ 
have been shown to be polyubiquitinated and degraded by the proteasome in a T3-dependent manner 
in fibroblasts and lymphocytes123.  These authors went on to show that the ligand binding domain 
(LBD) was required for the poly-ubiquitination of TRs (Figure 32), not unsurprising since T3 is 
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required for poly-ubiquitination of TRs123.  Unfortunately, this study did not identify the ubiquitin 
ligase that modifies TRα and TRβ, which still remains unknown.  The only other study that has 
addressed this type of post-translational modification is that of Liu et al.122 where the authors showed 
that both TRα and TRβ are mono-SUMOylated.  In this study, it was shown that TRs are 
SUMOylated by PIAS proteins, established SUMO ligases223; specifically, TRα is SUMOylated by 
PIASxβ and TRβ is SUMOylated by PIAS1, PIAS3, and PIASγ122.  Interestingly, dependence of TR 
SUMOylation on T3 differed for TRα and TRβ: TRα SUMOylation occurs independent of T3, while 
TRβ SUMOylation depends on T3122.  The effect of SUMOylation, however, was similar for both 
TRα and TRβ, in that SUMOylation inhibits TR transcriptional activity122.  While the lysines 
important for SUMOylation were both located in the LBD of TRα (K283 and K389) (Figure 32), 
lysines important for SUMOylation of TRβ we located in the A/B (K50), DNA-binding domain 
(DBD) (K146), and LBD (K443)122.  Importantly, the authors identified that mono-SUMOylated 
species of both TRα and TRβ were present in liver, white adipose, and cardiac tissue122, showing that 
this SUMO-dependent mechanism of TR regulation is relevant in vivo.  An essential detail in these 
findings is that SUMOylation of TRα was most robust in cardiac tissue, compared to liver and white 
adipose and compared to SUMOylation of TRβ in all tissues evaluated122.  These studies indicate that 
SUMOylation of TRα in the cardiomyocyte may be regulating the numerous activities of TRα that 
regulate myocardial contractility (Figure 1).           
 MuRF1-dependent inhibition of cardiac hypertrophy by TRα monoubiquitination.   
Other than SUMO-TRα expression in cardiac tissue122, studies of ubiquitin/SUMO modifications 
have not been studied in the myocardium.  Since T3-dependent TRα activity throughout the 
cardiomyocyte promotes cardiac growth (Figure 1) we were interested in determining how 
ubiquitination affects this mechanism.  The effect of TRα ubiquitination of TH-dependent cardiac 
hypertrophy, an adaptive form of growth, was especially interesting to us because we already found 
that ubiquitin-dependent inhibition of physiological hypertrophy induced by IGF-1 and exercise 
(Chapter 2126).  Specifically, we found that MuRF1 inhibits IGF-1/exercise induced cardiac 
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hypertrophy by its poly-ubiquitination and degradation of the transcription factor c-Jun (Chapter 2 
126); therefore we set out to determine the effect of MuRF1 on TH-dependent cardiac hypertrophy, 
hypothesizing that MuRF1 ubiquitinates of TRα.  The latter was the focus of our study because 
MuRF1 has also been shown to regulate PPARα by mono-ubiquitination70-72.  As described in 
Chapter 3, MuRF1 inhibits cell growth following T3 treatment in cardiac-derived HL-1 cells and 
primary NRVM (Figure 15A, B, and C).  MuRF1 also limited T3-dependent cardiac growth in vivo, 
where MuRF1-/- mice had exaggerated and MuRF1 Tg+ has blunted cardiac hypertrophy in response 
to T3 treatment (Figure 16).  Interestingly, MuRF1 also limited the expression of MCT10 (Figure 
19), a plasma membrane TH transporter (Figure 1).  Consequently, T3/T4 was found to accumulate 
in the serum in MuRF1 Tg+ animals (Figure 18B), suggesting that decreased expression of MCT10 
in the cardiac tissue of these animals is inhibiting the passage of TH into the cardiomyocyte (Figure 
1).   
 Lack of available T3 in the cardiomyocyte, in addition to inhibiting the activity of TRs 
(Figure 1), can have other adverse circumstances because T3/T4 itself activates pathways important 
for cardiomyocyte growth, contractility, and metabolism6, 40.  T3 can activate Akt signaling44, 224, 225, 
promoting transcription of growth genes and protein transcription (Figure 1).   T3 also increases 
phosphorylation of PLN226, inactivating PLN, releasing SERCa2 from PLN’s inhibition, and allowing 
for increased Ca2+ uptake into the sarcoplasmic reticulum (Figure 1).  These studies show that 
MuRF1’s systemic effect on TH tissue uptake, in addition to MuRF1’s inhibition of TRα (described 
below), is likely to adversely affect the heart based on TH’s stand-alone effect on the cardiomyocyte.   
 We chose to focus our attention on TRα in investigating the mechanism of MuRF1-
dependent inhibition of TH-dependent cardiac hypertrophy because 1) MuRF1 is already known to 
regulate PPARα, and 2) TRα activity in relation to cardiac hypertrophy is the most established 
mechanism of TH-dependent hypertrophy.  As shown in Chapter 3, MuRF1’s inhibits TRα 
transcriptional activity (Figure 20A) via mono-ubiquitination (Figure 25A) and not by poly-
ubiquitination-dependent degradation (Figure 25B).  Mono-ubiquitinated TRα accumulates in the 
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nucleus (Figures 21 and 23) and interacts with CAP350 (Figure 26) and intermediate filaments 
(desmin) (Figure 27) at the nuclear membrane specifically in the presence of T3.  While this was the 
first direct evidence of CAP350 in the cardiomyocyte, it was not altogether surprising that interaction 
with CAP350 inhibited TRα activity since this mechanism has already been recognized for PPARα125.  
We went on to show that MuRF1-dependent targeting of TRα to CAP350 was dependent on the 
lysines located to the E/F/LBD domain of TRα (Figures 30).  These data were exciting to us because 
that region of TRα contains the lysines which are ubiquitinated and SUMOylated (Figure 32), 
indicating that mono-ubiquitination of TRα’s E/F/LBD domain could compete with these other post-
translational modifications.  Indeed, we found that MuRF1 inhibits poly-ubiquitination of TRα 
(Figure 25B).  Regular turnover of some NRs, including ERα and GR (described above), is 
imperative for their transcriptional activity190, 208, explaining how MuRF1’s inhibition of TR poly-
ubiquitination (Figure 25B) inhibits rather than activates TRα transcriptional activity (Figure 20A).   
 Altogether, data provided in Chapter 3 establish that MuRF1 impairs TH-signaling in the 
cardiomyocyte via its mono-ubiquitination of TRα.  Moreover, the effect that mono-ubiquitination 
has on TRα in this context revealed a newfound mechanism by which TRα is inhibited—via 
interaction with CAP350 and inhibition of poly-ubiquitination.  TH supplementation therapy has 
recently been shown to improve cardiac function for patients in the clinic112, 227.  The new information 
this dissertation provides on the inhibitor function of MuRF1 on TH-dependent hypertrophy could be 
important in the treatment of these patients, since they might fare better on TH supplementation 
therapy if MuRF1 could be inhibited.     
Targeting MuRF1 in the clinic: druggable opportunities for heart failure?  
 Restoring the damaged myocardium by promoting a “physiologic” cardiac phenotype has 
been a dream of cardiac researchers and clinicians for some time and TH supplementation has so far 
been the avenue by which activation of adaptive cardiac remodeling hopes to be achieved in the 
clinic228, 229.  Serum levels of T3 are reduced in patients with congestive heart failure, undergo rapid 
decline in the week following myocardial infarction, and fall in infants undergoing cardiopulmonary 
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bypass surgery.  Consequently, several clinical studies have shown that TH repletion therapy 
improves symptoms of heart failure112, 227.  TH supplementation improves cardiac performance with 
minimal side effects in patients with ischemic and nonischemic heart failure and decreases 
postoperative time to extubation in infants who received surgery to correct cardiac defects112, 227.   
 Furthermore, recent studies have shown that a TH-dependent mechanism is responsible for 
the improvement of patients with end-stage heart failure who underwent regimented moderate 
intensity exercise training230.  Patients bridged to heart transplantation using a ventricular assist 
device (VAD) undertook an exercise regimen, where cardiac tissue was collected pre-VAD and at the 
time of heart transplantation.  The authors found that TRα1 and phospho-Akt expression were both 
increased in cardiac tissue over pre-VAD levels only in patients who received exercise training230.  It 
was also found that patients who exercised has increased serum concentrations of T3—suggesting 
that exercise-dependent increases in T3 may have causative effect on the positive regulation of TRα 
and phospho-Akt 230 (especially considering what we know about the T3-dependent activation of 
growth signaling6, 40).  This study is especially noteworthy and exciting in the context of this 
dissertation work, since it shows that both exercise and TH signaling, both of which are shown here to 
be inhibited by MuRF1 (Chapters 2 and 3), can promote a molecular “physiologic” phenotype in the 
damaged myocardium of humans.  One can only imagine how much more beneficial exercise training 
and TH supplementation could be for heart failure patients if MuRF1 were selectively inhibited in the 
myocardium.  Hopefully, the detailed mechanisms by which cardiac MuRF1 inhibits IGF-1-, 
exercise-, and TH-induced hypertrophic remodeling provided in this dissertation work will uncover at 
least one druggable interaction that will make an effectual treatment regimen possible that reverses 
the symptoms of heart failure.   
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APPENDIX: REGULATION OF THE CALPAIN AND UBIQUITIN PROTEASOME SYSTEMS 
IN A CANINE MODEL OF MUSCULAR DYSTROPHY7 
Introduction 
 The muscle damage sustained in Duchenne muscular dystrophy (DMD) is cleared by two 
major proteolytic systems: the calpain and ubiquitin proteasome systems153, 231.  The involvement of 
these proteolytic systems has prompted investigators to explore their role in the pathogenesis of DMD 
mainly using the mdx mouse model154, 231-242.  At least eight studies have tested the hypothesis that 
calpain and/or proteasome inhibition is beneﬁcial in disease, and most have shown signiﬁcant 
improvement in histology and function in short-term studies (as summarized in Tables 11 and 12)232-
236, 239-241.  Paralleling the therapeutic utility of calpain and proteasome inhibition on the mdx 
phenotype, there has been the largely uniform evidence that calpain and proteasome activities are 
enhanced in DMD (Tables 11 and 12). 
 These studies have been limited by their sampling of only one or two skeletal muscle types 
and their use of the mdx mouse model, which has a relatively mild phenotype compared with DMD in 
humans. We hypothesized that different muscle groups, including the heart, might have a more 
diverse expression and activity of calpain and the ubiquitin-proteasome systems. If so, it could result 
in unexpected and possibly unintended consequences in response to calpain and proteasome 
inhibition. In this study, we investigated the diversity of proteasome and calpain activities in ﬁve 
representative skeletal muscles and the heart in the GRMD model at 6 months of age. Despite the 
more severe disease phenotype in these animals, we found that only one (of six) muscle had increased 
trypsin-like (proteasome) activity. In all six muscles tested, including the left ventricle, no differences 
in caspase-like and chymotrypsin-like (proteasome) activities were seen. Similarly, none of the ﬁve 
skeletal muscles or the left ventricle had signiﬁcant increases in calpain 1 and 2 activities.  In 
addition, transcriptional regulation of the ubiquitin-proteasome system was most pronounced in the 
heart, where numerous components were signiﬁcantly decreased, including the ubiquitin ligases CHIP 
                                                     
7 This chapter previously appeared in Muscle and Nerve.  The original citation for the publication is as follows: 
Muscle Nerve 2011 Oct;44(4):553-62.   
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and MDM2, and the E2 enzyme uncoordinated phenotype 4/5 (UNC4/5).  The left ventricle also had 
decreased calpain 1 and 2 expression, without affecting the overall calpain 1 and 2 activities. These 
ﬁndings illustrate the muscle-speciﬁc differences in calpain and ubiquitin-proteasome system 
expression and activity in GRMD, a DMD model that parallels human disease in many ways243-246.  
These ﬁndings illustrate how proteasome and calpain inhibitors used to treat DMD might have 
unexpected consequences that are muscle-speciﬁc, particularly in the heart. 
Materials and Methods 
 Animals.  Dogs were cared for and utilized according to principles outlined in the Guide for 
the Care and Use of Laboratory Animals (National Institutes of Health). Newborn GRMD dogs were 
identiﬁed based on elevation of serum creatine kinase (CK). Genotype was conﬁrmed by polymerase 
chain reaction (PCR) when CK results were ambiguous. Dogs subsequently developed characteristic 
clinical signs. Long digital extensor, lateral head of gastrocnemius, vastus lateralis, biceps femoris, 
cranial sartorius, and left ventricle of the heart were harvested from 7 GRMD and 8 control dogs at 6 
months of age (Table 13). Dogs were anesthetized using conventional pre-anesthetic drugs, propofol 
(normal dogs only) and sevoﬂurane. Of the 15 dogs, 12 were harvested after being euthanized, and 3 
underwent biopsy before recovery and subsequent adoption (see Table 13). The muscle(s) were 
exposed sharply at surgery to allow removal of a sample of approximately 1 x 0.5 x 0.5 cm, snap 
frozen in liquid nitrogen, and stored at -80°C for further processing. These studies have been 
approved by the institutional animal care and use committee at the University of North Carolina. 
 Real-Time PCR Analysis of Ubiquitin-Proteasome System Components. Total RNA was 
isolated, cDNA was generated, and PCR products were ampliﬁed as described previously73.  TaqMan 
probes were from Applied Biosystems, Inc. (Carlsbad, California) and included dog-speciﬁc probes 
for calpain 1 (Cf02704115_m1), calpain 2 (Cf02645870_m1), CHIP (Cf02644017_m1), muscle 
atrophy F-box (MAFbx; Cf02667148_mi), MDM2 (Cf026759237_m1), muscle ring ﬁnger protein 1 
(MuRF1; Cf02649993_mi), proteasome subunit alpha type 6 (PSMA6; Cf02666165_g1), proteasome 
subunit beta type 4 (PSMB4; Cf01123846_m1), proteasome subunit activator type 1 (PSME1; 
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Cf02646187_g1), ubiquitin (Mm01622233_g1), UBC9 (Cf02655738_g1),   and UNC4/5 
(Cf02657121_m1). Relative mRNA expression was normalized to 18S (Hs99999901_s1). 
 Measuring 26S Proteasome Activity Using Fluorogenic Substrates. Assaying speciﬁc 
26S proteasome activities was performed as previously described247-249.  Brieﬂy, tissue was 
homogenized in lysis buffer [250 mM sucrose, 50 mM Tris (pH 7.5), 5 mM MgCl2,0.5 mM ethylene-
diamine tetraacetic acid (EDTA),1 mM dithiothreitol, 2 mM adenosine triphosphate (ATP), and 
0.025%  digitonin.  Approximately 25 ug of protein was added to the proteasome reaction buffer [50 
mM Tris (pH 7.5), 40 mM KCl, 1 mM MgCl2, 1 mM dithiothreitol, 0.5 mM ATP, and 0.05 mg/ml 
bovine serum albumin] that contained ﬂuorogenic substrates (75 uM of Suc-LLVY-AMC for 
chymotrypsin-like activity, 150 uM of Boc-LRR-AMC for trypsin-like activity, 75 uM of Ac-
nLPnLD-AMC for caspase-like activity; Enzo Life Sciences International, Inc., Farmingdale, New 
York). Fluorescence was measured using a spectrophotometer (excitation 355 nm, emission 460 nm; 
Wallace Victor 2) 40 times every 2 minutes at 37oC. Parallel samples were preincubated with the 
proteasome inhibitor epoxomicin (20 uM) for 30 min at 37oC to determine the non-speciﬁc substrate 
hydrolysis. These ﬂuorescence units were then subtracted from each measurement. 
 Measuring Calpain 1 and 2 Activity Using Fluorogenic Substrates. Calpain 1 and 2 
activity assays were performed using the Sensolyte AMC Calpain Activity Flurometric Assay Kit, 
according to the manufacturer’s protocol (Anaspec, Inc., Fremont, California). Brieﬂy, calpain 1 and 
2 activity in tissue extracts was assessed by hydrolysis of the ﬂuorogenic peptide substrate succinyl–
leucine–leucine–valine– tyrosine–4-methyl-7-courmarylamide (Suc-LLVY-AMC). Fifty micrograms 
per well of tissue extract was placed into a 96-well black opaque plate followed by addition of the 
substrate solution. Fluorescence was measured using a GENios microplate reader (excitation 355 nm 
and emission 442 nm; Tecan Group, Ltd., Durham, North Carolina). 
 Summaries of Previous Studies of Muscular Dystrophy, Proteasome, and Calpains. 
Summaries of previous studies are shown in Tables 11 and 12. The studies were identiﬁed by 
searching PubMed using the search criteria indicated in the tables. 
92 
 Statistical Analysis. A rank-sum test was performed because most of the data were 
determined to be non-parametric using a normality test and (when appropriate) an equal variance test 
in SigmaStat 2.03 (Systat Software, Inc., San Jose, California). Statistical signiﬁcance was set at P < 
0.05. 
Results 
 Differential Expression of Ubiquitin-Proteasome Components Is Muscle-Specific. The 
ubiquitin ligases MuRF1 and MAFbx/atrogin-1 have been prominently studied in skeletal muscle 
atrophy and are linked mechanistically to degradation of the sarcomere57.  Their role in cardiac 
hypertrophy, atrophy, and metabolism has also recently been reported52, 68, 73, 81.  Therefore, we 
investigated their expression in the GRMD model. MuRF1 and MAFbx/atrogin-1 mRNA levels in 
GRMD did not differ from age-matched controls in the muscles investigated (Figure 33A and B). 
The ﬁve GRMD skeletal muscles (long digital extensor, lateral head of the gastrocnemius, vastus 
lateralis, biceps femoris, and cranial sartorius) generally had increased MuRF1 and MaFBx 
expression compared with controls, but these increases were not uniform. 
 Apoptosis has also been linked to the pathophysiology of DMD250-252.  The ubiquitin ligases 
CHIP and MDM2 have been reported to inhibit apoptosis by targeting p53 for degradation by the 
proteasome253-256.  Furthermore, CHIP has been implicated in the pathogenesis of a Caenorhabditis 
elegans form of muscular dystrophy257.  We therefore measured CHIP and MDM2 expression in 
GRMD.  Both CHIP and MDM2 were signiﬁcantly decreased in the left ventricle (Figure 33C and 
D); MDM2 was increased only in the vastus lateralis (Figure 33D). Expression of CHIP and MDM2 
did not differ signiﬁcantly from that in control animals in the long digital extensor, lateral head of the 
gastrocnemius, biceps femoris, and cranial sartorius (Figure 33C and D). However, individual 
animals had increased CHIP and MDM2 in the biceps femoris and cranial sartorius. Expression of 
ubiquitin ligases in GRMD was largely unaffected in the skeletal muscles, whereas downregulation of 
two of the four investigated in this study was seen in the heart, as summarized in Table 9. 
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 To determine whether expression of other UPS components are altered in GRMD, we 
measured mRNA expression levels of the ubiquitin UNC4/5, a protein chaperone involved in 
integrating myosin into the sarcomere258, and ubiquitin-like protein SUMO-1–conjugating enzyme 9 
(UBC9), the sole conjugating (E2) enzyme for the small ubiquitin like modiﬁer protein (SUMO)259.  
There were no differences in mRNA expression levels of ubiquitin between GRMD and control 
muscles (Figure 34A), consistent with a previous study in DMD patients237.  UNC4/5 expression was 
decreased in GRMD left ventricle compared with controls, but it was unaffected in the ﬁve skeletal 
muscles (Figure 34B). UBC9 expression was signiﬁcantly increased only in the cranial sartorius 
compared with controls (Figure 34C). 
 Expression of Proteasome Subunits Is Significantly Decreased in GRMD Heart. We 
next determined the expression of three different proteasome subunits: PSMA6, PSMB4, and PSME1 
(Figure 35).  PSMA6 and PSMB4 are non-catalytic subunits of the 20S proteasome59, and PSME1 is 
the alpha subunit in the activator heteroheptamer ring, which binds to one or both ends of the 20S 
proteasome and allows peptides to enter the 20S subunit59.  GRMD left ventricle showed a signiﬁcant 
decrease in the expression of all three proteasome subunits (Figure 35A–C). PSMB4 was increased 
in four of the ﬁve GRMD skeletal muscles (Figure 35B). Expression of PSMA6 and PSME1 was 
unchanged in all GRMD skeletal muscles. 
 Proteasome Activity Is Generally Unchanged in GRMD Skeletal Muscle and Heart. 
Using a ﬂuorometric assay, we assayed proteasome trypsin-like, caspase-like, and chymotrypsin-like 
activities from GRMD and control animals in skeletal muscles and heart (Figure 36). The only 
signiﬁcantly different proteasome activity in GRMD muscles was found in the lateral head of the 
gastrocnemius, with increased trypsin-like activity. Individual animals had increases in caspase-like 
and chymotrypsin-like activity in the gastrocnemius as well, but these increases were not uniform. 
Similarly, all three activities were increased in the long-digital extensor, but this was not uniform 
among all the animals (i.e., not signiﬁcant). The disconnect between the decreased proteasome 
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expression shown in Figure 36 and the unaffected proteasome activities is pronounced in the GRMD 
left ventricle (Table 10). 
 Calpain 1 and 2 Expression Is Decreased in GRMD Heart. Calpains are Ca2+-dependent 
cysteine proteases that initiate the release of proteins from the myoﬁbril, making myoﬁbrillar proteins 
available for degradation by the UPS260.  Calpain 1 (µ-calpain) and calpain 2 (m-calpain), so named 
because they are activated by micromolar and millimolar Ca2+ concentrations, respectively, are the 
most widely studied members of the calpain family and have been shown to be involved in the 
pathogenesis of DMD232, 237, 238, 242, 261.  Because we found that the UPS is altered in GRMD muscle, 
we next measured calpain 1 and 2 expression in GRMD. Both calpain 1 and 2 expression were 
signiﬁcantly decreased in the GRMD left ventricle (Figure 37A and B). Calpain 2 expression was 
increased in many of the animals in all ﬁve GRMD skeletal muscles, although only three muscle 
groups reach signiﬁcance (gastrocnemius, vastus lateralis, and cranial sartorius) (Figure 37B). 
 Calpain 1 and 2 Activity Is Not Uniformly Increased in GRMD Skeletal Muscles and 
Heart. Calpain 1 and 2 activities were not signiﬁcantly different from that of age-matched controls in 
any of the skeletal muscles or left ventricle (Figure 37C). However, four of the ﬁve skeletal muscles 
and the left ventricle had individuals with increased calpain 1 and 2 activity, which did not reach 
signiﬁcance. 
Discussion 
 For nearly two decades, the role of intracellular proteolysis has been appreciated in DMD153.  
At least eight studies have reported that calpain and/or proteasome inhibition is beneﬁcial in disease 
(summarized in blue in Tables 11 and 12)232-236, 239-241.  Paralleling the therapeutic utility of calpain 
and proteasome inhibition with the mdx mouse phenotype, there has been largely uniform evidence in 
four studies that calpain and proteasome activities are enhanced in DMD (summarized in white in 
Tables 11 and 12). What is striking about these studies is that they largely investigated short-term 
proteasome and calpain inhibition on mainly the milder mdx muscular dystrophy in a very limited 
number of skeletal muscles, generally three or less. In this study, we investigated more broadly how 
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muscular dystrophy in the GRMD model affected components of the ubiquitin-proteasome system 
and the proteasome and calpain activities (summarized in Tables 9 and 10 and the Supplemental 
Results Section). Although we detected increased proteasome and calpain activities in a minority of 
the muscles tested, we found that the heart had dramatically decreased expression of ubiquitin ligases 
(CHIP, MDM2), the proteasome (PSMA6, PSMB4, PSME1), and calpains (calpain 1and calpain 2).  
This raises the concern that proteasome inhibition may inhibit proteasome and calpain activities in 
muscles that do not have increased proteolysis and may potentially further inhibit muscles that have 
decreased expression of ubiquitin proteasome components and calpains, particularly in the heart. 
 Inhibiting proteasome and calpain activities in muscles without increased activity is 
worrisome considering their diverse roles in the maintenance of the cell. This is a point that may have 
become obscured by the large number of studies implicating these proteolytic systems in the 
degradation of speciﬁc substrate targets in the sarcomere262, 263.  Activity of the proteasome has been 
implicated at multiple points in the regulation of gene expression264.  The 26S proteasome speciﬁcally 
plays a role in modifying activators, co-activators, and co-repressors of transcription necessary for 
gene transcription. Proteasome activity is also essential in numerous signaling pathways, including 
calcineurin, β-catenin, NF-κB, and caspases, which are responsible for the regulation of cell death265.  
Similar to the proteasome, the calpain system plays diverse roles in cell biology. For example, 
calpains have been implicated in proliferation, differentiation, cell cycle progression, apoptosis, and 
cell signaling266.  Calpain activity has been implicated in signal transduction through PKC, GSK3β, 
calcium/ calmodulin-dependent protein kinase (CaMK) II and IV, MLK kinase, and calcineurin 
(recently reviewed by Bukowska et al.266).  Calpains have also been implicated in the regulation of 
transcription factor regulation, including NF-κB, AP-1/c-Jun/c-Fos, and c-Myc, among others266.  
Given the diverse roles both the proteasome and calpains play in cell biology, inhibiting their activity 
broadly throughout all cells could potentially uncover many side effects, at the very least, and 
potentially worsen outcomes. 
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 Examples of potential side effects come from experimental studies of proteasome inhibitors. 
Proteasome inhibitors are useful for the treatment of multiple myeloma, because they enhance cell 
death in myeloma cells267.  How the heart may be affected by these therapies is just now starting to be 
appreciated. For example, inhibiting the proteasome in cardiomyocytes can induce cell death in 
cultured cardiomyocytes268, 269 and can adversely affect cardiac function in hearts challenged by 
pressure overload168, 270.  In humans treated with proteasome inhibitors for multiple myeloma, 
ischemic heart disease complications have been reported167, raising the concern of systemic 
proteasome inhibition. The activity of calpains in cardiomyocytes has also been implicated in cardiac 
pathology266.  Although inhibiting calpains experimentally has been shown to reduce myocardial 
stunning, contractile dysfunction due to tachypacing, and damage due to atrial ﬁbrillation, long-term 
therapeutic beneﬁts have not been studied266.  For example, although calpain inhibition may inhibit 
apoptosis in some cardiac conditions, it is not clear if this is protective or whether it induces 
alternative forms of cell death, namely necrosis 19813082.  Last, the complexity of interpreting all 
these studies is that DMD patients largely have an underlying cardiac defect caused by DMD itself. 
Speciﬁcally, most DMD patients exhibit dilated cardiomyopathy and ventricular arrhythmias due to 
their disease271-277, thus the heart has increases susceptibility to further insult.  This should raise 
concerns for unexpected side effects from inhibiting proteasome or calpain activity in a more 
complex milieu of DMD-related cardiac disease and should highlight the need for testing these 
therapies in DMD patients. 
 Limiting factors in this investigation include the number of animals studied and the 
variability seen in the GRMD disease model. Although statistical differences were seen in 19 of the 
parameters tested, an additional 19 parameters had trends that were close, but not statistically 
different (see Tables 9 and 10). The trends that did not reach statistical signiﬁcance were likely due 
to the fact that our study utilized a limited number of highly variable samples. This variation makes it 
more difﬁcult to delineate differences because of the heterogeneity of the population being 
investigated.  Despite these weaknesses, our major conclusions are largely not affected by these 
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issues and allow us to show that both the calpain and ubiquitin-proteasome systems are differentially 
regulated by different muscle types and are for the most part not increased. 
 Although we have emphasized the expanding role of the ubiquitin-proteasome and calpain 
systems in diverse biological processes, they are best known for their roles in protein quality control 
in muscle262, 263.  Because widespread destruction of muscle and the sarcomere is involved in the 
pathophysiology of muscular dystrophy, inhibiting the destruction of damaged proteins may be one 
reason that proteasome and calpain inhibition have worked. By slowing the destruction of damaged 
sarcomere, more sarcomere is kept and used, despite its imperfect quality. The build-up of 
posttranslational modiﬁcations and reduced quality control could be the compromise needed to 
maintain function. However, the concern is not so much for the few skeletal muscles improved with 
proteasome and/or calpain inhibition.  It is more for the heart, which in DMD patients is 
compromised to begin with and insulted further by inhibition of two of the three proteolytic systems 
necessary for maintaining the cardiomyocytes. 
Figure Legends 
 Figure 33. Ubiquitin ligase (E3) expression in golden retriever muscular dystrophy 
(GRMD). Quantitative mRNA expression analysis of the ubiquitin ligases (A) muscle ring finger 1 
(MuRF1), (B) muscle F-box protein (MAFbx), (C) carboxyl terminus of Hsp70-interacting protein 
(CHIP), and (D) mouse double minute-2 (MDM2) in GRMD lateral digital extensor, the lateral head 
of the gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. mRNA 
expression is shown as the fold change compared with age-matched control animals. Data represent 
3–5 dogs per group (outlined in Table 13), as indicated above each vertical boxplot. The vertical 
boxplot presents the median (50% percentile), indicated by the middle line inside the box, the 75th 
percentile indicated by the top of the box, and the 25th percentile indicated by the bottom of the box. 
A rank-sum test was used to determine the differences in mRNA expression. *P< 0.05. 
 Figure 34.  Expression of ubiquitin, UNC4/5, and the E2 ubiquitin-conjugating enzyme 
UBC9 in GRMD skeletal muscle and heart. Quantitative mRNA expression analysis of (A) 
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ubiquitin, (B) the protein chaperone UNC4/5, and (C) E2 UBC9 in the GRMD lateral digital extensor, 
the lateral head of the gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial 
sartorius. mRNA expression is shown as the fold change compared with age-matched control animals. 
Data represent 3–5 dogs per group (outlined in Table 13), as indicated above each vertical boxplot. 
The vertical boxplot presents the median (50th percentile), indicated by the middle line inside the 
box, the 75th percentile indicated by the top of the box, and the 25th percentile indicated by the 
bottom of the box. A rank-sum test was used to determine the differences in mRNA expression. *P < 
0.05. 
 Figure 35. Proteasome subunit expression in GRMD skeletal muscle and heart. 
Quantitative mRNA expression analysis of the proteasome subunits (A) PSMA6, (B) PSMB4, 
and (C) PSME1 in GRMD long digital extensor, lateral head of the gastrocnemius, vastus lateralis, 
biceps femoris, left ventricle, and cranial sartorius. mRNA expression is shown as the fold change 
compared with age-matched control animals. Data represent 3–5 dogs per group (outlined in Table 
13), as indicated above each vertical boxplot. The vertical boxplot presents the median (50th 
percentile), indicated by the middle line inside the box, the 75th percentile indicated by the top of the 
box, and the 25th percentile indicated by the bottom of the box. A rank-sum test was used to 
determine the differences in mRNA expression. *P<0.05. 
 Figure 36. Muscle-specific proteasome activities in GRMD. (A) Trypsin-like, (B) caspase-
like, and (C) chymotrypsin-like activities in GRMD long digital extensor, lateral head of the 
gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. Proteasome 
activities are presented as arbitrary fluorescent units (AFU). Data represent 3–5 dogs per group 
(outlined in Table 13), as indicated above each vertical boxplot. The vertical box plot presents the 
median (50th percentile), indicated by the middle line inside the box, the 75th percentile indicated by 
the top of the box, and the 25th percentile indicated by the bottom of the box. A rank-sum test was 
used to determine the differences in proteasome activity. *P <0.05. 
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 Figure 37. Muscle-specific calpain 1 and 2 activities in GRMD. Quantitative mRNA 
expression analysis of (A) calpain 1, and (B) calpain 2 in GRMD long digital extensor, lateral head of 
the gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. Expression 
levels are presented as a percentage of age-matched controls. (C) Calpain 1 and 2 activity determined 
by a fluorometric assay based on GRMD long digital extensor, lateral head of the gastrocnemius, 
vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. mRNA expression is shown as the 
fold change compared with age-matched control animals. Calpain 1 and 2 activity presented as 
relative fluorometric units. Data represent 3–5 dogs per group (outlined in Table 13), as indicated 
above each vertical boxplot. The vertical boxplot presents the median (50th percentile), indicated by 
the middle line inside the box, the 75th percentile indicated by the top of the box, and the 25th 
percentile indicated by the bottom of the box. A rank-sum test was used to determine the differences 
in mRNA expression and calpain 1 and 2 activity. *P< 0.05. 
Supplemental Results 
 Previous studies of the proteasome and calpain systems in muscular dystrophy.  The 
effects of proteasome inhibition on the mdx mouse phenotype has been reported at least 3 times on 
mice 7 weeks, 6 months, and 8 months old (Table 11)233, 234, 239.  These studies have shown 
improvement in terms of the dystrophin-glycoprotein-complex stability histologically in the 
gastrocnemius and diaphragm using mdx mice 7 weeks to 8 months old as determined by muscle 
architecture after 24 hours to 14 days233, 234, 239.  In humans, the proteasome inhibitor Velcade was just 
reported to stabilize the dystrophin-glycoprotein-complex in quadricep explants from 8 DMD patients 
after 16 hours at 2 doses239.  While these studies are impressive, they do not address a number of 
issues raised in the present study. First, they have not looked at the effect of proteasome therapy in a 
diversity of muscles, particularly the heart, where the ubiquitin proteasome system has been shown to 
regulate many signaling processes associated with cardiac disease (as recently reviewed278).  The 
present study demonstrates that many skeletal muscles and the heart do not have enhanced 
proteasome activities (Table 9), raising the question of how therapies which inhibit the proteasome 
100 
may complicate DMD disease by altering the protein quality control mechanisms largely attributed to 
the ubiquitin proteasome system103, 265, 278, 279.   
 Five previous studies have reported the efficacy of calpain inhibition in the mdx model of 
DMD (Table 12).  Mdx mice ages 2-5 weeks old were treated with pharmacologic calpain inhibitors 
or had transgenic expression of the calpain inhibitor calpastatin232, 235, 236, 240, 241.  These studies found 
histological and functional improvements in ~6 muscles after 4 weeks of treatment. However, studies 
investigating the effects of calpain inhibition for 6 months did not find durable improvement in 
diaphragm function240.  Since only the diaphragm was tested in this study, it is difficult to extrapolate 
these findings to other critical muscles. Similarly, it is difficult to extrapolate the uniform 
improvement of muscle histologically over short term treatments in a model of DMD that is so mild 
(mdx). In more severe disease, such as GRMD, it is not clear how calpain inhibition would affect the 
muscles which do not have enhanced calpain activities, such as the gastrocnemius, vastus lateralis, 
and cranial sartorius (Table 9). 
Supplemental Discussion 
 In the current study, we identified that the expression of ubiquitin is not significantly affected 
in GRMD (Figure 26A). Only 1 previous study has investigated how the expression of ubiquitin is 
regulated in DMD patients. Like the current study, 5 patients ages 7-21 did not have changes in 
ubiquitin expression280.  The changes in UNC4/5 and UBC9 found in the current study have 
previously not been investigated. 
 The findings in the current study suggest that the proteasome number is decreased in the 
heart. The expression of the β-subunit of the proteasome (e.g. PSMB4) is generally indicative of the 
number of assembled proteasomes in the cell280, 281.  In Figure 27B, we identified decreased PSMB4, 
which may indicate a decrease in proteasome number in the GRMD heart. Yet PSMB4 is increased in 
four of the five GRMD skeletal muscles tested (Figure 27B). A study of 2 DMD patients reported 
that biceps and rectus femoris biopsies had significantly increased 26S proteasome-positive fibers by 
IHC154.  Another study of 5 DMD patients (ages 7-21) identified no changes in the RC2 and HC2 
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proteasome subunits in the deltoid, triceps, hip adductor, and tensor fasciae237.  The findings in the 
current study on skeletal muscle are consistent with both of these studies with either increases of or 
no effect on proteasome numbers. Our identification of decreased expression of all three proteasome 
subunits in in the heart is the first known report of the cardiac proteasome makeup in DMD and/or 
DMD models and may reflect its unique biology. 
 Despite either increases in PSMB4 subunits in 4 of the 5 skeletal muscles, we only identified 
increases in proteasome activity in the lateral head of the gastrocnemius. Here we only saw increases 
in the trypsin like activity (Figure 28A). This disconnect between expression and activity may be 
due to the influence of post-translational modifications on proteasome activity, such as 
phosphorylation.  For example, recent studies have shown that PKA phosphorylation of the catalytic 
subunits in the core 20S proteasome in the heart stimulates all three types of proteasome activities 282.  
Since abnormal changes in PKA localization and activity have been reported in dystrophic muscle283, 
284, it is possible that dystrophic regulation of PKA may alter proteasome activities, and these 
alterations are muscle/heart specific. 
 A similar disconnect between increased calpain 2 mRNA expression and activity was also 
identified in Figure 29. The increased calpain 2 expression in the 3 skeletal muscles did not affect the 
calpain 1/2 activity (gastrocnemius, vastus lateralis, cranial sartorius) (Table 9). Similarly, the 
decreased calpain 1 and 2 expression did not affect calpain 1/2 activity in the left ventricle (Table 9). 
One possible explanation for this disconnect may be the muscle-specific levels of Ca2+ in GRMD 
muscles. Increased intracellular Ca2+ has been reported in the necrotic fibers of several GRMD 
muscles285.  In addition, the flexor digitorum brevis, lumbrical muscles of the hind limb, isolated 
myotubes, and cardiomyocytes of mdx mice have been shown to have increased intracellular Ca2+ 
concentration286-290.  Millay and colleagues291 have shown that Ca2+ influx alone, through the 
overexpression of a nonselective cation channel called transient receptor potential canonical 3 
(TRPC3), can induce a muscular dystrophy-like phenotype in mouse quadriceps. The increased 
intracellular Ca2+
 
in dystrophic myocytes is believed to occur by several mechanisms, including the 
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dysregulation of sarcolemmal and sarcoplasmic reticulum Ca2+
 
channels, microruptures in the 
sarcolemma and the sarcoplasmic reticulum, and involvement of Ca2+-binding proteins292.  Therefore, 
muscle-specific increases in Ca2+ may therefore drive calpain 1/2 activity in GRMD muscles, 
independent of the expression of calpain 1 and 2. 
 The X-linked GRMD model of muscular dystrophy is caused by a mutation at the consensus 
splice acceptor site in intron 6 of the canine dystrophin gene293.  Previous studies on the GRMD 
cohort used in these studies have determined that specific skeletal muscle types atrophy (long digital 
extensor) while others demonstrate true hypertrophy (cranial sartorius), as summarized in Table 9, 
right columns161.  In the present study we found that the muscle with severe atrophy (long digital 
extensor) unique had the most upregulation of the ubiquitin proteasome and calpain systems, although 
many of these are near signficance (Table 9, top row). However, muscles undergoing atrophy 
(gastrocnemius and biceps formalis) or hypertrophy (cranial sartorius) do not have unique 
UPS/calpain system expression or activity signatures (Table 9), indicating that the 2 may not 
necessarily be related and/or the complex pathophysiology of DMD may be complicating the 
relationship between the two.
103 
TABLES 
TABLE 1 – Echocardiographic analysis of conscious MuRF1 +/+ and sibling-matched wildtype control 
mice at baseline and 5 weeks after voluntary running (or sham conditions). 
104 
Rarely, mice stopped running and were excluded from further study (preventing a repeated measures 
statistical analysis).  Data is represented as mean±standard error. A one-way ANOVA was performed to 
compare among all 8 groups.  *p<0.01 vs. all other groups.  **p<0.05 vs. all baseline8 
                                                     
8 As of this writing, this table appears in an Article in Press (published January 14, 2014) in American Journal of 
Physiology Endocrinology and Metabolism at the following website: 
http://ajpendo.physiology.org/content/early/2014/01/09/ajpendo.00326.2013 DOI:10.1152/ajpendo.00326.2013 
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TABLE 2 – Echocardiographic analysis of conscious MuRF1 Tg+ and sibling-matched wildtype control 
mice at baseline and 5 weeks after voluntary running (or sham conditions).  
     
106 
Rarely, mice stopped running and were excluded from further study (preventing a repeated measures 
statistical analysis).  Data is represented as mean±standard error. A one-way ANOVA was performed to 
compare among all 8 groups.  *p<0.01 vs. all other groups.  **p<0.05 vs. all other groups (except MuRF1 
Wildtype Baseline Sham).  &p<0.01 vs. MuRF1 Wildtype Baseline groups.  &&p<0.01 vs. all wildtype 
groups9 
                                                     
9 As of this writing, this table appears in an Article in Press (published January 14, 2014) in American Journal of 
Physiology Endocrinology and Metabolism at the following website: 
http://ajpendo.physiology.org/content/early/2014/01/09/ajpendo.00326.2013 DOI:10.1152/ajpendo.00326.2013 
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TABLE 3 – Voluntary wheel running exercise performance of MuRF1+/+ and MuRF1-/- mice.   
 
108 
MuRF1+/+ n=8-9 per group per week; MuRF1-/- n=8 per week.  Rarely, mice stopped running and were 
excluded from further study (preventing a repeated measures statistical analysis).  Data is represented as 
mean±standard error.  A Student’s t-test was performed to compare MuRF1+/+ and MuRF1-/- for each 
week.  *p<0.05, #<0.00110 
                                                     
10 As of this writing, this table appears in an Article in Press (published January 14, 2014) in American Journal of 
Physiology Endocrinology and Metabolism at the following website: 
http://ajpendo.physiology.org/content/early/2014/01/09/ajpendo.00326.2013 DOI:10.1152/ajpendo.00326.2013 
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TABLE 4 – Voluntary wheel running exercise performance of WildtypeMuRF1Tg+ and MuRF1Tg+ mice 
 
110 
WildtypeMuRF1Tg+ n=6-8 per week; MuRF1Tg+ n=7 per week.  Rarely, mice stopped running and were 
excluded from further study (preventing a repeated measures statistical analysis).  Data is represented as 
mean±standard error.  A Student’s t-test was performed to compare WildtypeMuRF1Tg+ and MuRF1Tg+ for 
each week.  No differences between groups was identified (p>0.05)11 
                                                     
11 As of this writing, this table appears in an Article in Press (published January 14, 2014) in American Journal of 
Physiology Endocrinology and Metabolism at the following website: 
http://ajpendo.physiology.org/content/early/2014/01/09/ajpendo.00326.2013 DOI:10.1152/ajpendo.00326.2013 
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TABLE 5 – High resolution transthoracic echocardiography performed on conscious MuRF1-/- and age-
matched wild type mice at baseline, 1 week, and 2 weeks after daily i.p. T3 treatment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MuRF1 
+/+ 
Baseline 
N=10 
 
MuRF1  
-/- 
Baseline 
N=12 
MuRF1 
+/+ 
Thyroid 
Hormone 
1 Week 
N=10 
MuRF1  
-/- 
Thyroid 
Hormone 
1 Week 
N=12 
MuRF1 
+/+ 
Thyroid 
Hormone 
2 Weeks 
N=10 
MuRF1  
-/- 
Thyroid 
Hormone 
2 Weeks 
N=12 
AWTD (mm) 1.05+ 
0.02 
1.13+ 0.04 1.20+ 0.03 1.60+ 0.09 1.38+ 0.04 1.70+ 0.07 
LVEDD (mm) 3.03+ 
0.11 
3.08+ 0.12 3.13+ 0.13 3.87+ 0.15 3.11+ 0.11 3.00+ 0.14 
PWTD (mm) 0.97+ 
0.02 
1.04+ 0.04 1.12+ 0.02 1.37+ 0.07 1.28+ 0.05 1.58+ 0.05 
AWTS (mm) 1.77+ 
0.04 
1.82+ 0.06 1.97+ 0.02 2.23+ 0.08 2.23+ 0.07 2.44+ 0.06 
LVEDS (mm) 1.36+ 
0.05 
1.42+ 0.07 1.44+ 0.08 1.11+ 0.07 1.42+ 0.08 1.25+ 0.08 
PWTS (mm) 1.58+ 
0.01 
1.65+ 0.07 1.81+ 0.06 2.10+ 0.08 1.93+ 0.08 2.18+ 0.07 
LV Vol;d (l) 36.5+ 3.3 38.2+ 3.8 39.8+ 3.7 32.6+ 3.8 39.0+ 3.4 36.3+ 4.1 
LV Vol;s (l) 4.8+ 0.5 5.5+ 0.8 5.8+ 0.8 3.0+ 0.5 5.7+ 1.0 4.0+ 0.7 
EF% 86.8+ 0.5 86.0+ 0.6 86.0+ 1.0 90.9+ 0.8 86.0+ 1.3 89.4+ 0.7 
FS% 55.0+ 0.6 54.1+ 0.7 54.3+ 1.2 61.2+ 1.3 54.5+ 1.5 58.8+ 1.1 
LV Mass (mg) 
107.3+ 
6.1 
124.8+ 
11.1 
139.4+ 7.6 187.8+ 
17.6 
170.3+ 8.8 237.4+ 
19.8 
LV Mass/BW 
(mg/g) 
4.1+ 0.3 4.7+ 0.2 5.2+ 0.3 6.4+ 0.2 5.9+ 0.3 8.0+ 0.2 
BW (g) 26.1+ 0.8 26.7+ 2.5 27.3+ 0.7 29.0+ 1.9 28.9+ 1.1 29.5+ 1.8 
LV Mass/TL (mm) 6.3+ 0.3 7.5+ 0.7 8.2+ 0.4 11.4+ 0.9 10.0+ 0.5 14.3+ 1.0 
HR (bpm) 665+ 9 670+ 13 708+ 21 727+ 11 730+ 14 729+ 10 
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Data represent means ± SEM.  HR, heart rate; ExLVD, external left ventricular diameter; bpm, heart beats 
per minute; AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole; PWTD, 
posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; LVEDD, left ventricular 
end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, 
calculated as (LVEDD-LVESD)/LVEDD x 100; EF%, ejection fraction calculated as (end Simpson’s 
diastolic volume – end Simpson’s systolic volume)/end Simpson’s diastolic volume * 100 
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TABLE 6 – High resolution transthoracic echocardiography performed on conscious on MuRF1 Tg+ and 
age-matched wild type mice at baseline, 1 week, and 2 weeks after daily i.p. T3 treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MuRF1 
wildtypeT
g+ 
Baseline 
N=16 
 
MuRF1 
Tg+ 
Baseline 
N=11 
MuRF1  
wildtypeTg
+ 
Thyroid 
Hormone 
1 Week 
N=16 
MuRF1 
Tg+ 
Thyroid 
Hormon
e 1 Week 
N=10 
MuRF1 
wildtypeTg+ 
Thyroid 
Hormone 2 
Weeks 
N=16 
MuRF1 
Tg+ 
Thyroid 
Hormone 
2 Weeks 
N=11 
AWTD (mm) 1.05+0.02 0.96+0.0
3 
1.35+0.03 1.08+0.0
3 
1.44+0.04 1.10+0.04 
LVEDD (mm) 3.06+ 0.08 3.17+0.1
6 
2.12+ 0.04 1.78+ 
0.04 
2.12+ 0.04 1.70+ 0.05 
PWTD (mm) 1.02+ 0.02 0.96+ 
0.02 
3.15+ 0.10 3.27+ 
0.11 
3.20+ 0.11 3.54+ 0.13 
AWTS (mm) 1.70+ 0.05 1.54+ 
0.06 
1.48+ 0.07 1.80+ 
0.09 
1.64+ 0.10 2.23+ 0.14 
LVESD (mm) 1.53+ 0.07 1.88+ 
0.14 
1.36+ 0.06 1.18+ 
0.12 
1.41+ 0.04 1.11+ 0.03 
PWTS (mm) 1.58+ 0.04 1.33+ 
0.06 
1.86+ 0.05 1.60+ 
0.03 
1.92+ 0.05 1.50+ 0.06 
LV Vol;d (l) 37.4+ 2.4 41.6+ 4.6 40.3+ 3.0 44.1+ 3.7 42.1+ 3.3 53.4+ 4.6 
LV Vol;s (l) 6.8+ 0.8 12.0+ 2.1 6.3+ 0.9 10.4+ 1.1 8.5+ 1.4 17.9+ 2.4 
EF% 82.5+ 1.3 72.9+ 2.4 84.9+ 1.1 74.6+ 4.1 81.3+ 1.8 67.4+ 3.1 
FS% 50.4+ 1.4 41.2+ 1.9 53.1+ 1.3 43.6+ 3.4 49.4+ 1.8 37.3+ 2.5 
LV Mass (mg) 
116.6+ 7.3 107.4+ 
9.3 
178.5+ 8.3 137.7+ 
7.4 
201.8+ 
110.8 
155.0+ 
10.2 
LV Mass/BW (mg/g) 4.1+ 0.3 5.1+ 0.7 6.2+ 0.2 5.2+ 0.3 6.7+ 0.2 5.5+ 0.3 
BW (g) 29.3+ 1.3 27.7+ 1.8 29.9+ 1.1 26.9+ 1.5 29.8+ 0.9 28.1+ 1.1 
LV Mass/TL (mm) 6.8+ 0.4 5.1+ 0.5 10.3+ 0.5 7.9+ 0.4 11.8+ 0.6 9.2+ 0.7 
HR (bpm) 711+ 13 679+ 10 802+ 9 802+ 7 798+ 13 768+ 6 
 
114 
Data represent means ± SEM.  HR, heart rate; ExLVD, external left ventricular diameter; bpm, heart beats 
per minute; AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole; PWTD, 
posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; LVEDD, left ventricular 
end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, 
calculated as (LVEDD-LVESD)/LVEDD x 100; EF%, ejection fraction calculated as (end Simpson’s 
diastolic volume – end Simpson’s systolic volume)/end Simpson’s diastolic volume * 100 
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TABLE 7 – High resolution transthoracic echocardiography performed on conscious MuRF1-/- and age-
matched wild type mice at baseline, 1 week, and 2 weeks after sham daily i.p. treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MuRF1  
+/+ 
Baseline 
N=4 
MuRF1  
-/- 
Baseline 
N=5 
MuRF1  
+/+ 
Vehicle 
1 Week 
N=8 
MuRF1  
-/- 
Vehicle 
1 Week 
N=8 
MuRF1  
+/+ 
Vehicle 
 2 Weeks 
N=7 
MuRF1  
-/- 
Vehicle 
 2 Weeks 
N=8 
AWTD (mm) 1.00+0.02 1.12+ 0.07 1.05+ 0.02 1.17+ 0.04 1.05+ 0.03 1.15+ 0.04 
LVEDD (mm) 3.13+ 0.30 3.38+ 0.37 2.84+ 0.08 3.15+ 0.08 3.05+ 0.11 3.07+ 0.19 
PWTD (mm) 1.06+ 0.05 1.13+ 0.05 1.04+ 0.03 1.19+ 0.03 1.03+ 0.03 1.19+ 0.03 
AWTS (mm) 1.69+ 0.02 1.93+ 0.13 1.77+ 0.04 2.13+ 0.04 1.72+ 0.03 2.07+ 0.06 
LVEDS (mm) 1.48+ 0.15 1.51+ 0.21 1.25+ 0.06 1.39+ 0.05 1.38+ 0.08 1.39+ 0.11 
PWTS (mm) 1.69+ 0.03 1.91+ 0.04 1.69+ 0.05 2.08+ 0.07 1.64+ 0.04 2.00+ 0.06 
LV Vol;d (l) 39.8+ 6.4 50.2+ 12.0 30.9+ 2.1 39.7+ 2.3 37.0+ 3.1 38.8+ 5.8 
LV Vol;s (l) 6.3+ 1.7 7.1+ 2.5 3.9+ 0.5 5.0+ 0.4 5.1+ 0.72 5.4+ 1.1 
EF% 85.0+ 1.8 87.0+ 1.4 87.7+ 0.80 87.5+ 0.5 86.6+ 1.1 86.8+ 0.9 
FS% 53.0+ 2.0 55.7+ 1.4 56.0+ 1.0 56.1+ 0.7 55.0+ 1.5 55.2+ 1.0 
LV Mass (mg) 
117.6+ 
17.0 
153.0+ 
26.5 
102.9+ 3.0 153.7+ 7.0 91.5+ 5.8 143.2+ 
13.0 
LV Mass/BW (mg/g) 4.59+ 0.68 4.83+ 0.65 4.40+ 0.30 5.11+ 0.27 5.2+ 0.4 5.4+ 1.1 
BW (g) 25.7+ 0.8 31.1+ 2.0 24.9+ 0.40 30.4+ 1.4 24.6+ 0.6 30.0+ 1.3 
LV Mass/TL 
(mg/mm) 
6.7+ 0.9 9.0+ 1.7 5.8+ 0.2 8.3+ 0.5 6.5+ 0.4 6.5+ 0.8 
HR (bpm) 618+ 41 616+ 25 717+ 8 632+ 21 683+ 18 631+ 27 
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Data represent means ± SEM.  HR, heart rate; ExLVD, external left ventricular diameter; bpm, heart beats 
per minute; AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole; PWTD, 
posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; LVEDD, left ventricular 
end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, 
calculated as (LVEDD-LVESD)/LVEDD x 100; EF%, ejection fraction calculated as (end Simpson’s 
diastolic volume – end Simpson’s systolic volume)/end Simpson’s diastolic volume * 100
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TABLE 8 – High resolution transthoracic echocardiography performed on conscious on MuRF1 Tg+ and 
age-matched wild type mice at baseline, 1 week, and 2 weeks after sham daily i.p. treatment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MuRF1 
wildtypeTg+ 
Baseline 
 
N=4 
 
MuRF1 
Tg+ 
Baseline 
 
N=5 
 
MuRF1  
wildtypeTg+ 
Vehicle 
1 Week 
N=4 
 
MuRF1 
Tg+ 
Vehicle 
1 Week 
N=5 
 
MuRF1 
wildtypeTg 
Vehicle 
2 Weeks 
N=4 
 
MuRF1 
Tg+ 
Vehicle 
2 Weeks 
N=4 
AWTD (mm) 0.98+ 0.03 0.98+ 0.06 0.96+  0.04 0.93+ 0.04 0.99+ 0.04 0.97+ 0.08 
LVEDD (mm) 3.09+ 0.23 2.80+ 0.05 2.99+ 0.21 2.87+ 0.02 2.97+ 0.11 3.02+ 0.18 
PWTD (mm) 1.01+ 0.05 1.00+ 0.06 1.06+ 0.03 1.04+ 0.05 1.05+ 0.05 0.98+ 0.07 
AWTS (mm) 1.72+ 0.10 1.51+ 0.09 1.70+ 0.02 1.59+ 0.06 1.69+ 0.08 1.55+ 0.13 
LVEDS (mm) 1.51+ 0.22 1.45+ 0.13 1.40+ 0.22 1.35+ 0.09 1.34+ 0.15 1.53+ 0.13 
PWTS (mm) 1.50+ 0.09 1.48+ 0.10 1.54+ 0.10 1.53+ 0.12 1.60+ 0.05 1.49+ 0.12 
LV Vol;d (l) 38.7+ 7.0 31.4+ 2.0 35.7+ 6.1 31.3+ 0.4 34.4+ 3.1 36.5+ 5.2 
LV Vol;s (l) 4.4+ 0.9 5.9+ 1.1 5.8+ 2.2 4.8+ 0.8 4.9+ 1.4 6.8+ 1.4 
EF% 83.6+ 3.7 81.4+ 3.6 85.4+ 3.8 84.8+ 2.6 86.5+ 2.8 81.4+ 3.5 
FS% 51.8+ 3.7 49.2+ 3.6 54.2+ 4.3 52.8+ 3.0 55.2+ 3.5 49.2+ 3.7 
LV Mass (mg) 
107.6+ 11.6 95.2+ 7.5 105.8+ 13.2 94.4+ 5.8 104.8+ 2.8 102.2+ 
13.6 
LV Mass/BW (mg/g) 4.5+ 0.8 4.1+ 0.2 4.5+ 0.6 4.2+ 0.1 4.4+ 0.3 4.1+ 0.3 
BW (g) 24.8+ 1.0 23.0+ 0.5 23.3+ 1.1 22.3+ 0.8 24.1+ 1.1 24.4+ 1.7 
LV Mass/TL (mg/mm) 5.4+ 1.3 5.6+ 0.5 6.3+ 0.8 5.3+ 0.3 6.3+ 0.2 6.0+ 0.7 
HR (bpm) 707+ 24 703+ 9 709+ 16 711+ 20 698+ 13 738+ 11 
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Data represent means ± SEM. HR, heart rate; ExLVD, external left ventricular diameter; bpm, heart beats 
per minute; AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole; PWTD, 
posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; LVEDD, left ventricular 
end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, 
calculated as (LVEDD-LVESD)/LVEDD x 100; EF%, ejection fraction calculated as (end Simpson’s 
diastolic volume – end Simpson’s systolic volume)/end Simpson’s diastolic volume * 100
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TABLE 9 – Summary of ubiquitin-proteasome system expression in Golden retriever muscular dystrophy 
(GRMD) skeletal muscle and heart compared with age-matched controls.   
120 
‘‘Inc’’: mRNA expression or protease activity was significantly increased for the indicated GRMD 
muscle compared with wildtype; ‘‘—’’: protease activity was unchanged for the indicated GRMD muscle 
compared with wildtype; ‘‘Dec’’: expression was decreased in GRMD samples compared with controls. 
P-values given for relationships trending (<0.2); the direction of the trend is given in parentheses12
                                                     
12 This table previously appeared in Muscle and Nerve.  The original citation for the publication which includes this 
table is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
121 
TABLE 10 – Summary of proteasome and calpain expression and activities in Golden retriever muscular 
dystrophy (GRMD) skeletal muscle and heart compared with age-matched controls
122 
“Exp”: expression; Atrophy/hypertrophy data adapted from Kornegay et al.161.  “Inc”: mRNA expression 
or protease activity was significantly increased for the indicated GRMD muscle compared with the 
wildtype; “—“: protease activity was unchanged for the indicated GRMD muscle compared with 
wildtype; “Dec”: expression was decreased in GRMD samples compared with wildtype.  “ND”: denotes 
that the atrophy/hypertrophy data was not previously determined.  P-values given for relationships 
trending (<0.2); the direction of the trend is given in parentheses13  
                                                     
13 This table previously appeared in Muscle and Nerve.  The original citation for the publication which includes this 
table is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
123 
TABLE 11 – The regulation of proteasome activity and role of proteasome inhibition in Duchenne 
muscular dystrophy. 
124 
Studies using proteasome inhibitors are shaded in blue.  Search criteria included:  “muscular 
dystrophy proteasome inhibition” and “muscular dystrophy proteasome” in PubMed. “DGC”: 
dystrophin-glycoprotein complex14 
                                                     
14 This table previously appeared in Muscle and Nerve.  The original citation for the publication which includes 
this table is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
125 
TABLE 12 – The regulation of calpain activity and role of calpain inhibition in Duchenne muscular 
dystrophy
126 
Studies using calpain inhibitors are shaded in blue.  Search criteria included: “muscular dystrophy 
calpain inhibitor”, “muscular dystrophy calpain”, and “mdx calpain” in PubMed15 
                                                     
15 This table previously appeared in Muscle and Nerve.  The original citation for the publication which includes 
this table is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
127 
TABLE 13 – Sample information for Golden retriever muscular dystrophy (GRMD) and control dogs.  
128 
Skeletal muscle and heart samples were collected from both GRMD and control canines at 6 months of 
age. X=used in this study. N=samples collected at necropsy; B=samples collected by biopsy. Yellow 
indicates samples used for one muscle type only16 
                                                     
16 This table previously appeared in Muscle and Nerve.  The original citation for the publication which includes this 
table is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
129 
FIGURES 
FIGURE 1 – Molecular mechanisms driving physiological cardiac hypertrophy 
130 
FIGURE 2 – The ubiquitin proteasome system17 
 
  
 
 
                                                     
17 Part of this figure has previously appeared in American Journal of Physiology Heart and Circulatory Physiology.  
The original citation for the publication which includes this figure is as follows: Am J Physiol Heart Circ Physiol 
2012 Feb 1;302(3):H515-26. 
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FIGURE 3 – Knockdown of MuRF1 enhances and increased expression of MuRF1 represses insulin-
like growth factor-1 (IGF-1)-induced cardiomyocyte hypertrophy18 
 
                                                     
18 As of this writing, this figure appears in an Article in Press (published January 14, 2014) in American Journal 
of Physiology Endocrinology and Metabolism at the following website: 
http://ajpendo.physiology.org/content/early/2014/01/09/ajpendo.00326.2013 DOI:10.1152/ajpendo.00326.2013 
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A. MuRF1 was knocked down using AdshMuRF1, with Adshscrambled as control, at MOI 60 for 24 
hours in serum-free DMEM followed by treatment with 10nM IGF-1 for 18 hours. Cells were fixed 
and observed with a fluorescent microscope using a 40X objective lens. Shown are representative 
images of vehicle or IGF1-treated HL-1 cardiomyocytes transduced with either Adshscrambled or 
AdshMuRF1. B. Cardiomyocyte area (mm2) measurements of vehicle or IGF1-treated HL-1 
cardiomyocytes transduced with either Adshscrambled or AdshMuRF1, averaged over at least 200 
cardiomyocytes. Black bars represent vehicle and gray bars represent IGF-1-treated cells C. MuRF1 
was increased in expression using AdMuRF1, with AdGFP as a control, at MOI 25 for 24 hours in 
serum-free DMEM followed by treatment with IGF-1 for 18 hours. Shown are representative 
fluorescent images of vehicle or IGF1-treated HL-1 cardiomyocytes transduced with either AdGFP or 
AdMuRF1. D. Cardiomyocyte area (mm2) measurements of vehicle or IGF1-treated HL-1 
cardiomyocytes transduced with either AdGFP or AdMuRF1. Black bars represent vehicle-and gray 
bars represent IGF-1-treated cells. Cardiomyocyte area measurements are represented as mean area ± 
SEM. E. MuRF1 was increased in expression in NRVM using AdMuRF1, with AdGFP as a control, 
at MOI 25 for 24 hours in serum-free M199 followed by treatment with IGF-1 for 18 hours. Shown 
are representative fluorescent images of vehicle or IGF1treated cardiomyocytes transduced with 
either AdGFP or AdMuRF1. F. Cardiomyocyte area (mm2) measurements of vehicle or IGF1-treated 
NRVM transduced with either AdGFP or AdMuRF1. Black bars represent vehicle-and gray bars 
represent IGF-1-treated cells. Cardiomyocyte area measurements are represented as mean area ± 
SEM. A two-way ANOVA test was used to determine statistical significance. *indicates significance 
on level of adenovirus group, **indicates significance on level of treatment group. %indicates a 
significant interaction between adenovirus and treatment groups. The F statistic and degrees of 
freedom (DF) were reported when dependence between groups was found to be a significant source 
of variation.  Significance between groups is represented as #P< 0.05, ##P< 0.001 as determined 
using a pairwise post-test. 
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FIGURE 4 – Insulin-like growth factor-1 (IGF-1)-dependent expression of genes associated with Akt 
activity is inhibited by MuRF119 
                                                     
19 As of this writing, this figure appears in an Article in Press (published January 14, 2014) in American Journal of 
Physiology Endocrinology and Metabolism at the following website: 
http://ajpendo.physiology.org/content/early/2014/01/09/ajpendo.00326.2013 DOI:10.1152/ajpendo.00326.2013 
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A. AdshMuRF1 and control Adshscrambled were used at MOI 60 for 24 hours in serum-free DMEM to 
knockdown MuRF1 in HL-1 cardiomyocytes and transduced cells were treated with 10nM IGF-1 for 18 
hours. RNA was isolated and cDNA generated for use in measuring expression of MuRF1, MAPK13, 
RYR1, Igfbp5, and 18S (reference gene). Shown are RTPCR data for each of these genes in vehicle or 
IGF-1-treated HL-1 cardiomyocytes transduced with either Adshscrambled or AdshMuRF1. B. 
AdMuRF1 and control AdGFP were used at MOI 25 for 24 hours in serum-free DMEM to increase 
MuRF1 and transduced cells were treated with 10nM IGF-1 for 18 hours. Shown are RT-PCR data for 
MuRF1, MAPK13, RYR1, and Igfbp5 in cardiomyocytes transduced with either AdGFP or AdMuRF1 
and treated with either vehicle or IGF-1. Raw CT values from three independent experiments were 
normalized to their respective 18S values, averaged over experimental group, and subsequently 
normalized to either to vehicle control (MAPK13, RYR1, and Igfbp5) or adenovirus control (MuRF1). 
Final data is represented as mean fold change ± SEM. A two-way ANOVA test was used to determine 
statistical significance. * indicates significance on level of adenovirus group. **indicates significance on 
level of treatment group. % indicates a significant interaction between adenovirus and treatment groups. 
The F statistic and degrees of freedom (DF) were reported when dependence between groups was found 
to be a significant source of variation. Significance between groups are represented as #P< 0.05, ##P< 
0.001 as determined using a pairwise post-test.  $ indicates significance (p<0.05) between groups within 
the treatment group, as measured by a Student’s t-test. 
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FIGURE 5 – MuRF1 inhibits protein expression of Akt and glycogen synthase kinase 3β (GSK3β) in 
insulin-like growth factor-1 (IGF-1)-stimulated HL-1 cardiomyocytes20 
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A. HL-1 cells were transduced with AdMuRF1 or control AdGFP at MOI 25 for 24 hours in serum-free 
DMEM to increase MuRF1 expression, followed by treatment with 10nM IGF-1 for 30 minutes. 
Immunoblots using whole cell lysates from three independent experiments are shown for p-Akt S473, p-
Akt T308, Akt, GSK3β, and p-GSK3β S9. Primary antibody against myc was used to assess adenovirus-
dependent expression of myc-MuRF1 and immunoblot for MuRF1 was done to determine endogenous 
protein levels. β-actin was used as a loading control. Densitometry analysis of Akt, p-Akt S473, p-Akt 
T308, GSK3β, and p-GSK3β S9 are shown for vehicle or IGF-1-treated cardiomyocytes transduced with 
either AdGFP or AdMuRF1. Total protein levels were normalized to β-actin and phospho-protein levels 
were normalized first to β-actin and then to total protein levels. B. HL-1 cardiomyocytes were transduced 
with either AdshMuRF1 or control Adshscrambled at MOI 30 for 48 hours in serum-free DMEM, 
followed by treatment with 10nM IGF-1 for 30 minutes. Akt and GSK3β expression and phosphorylation 
in whole cell lysates from three independent experiments was assessed by immunoblot using primary 
antibodies raised against total Akt or GSK3β and p-Akt S473, p-Akt T308, and p-GSK3β S9, as 
indicated. Primary antibody against MuRF1 was used to confirm knockdown. β-actin was used as a 
loading control. Densitometry analysis of Akt, p-Akt S473, p-Akt T308, GSK3β, and p-GSK3β S9 are 
shown for vehicle or IGF-1-treated cardiomyocytes transduced with either Adshscrambled or 
AdshMuRF1. Densitometry analysis is represented as means ± SEM. A two-way ANOVA test was used 
to determine statistical significance. * indicates significance on level of adenovirus group. ** indicates 
significance on level of treatment group. % indicates a significant interaction between adenovirus and 
treatment groups. The F statistic and degrees of freedom (DF) were reported when dependence between 
groups was found to be a significant source of variation. Significance between groups are represented as 
#P< 0.05, ##P< 0.001 as determined using a pairwise post-test. 
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FIGURE 6 – MuRF1 inhibits protein expression of Akt and glycogen synthase kinase 3β (GSK3β) in 
insulin-like growth factor-1 (IGF-1)-stimulated NRVM21 
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NRVM were transduced with AdMuRF1 or control AdGFP at MOI 25 for 24 hours in serum-free 
M199 to increase MuRF1 expression, followed by treatment with 10nM IGF-1 for 30 minutes. 
Immunoblots using whole cell lysates from three independent experiments are shown for p-Akt S473, 
p-Akt T308, Akt, GSK3β, and p-GSK3β S9. Primary antibody against myc was used to assess 
adenovirus-dependent expression of myc-MuRF1. β-actin was used as a loading control. 
Densitometry analysis of Akt, p-Akt S473, p-Akt T308, and p-GSK3β S9 are shown for vehicle or 
IGF-1-treated cardiomyocytes transduced with either AdGFP or AdMuRF1. Total protein levels were 
normalized to β-actin and phospho-protein levels were normalized first to β-actin and then to total 
protein levels.  Densitometry analysis is represented as means ± SEM. A two-way ANOVA test was 
used to determine statistical significance. * indicates significance on level of adenovirus group ** 
indicates significance on level of treatment group. % indicates a significant interaction between 
adenovirus and treatment groups. The F statistic and degrees of freedom (DF) were reported when 
dependence between groups was found to be a significant source of variation. Significance between 
groups are represented as #P< 0.05, ##P< 0.001 as determined using a pair-wise post-test. 
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FIGURE 7 – MuRF1 knockdown in HL-1 cardiomyocytes induces total mammalian target of rapamycin 
(mTOR) protein levels to increase upon insulin-like growth factor-1 (IGF-1) stimulation22 
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HL-1 cardiomyocytes were transduced with either AdshMuRF1 or control Adshscrambled at MOI 30 for 
48 hours in serum-free DMEM, followed by treatment with 10nM IGF-1 for 30 minutes. Total and 
phosphorylated (S2481) mTOR was measuring by immunoblot of whole cell lysates from three 
independent experiments. β-actin was used as a loading control. Densitometry analysis of mTOR and p-
mTOR S2481 are shown for vehicle or IGF-1-treated cardiomyocytes transduced with either 
Adshscrambled or AdshMuRF1. Total protein levels were normalized to β-actin and phosphor-protein 
levels were normalized first to β-actin and then to total protein levels. Densitometry analysis is 
represented as means ± SEM. A two-way ANOVA test was used to determine statistical significance.  
*indicates significance on level of adenovirus group. **indicates significance on level of treatment group. 
%indicates a significant interaction between adenovirus and treatment groups.  The F statistic and degrees 
of freedom (DF) were reported when dependence between groups was found to be a significant source of 
variation. Significance between groups are represented as #P< 0.05, ##P< 0.001 as determined using a 
pairwise post-test.
141 
FIGURE 8 – MuRF1 inhibits HL-1 cardiomyocyte c-Jun protein levels and phosphorylation in the 
presence of insulin-like growth factor-1 (IGF-1)23 
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A. MuRF1 expression was increased in HL-1 cells using AdMuRF1 and control AdGFP at MOI 25 
for 24 hours in serum-free DMEM followed by treatment with 10nM IGF-1 for 30 minutes. c-Jun 
expression and phosphorylation in whole cell lysates from three independent experiments was 
assessed by immunoblot using primary antibodies raised against total c-Jun, p-c-Jun S63, p-c-Jun 
S73, and p-c-Jun T91, as indicated. Primary antibody against myc was used to confirm adenovirus-
dependent expression of myc-MuRF1. β-actin was used as a loading control. Densitometry analysis 
of c-Jun, p-c-Jun S63, p-c-Jun S73, and p-c-Jun T91 are shown for vehicle or IGF-1-treated 
cardiomyocytes transduced with either AdGFP or AdMuRF1. Total protein levels were normalized to 
β-actin and phospho-protein levels were normalized first to β-actin and then to total protein levels. B. 
AdshMuRF1 and control Adshscrambled were used at MOI 30 for 48 hours in serum-free DMEM to 
knockdown MuRF1 in HL-1 cardiomyocytes followed by IGF-1 treatment for 30 minutes. 
Immunoblot using whole cell lysates from three independent experiments are shown for c-Jun, p-c-
Jun S63, p-c-Jun S73, and p-c-Jun T91. MuRF1 primary antibody was used to confirm knockdown. 
β-actin was used as a loading control. Densitometry analysis of c-Jun, p-c-Jun S63, p-c-Jun S73, and 
p-c-Jun T91 are shown for vehicle or IGF-1-treated cardiomyocytes transduced with either 
Adshscrambled or AdshMuRF1. Total protein levels were normalized to β-actin and phospho-protein 
levels were normalized first to β-actin and then to total protein levels.  Densitometry analysis is 
represented as means ± SEM. A two-way ANOVA test was used to determine statistical significance. 
* indicates significance on level of adenovirus group ** indicates significance on level of treatment 
group. % indicates a significant interaction between adenovirus and treatment groups. The F statistic 
and degrees of freedom (DF) were reported when dependence between groups was found to be a 
significant source of variation. Significance between groups are represented as #P< 0.05, ##P< 0.001 
as determined using a pair-wise post-test. 
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FIGURE 9 – MuRF1 inhibits NRVM c-Jun protein levels and phosphorylation in the presence of 
insulin-like growth factor-1 (IGF-1)24  
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NRVM were transduced with AdMuRF1 or control AdGFP at MOI 25 for 24 hours in serum-free 
M199 to increase MuRF1 expression, followed by treatment with 10nM IGF-1 for 30 minutes. 
Immunoblots using whole cell lysates from three independent experiments are shown for c-Jun, p-c-
Jun S63, p-c-Jun S73, and p-c-Jun T91. Primary antibody against myc was used to assess adenovirus-
dependent expression of myc-MuRF1. β-actin was used as a loading control. Densitometry analysis 
of c-Jun, p-c-Jun S63, p-c-Jun S73, and p-c-Jun T91 are shown for vehicle or IGF-1-treated 
cardiomyocytes transduced with either AdGFP or AdMuRF1.  Densitometry analysis is represented 
as means ± SEM. A two-way ANOVA test was used to determine statistical significance. * indicates 
significance on level of adenovirus group ** indicates significance on level of treatment group. % 
indicates a significant interaction between adenovirus and treatment groups. The F statistic and 
degrees of freedom (DF) were reported when dependence between groups was found to be a 
significant source of variation. Significance between groups are represented as #P< 0.05, ##P< 0.001 
as determined using a pair-wise post-test. 
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FIGURE 10 – Exaggerated insulin-like growth factor-1 (IGF-1)-dependent cardiomyocyte growth 
with MuRF1 knockdown required c-Jun N-terminal kinase (JNK) activity25 
 
                                                     
25 As of this writing, this figure appears in an Article in Press (published January 14, 2014) in American Journal 
of Physiology Endocrinology and Metabolism at the following website: 
http://ajpendo.physiology.org/content/early/2014/01/09/ajpendo.00326.2013 DOI:10.1152/ajpendo.00326.2013 
146 
MuRF1 was knocked down using AdshMuRF1, with Adshscrambled as control, at MOI 60 for 24 
hours in serum-free DMEM followed by pre-treatment with 10µM SP600125 (JNK inhibitor) for 30 
minutes.  Cardiomyocytes were subsequently treated with 10nM IGF-1 for 18 hours. Cells were fixed 
and observed using with a fluorescent microscope using a 40X objective lens. Shown are 
representative images and quantification of cardiomyocyte area (mm2) averaged over at least 200 
cells per group. Cardiomyocyte area measurements are represented as mean area ± SEM. A three-way 
ANOVA test was used to determine statistical significance. * indicates significance on level of 
adenovirus group ** indicates significance on level of pre-treatment group. % denotes significant 
interactions between either the adenovirus, pre-treatment, or treatment groups, as indicated. %%% 
indicates a significant interaction between all three groups. The F statistic and degrees of freedom 
(DF) were reported when dependence between groups was found to be a significant source of 
variation. Significance between groups are represented as #P< 0.05, ##P< 0.001 as determined using 
a pairwise post-test. 
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FIGURE 11 – Exaggerated insulin-like growth factor-1 (IGF-1)-dependent Akt-associated gene 
expression with MuRF1 knockdown required c-Jun N-terminal kinase (JNK) activity26 
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AdshMuRF1 and control Adshscrambled were used at MOI 60 for 24 hours in serum-free DMEM to 
knockdown MuRF1 in HL-1 cardiomyocytes. Transduced cells were pre-treated with 10µM 
SP600125 (JNK inhibitor) for 30 minutes, followed by treatment with 10nM IGF-1 treatment for 18 
hours. RNA was isolated and cDNA generated for use in measuring expression of MuRF1, MAPK13, 
RYR1, and 18S (reference gene). Raw CT values from three independent experiments were 
normalized to their respective 18S values, averaged over experimental group, and subsequently 
normalized to either vehicle control (MAPK13, RYR1, and Igfbp5) or adenovirus control (MuRF1). 
Final data is represented as mean fold change ± SEM. Shown are RT-PCR data for each of these 
genes in cardiomyocytes transduced with either Adshscrambled or AdshMuRF1 and treated with 
vehicle or both JNK inhibitor and IGF-1.  A three-way ANOVA test was used to determine statistical 
significance. * indicates significance on level of adenovirus group ** indicates significance on level 
of pre-treatment group. % denotes significant interactions between either the adenovirus, pre-
treatment, or treatment groups, as indicated. %%% indicates a significant interaction between all 
three groups. The F statistic and degrees of freedom (DF) were reported when dependence between 
groups was found to be a significant source of variation. Significance between groups are represented 
as #P< 0.05, ##P< 0.001 as determined using a pairwise post-test.      
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FIGURE 12 – MuRF1 regulates physiological cardiac hypertrophy induced by exercise training in 
MuRF1-/- mice27 
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MuRF1-/- and sibling-matched wildtype control mice (MuRF1 +/+) were randomly assigned to either 
sedentary or running groups, where running groups were provided with an in-cage exercise wheel for 5 
weeks and sedentary groups were not. Cardiac growth and function were measured by echocardiography. 
A. Representative M-mode images, containing at least 10 waveforms, from echocardiography of 
sedentary and running MuRF1+/+ and MuRF1-/-. B. LV mass measurements, as measured by 
echocardiography, normalized to tibia length (TL) for MuRF1+/+ and MuRF1-/- mice assigned to either 
sedentary or running groups were also analyzed. C. Perfused and fixed paraffin-embedded heart sections 
from sedentary and running MuRF1-/- and wild type control mice were stained with Lectin-TRITC, 
imaged using fluorescent microscopy to visualize cardiomyocytes, and cross-sectional area analyzed from 
>180 cardiomyocytes from at least three animals per group. D. Histological analysis of hemotoxylin and 
eosin (HE) was also performed. E. RNA was isolated from whole heart tissue from sedentary and running 
MuRF1+/+ and MuRF1-/-, cDNA generated, and BNP, ANF, skeletal muscle actin, TATA box-binding 
protein (Tbp), and hypoxanthine phosphoribosyltransferase (Hprt) expression determined, where both 
Tbp and Hprt were used as reference genes. Raw CT values were normalized to the average Ct value over 
all groups within each genotype pair to calculate ΔCT values. ΔCT values for each animal were then 
divided by their respective reference gene correction factor (geometric mean of Tbp and Hprt ΔCT 
values) to obtain final expression data for target genes (BNP, ANF, and skeletal muscle actin). Three 
animals (n=3) were used per group. A two-way ANOVA test was used to determine statistical 
significance. A two-way ANOVA test was used to determine statistical significance. * indicates 
significance on level of genotype group. ** indicates significance on level of exercise (sedentary or 
running) group. % indicates a significant interaction between genotype and exercise groups. The F 
statistic and degrees of freedom (DF) were reported when dependence between groups was found to be a 
significant source of variation. Significance between groups are represented as #P< 0.05, ##P< 0.001 as 
determined using a pair-wise post-test. 
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FIGURE 13 – MuRF1 regulates physiological cardiac hypertrophy induced by exercise training in 
MuRF1Tg+ mice28 
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MuRF1 Tg+ and sibling-matched wildtype control mice (WildtypeMuRF1Tg+) were randomly assigned 
to either sedentary or running groups, where running groups were provided with an in-cage exercise 
wheel for 5 weeks and sedentary groups were not. Cardiac growth and function were measured by 
echocardiography.  A. Representative M-mode images, containing at least 10 waveforms, from 
echocardiography of sedentary and running MuRF1 Tg+ and WildtypeMuRF1Tg+ B. LV mass 
measurements, as measured by echocardiography, normalized to TL for MuRF1 Tg+ and 
WildtypeMuRF1Tg+ mice assigned to either sedentary or running groups were also analyzed. C. Perfused 
and fix paraffin-embedded heart sections from sedentary and running MuRF1 Tg+ and 
WildtypeMuRF1Tg+ control mice were stained with Lectin-TRITC, imaged using fluorescent 
microscopy to visualize cardiomyocytes, and cross-sectional area analyzed from >180 cardiomyocytes 
from at least three animals per and cross-sectional area analyzed from >180 cardiomyocytes from at least 
three animals per group. D. Histological analysis of HE was also performed. E. RNA was isolated from 
whole heart tissue from sedentary and running WildtypeMuRF1Tg+ and MuRFTg+ mice cDNA 
generated and BNP, ANF, skeletal muscle actin, Tbp, and Hprt expression determined, where both Tbp 
and Hprt were used as reference genes (described above).  A two-way ANOVA test was used to 
determine statistical significance. * indicates significance on level of genotype group. ** indicates 
significance on level of exercise (sedentary or running) group. % indicates a significant interaction 
between genotype and exercise groups. The F statistic and degrees of freedom (DF) were reported when 
dependence between groups was found to be a significant source of variation. Significance between 
groups are represented as #P< 0.05, ##P< 0.001 as determined using a pair-wise post-test.  
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FIGURE 14 – High power histological analysis of MuRF1 -/-, MuRF1 Tg+, and sibling wildtype control 
hearts29 
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Top: HE staining of representative cardiac sections from A. MuRF1-/- and B. MuRF1 Tg+ mice after 5 
weeks sham or running challenge. Bottom: Masson's trichrome (MT) staining of representative cardiac 
sections from C. MuRF1-/- and D. MuRF1 Tg+ mice after 5 weeks sham or running challenge. 
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FIGURE 15 – MuRF1 inhibits T3-induced cardiomyocyte hypertrophy in vitro 
 
156 
MuRF1 was knocked down in HL-1 cardiomyocytes using AdshMuRF1, with Adshscrambled as 
control, at MOI 60 for 24 hours in serum-free DMEM followed by treatment with 1µM T3 for 18 
hours.  Shown are representative fluorescent images and area analysis for vehicle-and T3-treated 
cardiomyocytes transduced with either Adshscrambled or AdshMuRF1.  B. MuRF1 was increased in 
expression in HL-1 cardiomyocytes using AdMuRF1, with AdGFP as a control, at MOI 25 for 24 
hours in serum-free DMEM followed by treatment with 1µM T3 for 18 hours. Shown are 
representative fluorescent images and area analysis of vehicle- or T3-treated HL-1 cardiomyocytes 
transduced with either AdGFP or AdMuRF1. C. MuRF1 was increased in expression in NRVM using 
AdMuRF1, with AdGFP as a control, at MOI 25 for 24 hours in serum-free M199 followed by 
treatment with 1µM T3 for 18 hours.  Shown are representative fluorescent images and area analysis 
of vehicle- or T3-treated NRVM transduced with either AdGFP or AdMuRF1.  Data are represented 
as mean ± SEM.  Black bars represent vehicle and gray bars represent T3-treated cells or animals.  A 
two-way ANOVA test was used to determine statistical significance. *indicates significance on level 
of adenovirus or genotype group, **indicates significance on level of treatment group.  %indicates a 
significant interaction between adenovirus and treatment groups. The F statistic and degrees of 
freedom (DF) were reported when dependence between groups was found to be a significant source 
of variation.  Significance between groups is represented as #P< 0.05, ##P< 0.001, as determined 
using a pairwise post-test. 
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FIGURE 16 – MuRF1 inhibits T3-induced cardiomyocyte hypertrophy in vivo 
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MuRF1-/-, MuRF1 Tg+, and sibling-matched wildtype control mice (MuRF1 +/+, WildtypeMuRF1Tg+) 
were randomly assigned to either vehicle or T3 groups, where T3 groups were injected with 1mg/kg 
T3 and vehicle groups were injected with PBS intraperitoneally each day for 14 days. A.  Heart 
weight (HW) measurements normalized to body weight (BW) for MuRF1+/+ and MuRF1-/- vehicle 
and T3 groups.  B.  Heart weight (HW) measurements normalized to body weight (BW) for 
WildtypeMuRF1Tg+ and MuRF1 Tg+ vehicle and T3 groups.  C. Representative images of histological 
analysis of perfused and fixed heart sections stained with hemotoxylin and eosin (HE) from T3-
treated MuRF1+/+, MuRF1 -/-, WildtypeMuRF1Tg+, and MuRF1 Tg+.  D. Representative 100x images 
of histological analysis of perfused and fixed heart sections stained with Masson’s Trichrome (MT) 
from vehicle- and T3-treated MuRF1+/+ and MuRF1-/- used for cardiomyocyte area measurements.  
Analysis of cardiomyocyte area of vehicle- and T3-treated MuRF1+/+ and MuRF1-/-.  E.  
Representative 100x images of histological analysis of perfused and fixed heart sections stained with 
MT from vehicle- and T3-treated WildtypeMuRF1Tg+ and MuRF1 Tg+ used for cardiomyocyte area 
measurements.  Analysis of cardiomyocyte area of vehicle- and T3-treated WildtypeMuRF1Tg+ and 
MuRF1 Tg+.  Data are represented as mean ± SEM.  Black bars represent vehicle and gray bars 
represent T3-treated cells or animals.  A two-way ANOVA test was used to determine statistical 
significance. *indicates significance on level of adenovirus or genotype group, **indicates 
significance on level of treatment group.  %indicates a significant interaction between adenovirus and 
treatment groups. The F statistic and degrees of freedom (DF) were reported when dependence 
between groups was found to be a significant source of variation.  Significance between groups is 
represented as #P< 0.05, ##P< 0.001, as determined using a pairwise post-test. 
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FIGURE 17 – Gene expression associated with pathological hypertrophy is not altered in MuRF1-/- 
and MuRF1Tg+ mice treated with T3 
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A. RNA was isolated from whole heart tissue from vehicle- and T3-treated MuRF1+/+ and MuRF1-/-
, cDNA generated, and BNP, skeletal muscle actin, ANF, and TATA box-binding protein (Tbp) 
expression determined, where Tbp was used as a reference gene B. RNA was isolated from whole 
heart tissue from vehicle- and T3-treated WildtypeMuRF1Tg+ and MuRF1 Tg+, cDNA generated, and 
BNP, skeletal muscle actin, ANF, and TATA box-binding protein (Tbp) expression determined, 
where Tbp was used as a reference gene.  In vitro cardiomyocyte area measurements were averaged 
over at least 200 cardiomyocytes.  In vivo cardiomyocyte area measurements were averaged over at 
least 400 cardiomyocytes from three different animals per group.  RT-PCR analysis was carried out 
using the ΔΔCT method, where raw CT values were first normalized to Tbp (ΔCT values) and then to 
vehicle-treated wildtype groups (ΔΔCTvalues).  RT-PCR data were averaged over 3 animals per 
group.  Data are represented as mean ± SEM.  Black bars represent vehicle and gray bars represent 
T3-treated cells or animals.    
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FIGURE 18 – MuRF1 inhibits TH cardiac uptake 
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A. Serum T3 and T4 analysis of MuRF1-/- and sibling-matched wildtype control mice (MuRF1 +/+) 
injected with either 1mg/kg T3 or vehicle (PBS) intraperitoneally each day for 14 days.  Black bars 
represent MuRF1+/+ and gray bars represent MuRF1-/-.  B. Serum T3 and T4 analysis of MuRF1 
Tg+ and sibling-matched wildtype control mice (WildtypeMuRF1Tg+) injected with either 1mg/kg T3 or 
vehicle (PBS) intraperitoneally each day for 14 days.  Black bars represent WildtypeMuRF1Tg+ and gray 
bars represent MuRF1 Tg+.  Data are represented as mean ± SEM.  A two-way ANOVA test was 
used to determine statistical significance. *indicates significance on level of adenovirus group, 
**indicates significance on level of treatment group %indicates a significant interaction between 
adenovirus and treatment groups. The F statistic and degrees of freedom (DF) were reported when 
dependence between groups was found to be a significant source of variation.  Significance between 
groups is represented as #P< 0.05, ##P< 0.001 as determined using a pairwise post-test. 
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FIGURE 19 – MuRF1 inhibits cardiac gene expression of the TH transporter MCT10 
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A. RNA was isolated from whole heart tissue from vehicle- and T3-treated MuRF1+/+ and MuRF1-/-
, cDNA generated, and monocarboxylate transporter 8 (MCT8), MCT10, and Tbp expression 
determined, where Tbp was used as a reference gene. Black bars represent MuRF1+/+ and gray bars 
represent MuRF1-/-. B.  RNA was isolated from whole heart tissue from vehicle- and T3-treated 
WildtypeMuRF1Tg+ and MuRF1 Tg+, cDNA generated, and monocarboxylate transporter 8 (MCT8), 
MCT10, and Tbp expression determined, where Tbp was used as a reference gene.  Black bars 
represent WildtypeMuRF1Tg+ and gray bars represent MuRF1 Tg+. RT-PCR analysis was carried out 
using the ΔΔCT method, where raw CT values were first normalized to Tbp (ΔCT values) and then to 
vehicle-treated wildtype groups (ΔΔCTvalues).  RT-PCR data were averaged over 3 animals per 
group.  Data are represented as mean ± SEM.  A two-way ANOVA test was used to determine 
statistical significance. *indicates significance on level of adenovirus group, **indicates significance 
on level of treatment group %indicates a significant interaction between adenovirus and treatment 
groups. The F statistic and degrees of freedom (DF) were reported when dependence between groups 
was found to be a significant source of variation.  Significance between groups is represented as #P< 
0.05, ##P< 0.001 as determined using a pairwise post-test.     
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FIGURE 20 – MuRF1 inhibits TRα transcriptional activity, but does not target TRα for proteasomal 
degradation 
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A. To assess the role of MuRF1 on TRα transcriptional activity, Cos-7 cells were co-transfected with 
luciferase plasmid driven by the thyroid response element (TRE) of the GH gene, as described 
previously122, β-galactosidase plasmid (for transfection control), and FLAG-TRα plasmid, with empty 
FLAG as a control, transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours, and 
treated with 1µM T3 for 24 hours.  Parallel plates were used to confirm expression of FLAG-TRα and 
myc-MuRF1 by immunoblot using FLAG and myc antibodies, respectively.  Black bars represent 
AdGFP- and gray bars represent AdMuRF1-transduced cells.  B.  MuRF1 was knocked down in HL-
1 cardiomyocytes using AdshMuRF1, with Adshscrambled as control, at MOI 60 for 24 hours.  
Immunoblot using whole cell lysates was used to access protein expression of endogenous TRα.  
MuRF1 antibody was used to confirm knockdown. β-actin was used as a loading control.  C.  MuRF1 
was increased in expression in HL-1 cardiomyocytes using AdMuRF1, with AdGFP as a control, at 
MOI 25 for 24 hours.  Immunoblot using whole cell lysates was used to access protein expression of 
endogenous TRα.  Myc antibody was used to confirm expression of myc-MuRF1.  β-actin was used 
as a loading control.  Luciferase data is representative of three independent experiments.  Data are 
represented as mean ± SEM.  A two-way ANOVA test was used to determine statistical significance. 
*indicates significance on level of plasmid group.  %indicates a significant interaction between 
adenovirus and treatment groups. The F statistic and degrees of freedom (DF) were reported when 
dependence between groups was found to be a significant source of variation.  Significance between 
groups is represented as #P< 0.05 as determined using a pairwise post-test. 
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FIGURE 21 – Localization of TRα in the nucleus of cardiomyocytes is increased by MuRF1 
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HL-1 cardiomyocytes were transfected with FLAG-TRα plasmid, or with empty FLAG as a control 
(see Figure 22), transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours, and 
treated with 1µM T3 for 2 hours.  A. Nuclear localization of TRα was assessed using confocal 
microscopy, immunofluorescent staining of TRα (anti-FLAG, red) and nuclei (DAPI, blue), and 
quantitatively evaluated by determining the degree of TRα (red) and DAPI (blue) overlap via 
correlation coefficient measurements.  B. The co-localization of MuRF1 and TRα in the nucleus was 
assessed using confocal microscopy, immunofluorescent staining of MuRF1 (anti-myc, green) and 
TRα (anti-FLAG, red), and quantitatively evaluated by determining the degree of MuRF1 (green) and 
TRα (red) overlap, isolated to the nucleus, via correlation coefficient measurements. C. Control 
confocal analysis of immunofluorescent staining with secondary antibodies (568 for TRα and 647 for 
MuRF1) alone.  Quantitative immunofluorescence measurements were made using Volocity imaging 
software.  For correlation coefficients, numeric range is from 0 to 1, where 0 indicates no correlation 
and 1 indicated perfect correlation. Data are represented as mean ± SEM.  For TRα/DAPI co-
immunofluorescence, a two-way ANOVA test was used to determine statistical significance. 
*indicates significance on level of adenovirus group, **indicates significance on level of treatment 
group.  Significance between groups is represented as ##P< 0.001 as determined using a pairwise 
post-test.  For TRα/MuRF1 coimmunofluorescence, a Student’s t-test was used to measure statistical 
significance where $ indicates P<0.001 between groups. 
169 
FIGURE 22 – Empty FLAG vector controls for FLAG-TRα immunofluorescence 
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HL-1 cardiomyocytes were transfected with empty FLAG as a control, transduced with AdMuRF1, 
with AdGFP as a control, at MOI 25 for 4 hours, and treated with 1µM T3 for 2 hours.  Control 
confocal analysis of immunofluorescent staining with anti-FLAG (red) and nuclei (DAPI, blue). 
171 
FIGURE 23 – Endogenous TRα accumulates in nucleus enriched fractions in a MuRF1- and T3-
dependent manner 
172 
MuRF1 was increased in expression in HL-1 cardiomyocytes using AdMuRF1, with AdGFP as a 
control, at MOI 25 for 24 hours in serum-free DMEM followed by treatment with 1µM T3 for 2 
hours.  Immunoblot using nuclear- and cytoplasmic-enriched fractions was used to access nuclear 
localization of endogenous TRα.  p-Rb was used as a nuclear marker and GAPDH was used as a 
cytoplasmic marker.  Densitometry analysis of TRα is shown for AdGFP- and AdMuRF1-transduced 
cardiomyocytes treated with vehicle (PBS) or T3.  Data are represented as mean ± SEM.  A two-way 
ANOVA test was used to determine statistical significance. *indicates significance on level of 
adenovirus group, **indicates significance on level of treatment group %indicates a significant 
interaction between adenovirus and treatment groups. The F statistic and degrees of freedom (DF) 
were reported when dependence between groups was found to be a significant source of variation.  
Significance between groups is represented as #P< 0.05 as determined using a pairwise post-test. 
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FIGURE 24 – MuRF1 interacts with TRα in the presence of T3 
174 
Cos-7 cells were transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 24 hours, and 
treated with 1µM T3 for 2 hours.  To determine if MuRF1 physically interacts with TRα, whole cell 
lysates were submitted to specific immunoprecipitation of myc-MuRF1 followed by immunoblot of 
endogenous TRα.   
175 
FIGURE 25 – MuRF1 mono-ubiquitinates TRα, inhibiting TRα’s poly-ubiquitination 
176 
Cos-7 cells were co-transfected with HA-Ub and FLAG-TRα plasmids, with empty HA and FLAG as 
controls, and transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours.  To assess 
the effect of MuRF1 expression on TRα mono-ubiquitination (B), whole cell lysates were submitted 
to specific immunoprecipitation of FLAG-TRα followed by immunoblot of HA using anti-HA-
horseradish peroxidase (HRP)-linked primary antibody (to prevent IgG heavy chain signal).  To 
assess the effect of MuRF1 expression on TRα poly-ubiquitination (C), whole cell lysates were 
submitted to specific immunoprecipitation of FLAG-TRα followed by immunoblot of HA using 
primary anti-HA and HRP-linked secondary antibody.    
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FIGURE 26 – MuRF1 promotes the interaction of TRα and CAP350 in the nucleus 
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.  HL-1 cardiomyocytes were transfected with FLAG-TRα plasmid, or with empty FLAG as a control 
(see Figure 22), transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours, and 
treated with 1µM T3 for 2 hours.  A.  The co-localization of TRα and endogenous centrosome-
associated protein 350 (CAP350) in the nucleus was assessed using confocal microscopy, 
immunofluorescent staining of TRα (anti-FLAG, red) and CAP350 (green), and quantitatively 
evaluated by determining the degree of TRα (red) and CAP350 (green) overlap, isolated to the 
nucleus, via correlation coefficient measurements. B. Control confocal analysis of immunofluorescent 
staining with secondary antibodies (568 for TRα and 488 for CAP350) alone.  Quantitative 
immunofluorescence measurements were made using Volocity imaging software.  For correlation 
coefficients, numeric range is from 0 to 1, where 0 indicates no correlation and 1 indicated perfect 
correlation. Data are represented as mean ± SEM.  A two-way ANOVA test was used to determine 
statistical significance. *indicates significance on level of adenovirus group, **indicates significance 
on level of treatment group.  Significance between groups is represented as ##P< 0.001 as determined 
using a pairwise post-test. 
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FIGURE 27 – Interaction between desmin and TRα at the cardiomyocyte nuclear membrane is 
MuRF1- and T3-dependent 
180 
HL-1 cardiomyocytes were transfected with FLAG-TRα plasmid, or with empty FLAG as a control 
(see Figure 22), transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours, and 
treated with 1µM T3 for 2 hours.  A.  The co-localization of TRα and endogenous desmin at the 
nuclear membrane was assessed using confocal microscopy, immunofluorescent staining of TRα 
(anti-FLAG, red) and desmin (green), and quantitatively evaluated by determining the degree of TRα 
(red) and desmin (green) overlap, isolated to the nuclear membrane, via correlation coefficient 
measurements. B. Control confocal analysis of immunofluorescent staining with secondary antibodies 
(568 for TRα and 488 for desmin) alone.  Quantitative immunofluorescence measurements were 
made using Volocity imaging software.  For correlation coefficients, numeric range is from 0 to 1, 
where 0 indicates no correlation and 1 indicated perfect correlation. Data are represented as mean ± 
SEM.  A two-way ANOVA test was used to determine statistical significance. *indicates significance 
on level of adenovirus group, **indicates significance on level of treatment group %indicates a 
significant interaction between adenovirus and treatment groups. The F statistic and degrees of 
freedom (DF) were reported when dependence between groups was found to be a significant source 
of variation.  Significance between groups is represented as #P< 0.05 as determined using a pairwise 
post-test. 
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FIGURE 28 – T3 promotes the interaction between laminβ1 and TRα, which is inhibited by MuRF1 
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HL-1 cardiomyocytes were transfected with FLAG-TRα plasmid, or with empty FLAG as a control 
(see Figure 22), transduced with AdMuRF1, with AdGFP as a control, at MOI 25 for 4 hours, and 
treated with 1µM T3 for 2 hours.  A.  The co-localization of TRα and endogenous laminβ1 at the 
nuclear membrane was assessed using confocal microscopy, immunofluorescent staining of TRα 
(anti-FLAG, red) and laminβ1 (green), and quantitatively evaluated by determining the degree of TRα 
(red) and laminβ1 (green) overlap, isolated to the nuclear membrane, via correlation coefficient 
measurements. B. Control confocal analysis of immunofluorescent staining with secondary antibodies 
(568 for TRα and 488 for laminβ1) alone.  Quantitative immunofluorescence measurements were 
made using Volocity imaging software.  For correlation coefficients, numeric range is from 0 to 1, 
where 0 indicates no correlation and 1 indicated perfect correlation. Data are represented as mean ± 
SEM. A two-way ANOVA test was used to determine statistical significance. *indicates significance 
on level of adenovirus group, **indicates significance on level of treatment group %indicates a 
significant interaction between adenovirus and treatment groups. The F statistic and degrees of 
freedom (DF) were reported when dependence between groups was found to be a significant source 
of variation.  Significance between groups is represented as #P< 0.05, ##P< 0.001 as determined 
using a pairwise post-test. 
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FIGURE 29 – Amino acid sequences of mouse TRα domain lysine mutants 
 
184 
Final amino acid sequences of TRα WT, TRα A/B KtoR, TRα C KtoR, TRα D KtoR, and TRα E/F 
KtoR, as expressed via the p3XFLAG®-CMV-14 vector.  Plasmid cloning described in data 
supplement. 
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FIGURE 30 – Mutation of the lysine residues within the E/F region of TRα inhibits MuRF1-
dependent TRα nuclear accumulation 
186 
HL-1 cardiomyocytes were transfected with indicated FLAG-TRα domain lysine to arginine (KtoR) 
mutant plasmids, or with empty FLAG as a control (see Figure 22), transduced with AdMuRF1 at 
MOI 25 for 4 hours, and treated with 1µM T3 for 2 hours.  A.  Nuclear localization of TRα was 
assessed using confocal microscopy, immunofluorescent staining of TRα (anti-FLAG, red) and nuclei 
(DAPI, blue), and quantitatively evaluated by determining the degree of TRα (red) and DAPI (blue) 
overlap via correlation coefficient measurements.  B. The co-localization of MuRF1 and TRα in the 
nucleus was assessed using confocal microscopy, immunofluorescent staining of MuRF1 (anti-myc, 
green) and TRα (anti-FLAG, red), and quantitatively evaluated by determining the degree of MuRF1 
(green) and TRα (red) overlap, isolated to the nucleus, via correlation coefficient measurements.  C. 
The co-localization of TRα and endogenous CAP350 in the nucleus was assessed using confocal 
microscopy, immunofluorescent staining of TRα (anti-FLAG, red) and CAP350 (green), and 
quantitatively evaluated by determining the degree of TRα (red) and CAP350 (green) overlap, 
isolated to the nucleus, via correlation coefficient measurements.  Quantitative immunofluorescence 
measurements were made using Volocity imaging software.  For correlation coefficients, numeric 
range is from 0 to 1, where 0 indicates no correlation and 1 indicated perfect correlation.  Data are 
represented as mean ± SEM.  A one-way ANOVA test was used to determine statistical significance. 
Significance between groups is represented as ##P< 0.001 as determined using a pairwise post-test. 
187 
 FIGURE 31 – Cardiac hypertrophy is associated with biasing the balance of protein synthesis and 
degradation towards synthesis30 
                                                     
30 This figure was modified from Willis and Patterson178 
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FIGURE 32 – Regions of TRα known to be modified by ubiquitination/SUMOylation 
 
 
 
 
 
189 
FIGURE 33 – Ubiquitin ligase (E3) expression in Golden retriever muscular dystrophy (GRMD)31 
                                                     
31 This figure previously appeared in Muscle and Nerve.  The original citation for the publication which 
includes this figure is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
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Quantitative mRNA expression analysis of the ubiquitin ligases (A) muscle ring finger 1 (MuRF1), 
(B) muscle F-box protein (MAFbx), (C) carboxyl terminus of Hsp70-interacting protein (CHIP), and 
(D) mouse double minute-2 (MDM2) in GRMD lateral digital extensor, the lateral head of the 
gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. mRNA expression 
is shown as the fold change compared with age-matched control animals. Data represent 3–5 dogs per 
group (outlined in Table 13), as indicated above each vertical boxplot. The vertical boxplot presents 
the median (50% percentile), indicated by the middle line inside the box, the 75th percentile indicated 
by the top of the box, and the 25th percentile indicated by the bottom of the box. A rank-sum test was 
used to determine the differences in mRNA expression. *P< 0.05. 
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FIGURE 34 – Expression of ubiquitin, uncoordinated phenotype 4/5 (UNC4/5), and the E2 ubiquitin-
conjugating enzyme ubiquitin-like protein small ubiquitin-like modifier (SUMO)-1-conjugating 
enzyme (UBC9) in Golden retriever muscular dystrophy (GRMD) skeletal muscle and heart32 
                                                     
32 This figure previously appeared in Muscle and Nerve.  The original citation for the publication which 
includes this figure is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
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Quantitative mRNA expression analysis of (A) ubiquitin, (B) the protein chaperone UNC4/5, and (C) 
E2 UBC9 in the GRMD lateral digital extensor, the lateral head of the gastrocnemius, vastus lateralis, 
biceps femoris, left ventricle, and cranial sartorius. mRNA expression is shown as the fold change 
compared with age-matched control animals. Data represent 3–5 dogs per group (outlined in Table 
13), as indicated above each vertical boxplot. The vertical boxplot presents the median (50th 
percentile), indicated by the middle line inside the box, the 75th percentile indicated by the top of the 
box, and the 25th percentile indicated by the bottom of the box. A rank-sum test was used to 
determine the differences in mRNA expression. *P < 0.05. 
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FIGURE 35 – Proteasome subunit expression in Golden retriever muscular dystrophy (GRMD) 
skeletal muscle and heart33 
 
                                                     
33 This figure previously appeared in Muscle and Nerve.  The original citation for the publication which 
includes this figure is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
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(A) PSMA6, (B) PSMB4, and (C) PSME1 in GRMD long digital extensor, lateral head of the 
gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. mRNA expression 
is shown as the fold change compared with age-matched control animals. Data represent 3–5 dogs per 
group (outlined in Table 13), as indicated above each vertical boxplot. The vertical boxplot presents 
the median (50th percentile), indicated by the middle line inside the box, the 75th percentile indicated 
by the top of the box, and the 25th percentile indicated by the bottom of the box. A rank-sum test was 
used to determine the differences in mRNA expression. *P<0.05. 
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FIGURE 36 – Muscle-specific proteasome activities in Golden retriever muscular dystrophy 
(GRMD)34 
                                                     
34 This figure previously appeared in Muscle and Nerve.  The original citation for the publication which 
includes this figure is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
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(A) Trypsin-like, (B) caspase-like, and (C) chymotrypsin-like activities in GRMD long digital 
extensor, lateral head of the gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial 
sartorius. Proteasome activities are presented as arbitrary fluorescent units (AFU). Data represent 3–5 
dogs per group (outlined in Table 13), as indicated above each vertical boxplot. The vertical box plot 
presents the median (50th percentile), indicated by the middle line inside the box, the 75th percentile 
indicated by the top of the box, and the 25th percentile indicated by the bottom of the box. A rank-
sum test was used to determine the differences in proteasome activity. *P <0.05. 
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FIGURE 37 – Muscle-specific calpain 1 and 2 activities in Golden retriever muscular dystrophy 
(GRMD)35 
 
 
 
 
                                                     
35 This figure previously appeared in Muscle and Nerve.  The original citation for the publication which 
includes this figure is as follows: Muscle Nerve 44, no. 4 (October 2011): 553-62. 
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Quantitative mRNA expression analysis of (A) calpain 1, and (B) calpain 2 in GRMD long digital 
extensor, lateral head of the gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial 
sartorius. Expression levels are presented as a percentage of age-matched controls. (C) Calpain 1 and 
2 activity determined by a fluorimetric assay based on GRMD long digital extensor, lateral head of 
the gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. mRNA 
expression is shown as the fold change compared with age-matched control animals. Calpain 1 and 2 
activity presented as relative fluorometric units. Data represent 3–5 dogs per group (outlined in Table 
13), as indicated above each vertical boxplot. The vertical boxplot presents the median (50th 
percentile), indicated by the middle line inside the box, the 75th percentile indicated by the top of the 
box, and the 25th percentile indicated by the bottom of the box. A rank-sum test was used to 
determine the differences in mRNA expression and calpain 1 and 2 activity. *P< 0.05. 
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